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The allergic response is mediated through the figand-receptor pair immunoglobulin E (IgE), produced 
by B lymphocytes, and the high affinity receptor for IgE (FcdR-I), present on certain myeloid cells. 
When IgE is attached to the receptor it can bind allergen, which cross-links receptors on the cell 
surface, causing the release of histamine, prostaglandins, cytokines, and other mediators of the allergic 
reaction, resulting in among other effects, the up-regulation of IgE levels. A number of important 
events in the regulation of IgE were studied, including the cloning and characterisation of the gene for 
the FccRI(x subunit, the analysis of a switch recombination event to IgE, the clonin& expression, and 
regulation of the germline gene transcript for IgF, and the mechanism of glucocorticoid enhancement of 
IgE secretion. 
Due to its important role in the transduction of signals involved in the allergic reaction, the gene for the 
IgE binding subunit FczRIoc was cloned and its structure analysed. A promoter fi7agment was identified 
that contained a C/T polymorphism at a potential GATA transcription factor binding site that may be 
linked to allergy. All 4 of the individuals containing aC allele were non-atopic, from a group of 15 
atopics and 15 non-atopics. 
IgE is expressed by B cells after an isotype switchin event fi7orn Ig. K or another isotype. To 4:;; "- 9 determine if switching to IgE corresponded to a DNA recombination event in the immunoglobulin 
heavy chain locus, the region upstream of the epsilon locus was sequenced in aB cell line, U266, that 
underwent switching to IgE. U266 was shown to be the result of a IgM->IgA I -->Ig)E series of Switch 
recombination events and to be the first example of sequential switching. 
Prior to switch recombination, transcription (gem&e gene transcription) occurs through the mu locus 
and within the constant region locus to which switching is directed. The gernifine gene transcript 
(GLT) for IgE was cloned, and its expression was found to precede the secretion of IgE in peripheral 
blood mononuclear ceUs (PBMC). F--GLT were detected 12 hours after IIL-4 induction, reaching a 
maximum at 3 days. Transcription start sites were heterogeneous within a 220 base region upstream of 
the gem-dine exon. A 650 bp fi7agment was found to have promoter activity in B lymphoblastoid lines 
and to bind the transcription factor BSAP in vitro. BSAP was found to be required for the IIL4 and 
CD40 mediated up-regulation of transcription and is thought to be responsible for its B cefl specific 
expression. 
Glucocorticoids (GQ provide a co-stimulus to purified B cells to switch to IgE in the presence of IIL4. 
GC also enhance IgE synthesis in vivo, and in PBMC. Surprisingly, GC are the main phan-nacological 
agent used to control the symptoms of allergy. The mechanism of the GC potentiation of IgJE synthesis 
in PBMC was investigated to elucidate this potentially antagonistic phenomenon. IgE enhancement 
was found to occur only after 10 days of glucocorticoid addition in vitro. Germline gene and 
productive epsilon transcription was not enhanced in the presence of IL4 by glucocorticoid at 4.5 days 
of culture, indicating that glucocorticoids could act on switching though a unique mechanism later in 
the culture period. 
Confirmation of the linkage of the FczRI(x polymorphism to allergy could lead to the discovery of 
transcription factors that bind to this sequence which could be targets for anti-allergy strategies. Further 
work on the role of the e-GLT, and the structure of the switch region in the mechanism of switching 
could help to clarify the role of transcription and chromatin structure in recombination. A knowledge 
of the mechanism of GC potentiation of IgE secretion could lead to new IgE regulatory routes, and 
help improve the efficacy of glucocorticoids in the treatment of allergy. 
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CHAPTER 1: Introduction 
1.1 Antibody structure, function and expression. 
During an immune response, antibodies specific to a foreign antigen are produced by B cells. 
Antibodies are composed of four polypeptide chains, two light chains, and two heavy chains, 
encoded on two genes (for review see Blackwell and Alt 1988; Casali and Schettino 1996). 
Antigen binding occurs via the variable region at the arnino terminus, and effector functions 
occur via the constant region (Fig. 1.1). In humans, five classes (isotypes) of antibodies are 
produced, IgK IgD, IgG, IgE, and IgA, and six subclasses, IgGI-IgG4 and IgAl and 2, all 
differing at their heavy chain constant region (C11). After heavy chain variable region gene 
assembly, the antibody IgM is expressed in the cytoplasm (Fig. 1.2). The presence of 
cytoplasmic mu chain signals light chain variable region assembly, allowing production of 
light chain protein and the expression of an IgM molecule on the cell surface. Initially IgK 
and by alternative splicing IgD, are produced by the B cell. Later, after antigen is 
encountered, the effector functions of the antibody can change in a class switching event that 
replaces the ýt, or 6 constant region with that of y, F, or (x. Class switching allows the IgG, 
IgE, and IgA isotypes to be produced without changing the variable region expressed. 
IgM comprises the initial rapid antibody response in the blood, and at sites of infection after 
vascular pen-neability is increased. IgD is expressed on the surface of mature B cells and may 
be involved in B ceN activation (Finkelman et al. 1992). IgG is the principal antibody of the 
blood and extracellular fluid. IgA is the principal isotype in secretions, most importantly the 
mucus membranes of the intestinal, and respiratory tracts. IgE is produced in low amounts in 
peripheral blood or extracellular fluid. IgE is involved in the cell mediated killing of parasitic 
worms (helminths) (Butterworth et al. 1992; Capron et al. 1992; Gounni et al. 1994), and 
mediates allergic disease. 
1.2 The immunological basis of allergic disease. 
Helminth infection affects two thirds of the world's population, and in some tropical areas, 
chronic schistosorniasis is the most pressing health concern. Allergic disease affects about 20 
percent of the world's population (Casolaro el al. 1996), and because of its prevalence in the 
16 
western world, most of the research on IgE has been from the viewpoint of allergy. The 
nature of the IgE directed response to helrnýinth infection, and its role in allergy are quite 
different. Although both allergy and helminth resistance share the use of the Th2 cytokines 
interleukin4 and interleukin-5 (EL4, IIL-5), (Coffinan et al. 1989; Thyphronitis et al. 1993; 
Bressler et aL 1997), in other respects the two functions appear to use different pathways. 
Resistance to helminth infection exhibits both a combined ThI/Th2 response, though in IL4 
deficient mice survival of the filarial nematode Brugia malayi is unaffected despite the lack of 
a Th2 pathway (Lawrence et al. 1995). Knockouts of the high affinity receptor for IgE alpha 
chain (FczRI(x) are resistant to anaphylaxis, but respond normally to helminth infection 
(Dombrowicz et aL 1993; Jankovic et aL 1997), indicating that interactions through the 
high affinity receptor is required for allergy but not helminth resistance. Curiously, 
individuals chronically infected with intestinal nematodes have less dermal allergic reactivity 
to common allergens than helnunth-free individuals in the same environment (Lynch el al. 
1993). One explanation for this phenomenon is that IgG4 levels are high in chronically 
infected individuals (Jassim, et aL 1987; Hagan et al. 1991; Derneure et al. 1993). High IgG4 
levels have been correlated with a resistance to allergic symptoms acting through a proposed 
antagonism between IgG4 and IgE (Hagan et aL 1991; Rihet et aL 1992; Demeure el aL 
1993). 
Variable Region 






Figure 1.1. Structure of an antibody. IgE is given as an example antibody. Four 
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1.3 The genetic basis for allergy. 
Although the causes of allergy are not known, much circumstantial data and a small amount 
of genetic linkage data have lead to some theories. Present evidence suggests multiple 
genetic loci are responsible for a predisposition to allergy (Bleecker et at 1997). Several 
reports have shown a genetic linkage to serum IgE levels at chromosome 5 q3 I -q3 3 near the 
EL-41 EL- 13 and EL-9 genes, at chromosome IIq 13 near the FceRI P gene, and at several 
markers on chromosome 12q (Marsh et al. 1994; Doull et al. 1996; Noguchi et al, 1997; 
Thomas et al. 1997). Other reports have not been able to confirm the linkage to 5 q3 I -q3 3 
and IIq 13 to serum IgE levels or asthma, (Laitinen et al. 1997; Thomas et al. 1997). The 
conflicting results could be due to differences in the populations studied, combined with the 
predicted low percentage of atopics that would correspond to these mutations. 
The type 2 cytokine locus appears to have the strongest genetic linkage to allergy. IL-4 is 
required for switching to IgE in vitro (Vercelli and Geha 1992; Coffinan et al. 1993), is 
elevated in the blood of some atopics (Matsumoto et al 1994; Ohshima et al. 1995), and in 
the local environment of the nasal epithelium after allergen challenge (Durham et al. 1997). 
The T cells of atopics also produce higher amounts of I[L-4 after stimulation than non-nal 
subjects (Pene et al 1994; Stanciu et al. 1997). IIL-4 knockout mice are defective in 
switching to IgE (Kuhn et al. 199 1; Lawrence et al. 1995). IL- 13 also induces switching to 
IgE in vitro (Punnonen et al. 1997), is secreted in response to allergen challenge (Huang el 
al. 1995; Gabrielsson et al. 1997), and is elevated in the bronchial epithelium of atopics 
(Kotsimbos et al. 1996; Humbert et al. 1997). 
1.4 High affinity receptor for IgE structure, function and expression. 
The constant region of IgE binds to two receptors, a high affinity receptor (FcF-RI) and a low 
affinity receptor (FceRII, CD23). Unlike all other isotypes, IgE can remain bound to its 
constant region (Fc) receptors in a stable, long lasting complex in the absence of antigen. The 
ability to remain bound in a stable complex to its Fc receptors in the absence of antigen might 
help to explain the speed at wWch an allergic reaction can occur, and the small amount of 
allergen required for cellular activation (Davenas et al. 1988). FCZRI is expressed on 
basophils, platelets, megakaiyocyte precursors (Joseph et al. 1997), eosinopNIs (Gounni et 
al. 1994), and activated monocytes (Maurer et al. 1994), in peripheral blood, and on mast 
19 
cells, and Langerhans cells in tissue (Bieber et al. 1992; Wang et al. 1992). FcF-RI is 
composed of 3 subunits; a, P and'y2 (Fig. 1.3). The a subunit binds to IgE, the P subunit 
is involved in amplifying the signal transduction functions of the 7 chains (Lin et al. 
1996). The P chain is not expressed on Langerhans cells, suggesting it is not crucial for 
receptor function (Jurgens et al. 1995). 
Little is known about the regulation of the high affinity receptor for IgE. The expression 
of FcF-RI is regulated by some of the stimuli that control the allergic reaction and helminth 
resistance. Namely, IIL-4 stimulates FcF-RI expression in cord blood mast cells (Toru et 
al. 1996), and nasal mast cells (Pawankar et al. 1997). IgE also regulates FcF-Rl 
expression (Lantz et al. 1997; Yamaguchi et al. 1997), suggesting receptor levels are 
regulated to accommodate increases in IgE during an immune reaction. As more 
becomes known about the regulation of the high affinity receptor, strategies to control 




Figure 1.3. Structure of the high affinity receptor for IgE. The immunoglobulin domains 
(x(l) and (x(2) of the high affinity receptor alpha chain 
bind the constant region of IgE. Each of 
the (x, P andY2 chains of the receptor contain trans-membrane portions. 
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1.5 The low affinity receptor for IgE: A dual regulatory role. 
CD23 exists in both a membrane bound form, and as soluble fragments, though the two 
molecules have strikingly different roles in the regulation of IgE (for review see Gould el 
aL 1997). sCD23 up-regulates both ongoing spontaneous IgE from atopic patients 
(Sarfati et aL 1984), and acts synergistically with sub-optimal IIL-4 concentrations to 
induce IgE synthesis in human B cells (Henchoz et aL 1994). An antibody against 
CD21, which is known to interact with CD23, provides the same co-signal to B cells, 
suggesting that the stimulus from sCD23 is transduced through the CD21 molecule 
(Henchoz et aL 1994). 
Cross-linkage of membrane CD23 has the opposite effect of sCD23 on IgE secretion, 
down-regulating spontaneous IgE production by PBMC from atopic (Sherr et al 1989. - 
Sarfati et aL 1990), and inhibiting the IL-4 induced IgE synthesis from normal PBMC 
(Pene et aL 1988; Sarfati and Delespesse 1988). Cross-linkage of membrane CD23 also 
caused an inhibition of growth and differentiation of peripheral blood B cells in the 
presence of IL-4, and anti-IgM or Staphylococcus aureus Cowan A (Luo et al. 1991). 
The inhibition of B cell growth and differentiation occurred whether by anti-CD23 
antibodies, polymeric IgE, or IgE immune complexes, but the cross-linking agent was 
required at the onset of culture. The down-regulation of ongoing IgE synthesis in B 
lymphoblastic lines was found to occur by a selective suppression of the secreted form of 
IgE mRNA (Saxon et aL 1991). CD23 knockout experiments support the conclusion 
that membrane CD23 contributes to a negative feedback route for IgE, demonstrating 
that in the absence of CD23, IgE levels increase 10 to 100-fold higher than wild-type 
mice (Yu et aL 1994). Further, over-expression of membrane CD23, but not soluble 
CD23 in transgenic mice caused a weaker IgE response than wild-type mice (Texido et 
al. 1994). 
1.6 The progression of the allergic reaction. 
Upon contact with allergen both an immediate and a delayed hypersensitivity reaction occur. 
Immediate hypersensitivity occurs within minutes and is initiated when IgE bound to a mast 
cell or basophil via its high affinity receptor recognises an allergen (for review see Beaven and 
Metzger 1993; Paul et al, 1993; Sutton and Gould 1993). Cross-linking of the high affinity 
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receptor on a mast cell or basophil causes cellular activation and the exocytosis of intracellular 
granules (Fig. 1.4), which contain numerous preformed intracellular mediators of the aller(-Yic 
reaction (Galli el a[ 1993). Mast cell and basophil degranulation releases histamine, which 
causes inflammation and swelling, neutral proteases, which have a variety of roles in 
inflarnmation, and proteoglycans which serve to facilitate the uptake and packaging of the 
other preformed mediators including histamine and proteases (Redington et al. 1995, 
Metcalfe et al. 1997). In addition to preformed mediators released from granules, mast cell 
activation also causes the release of several classes of mediators synthesised de novo from 
membrane lipids, including prostaglandins and leukotrienes, which are involved in 
inflammation and swelling (Redin on et al. 1995- Metcalfe et al. 1997). Cytokines are also 9t 
released during degranulation, and produced de novo after mast cell activation, including 
TNF-(x, IILA and EL-5 each of which play a role in many events involved in delayed 
hypersensitivity (Heusser et aL 1991; Walsh et aL 1991; Galli el al. 1993; Metcalfe et al. 
1997). 
Delayed hypersensitivity occurs through cellular interactions which are only recently 
becoming known. EL-4 recruits eosinophils and lymphocytes through the up-regulation of 
cellular adhesion molecules (Metcalfe et al. 1997). Similarly, EL-5 is responsible for 
eosinophil chernotaxis, proliferation and maturation (Walsh el al. 199 1; Metcalfe et al. 1997). 
EL-4 also up-regulates acquisition of a Th2 cytokine profile in T cells 
When FcF_RI is cross-linked on the surface of dendritic cells such as Langerhans cells, the. 
allergen is presented to T cells (Bieber 1997; Stingl and Maurer 1997), up-regulating both 
immediate and delayed hypersensitivity reactions. B cells can also present allergen to T cells 
through its binding to the low affirfity receptor for IgE (Pirron et al. 1990), resulting in T cell 
activation, up-regulating both immediate and delayed hypersensitivity reactions (Fig. 1.4). 
The presentation of allergen to T cells by both dendritic cells and B cells potentially results in 
the up-regulation of immunoglobulin class switching events from IgM, IgGi_4, or IgAj to IgE 
(Grewal and Flavell 1996; Mudde et al. 1996). 
Anti-allergy strategies involving disruption of the interaction between IgE and both the high 
and low affinity receptors appear to act through an inhibition of antigen presentation by B 
cells. Humanised antibodies against the high and low affinity receptor binding sites on IgE 
have been demonstrated to reduce basophil FcF_FJ expression, serum IgE levels, inhibit 
antigen induced skin reactions, reduce rhinitis symptoms and early and late phase 
bronchoconstriction responses (Heusser and Jardieu 1997; MacGlashan et al. 1997). The 
suppression of allergen induced EL-4 and EL-5 by production T cells and eosinophil infiltration 
to the lung by the anti-IgE antibodies is maintained in mast cell deficient mice, suggesting that 
inhibition of the CD23-IgE facilitated antigen presentation to T cells is at least one mechanism 
(Coyle et al. 1996). Similarly, FaRla peptide fragments corresponding to the IgE binding 
site also inhibit mast cell degranulation in vitro and IgE mediated graft-versus-host disease in 
mice (McDonnell et al. 1996; Korngold et al 1997), through competition with the high 
affinity receptor for IgE binding. 
IIL-4, and potentially EL-5, released from activated mast cells up-regulate immunoglobulin 
class switching to IgE (Vercelli ei al. 1989, Purkerson and Isakson 1992). TNF-(x, also 
released after mast cell activation, acts synergistically on the EL-4 induction of IgE synthesis 
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Figure 1.4. The role of mast cell activation and antigen presentation by B cells in 
switching to IgE. Allergen (purple) is processed by B cells and presented to T cells in the 
context of class 11 MHC, up-regulating heavy chain switching to IgE. The cross-linking of Fa-! Rl 
on the surface of mast cells causes the release ILA which is important for the dfferentiation of 
T cells to the Th2 phenotype and as a co-stimulus for switching to IgE. 
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1.7 Heavy chain switching. 
Immunoglobulin class switching requires at least two signals, a type 2 cytokine, EL4 and EL- 
13, and a second, cell contact mediated signal (Fig. 1.4). EL4 is provided by mast cells and 
basophils upon degranulation (Paul et al. 1993), and by T cells activated by antigen 
presentation events from dendritic cells and B cells. The cell contact mediated event can be 
provided between CD40, a member of the tumour necrosis factor receptor (TNF-R) 
superfamily, on the B cell surface and the CD40 ligand on activated T cells, basophils or mast 
cells (Gauchat et al. 1993; Pawankar et al. 1997; Yanagihara et al. 1998). FccRII on 
Langerhans cells can also interact with CR2/CD21 on B cells (Pirron ef al, 1990) and through 
this interaction soluble CD23 can up-regulate IL4 induced IgE synthesis (Henchoz). 
Furthen-nore, one report suggests soluble CD23 and may also provide a second signal for 
class switching (Saxon et al. 1990). 
CR2/CD21 is also the cellular receptor for Epstein-Barr virus (EBV). EBV encoded proteins 
provide B cells with a stimulus that can replace the cell contact mediated signal in vitro and 
trigger IgE switching in the presence of HA (Thyphronitis et a[ 1989; Jabara et al. 1990). 
CR2/CD21 may therefore transduce the second signal for switching after contact with EBV 
through the same mechanism as it does for FccRIL Both the EBV latent membrane protein 
I (LNWI) and CD40 interact with TNF-R-associated factors (TRAFs) (Cheng el al. 
1995; Mosialos et al. 1995), and activate nuclear factor kappa B (NF-xB) and trigger 
activating protein- I (AP-1) via the c-Jun N-terminal kinase (JNK) cascade (Kilger et aL 
1998). EBV and the CD40-L therefore appear to share some of the same signaling pathways. 
Whether the activity of FceRII on class switching also shares parts of the same pathway is 
not known. 
Glucocorticoids can also replace the contact mediated signal for class switching in the 
presence of IL-4 iii vitro (Jabara. et al. 1991). Curiously, glucocorticoids block induction 
of the JNK signaling cascade, and consequently the JNK activated transcription factors 
NF-icB, AIM, the Ets family member Elk-1, activating transcription factor-2 (ATF-2), 
and CREB-binding protein (CBP) recruitment (Adcock et al. 1995, Caelles et aL 1997). 
Glucocorticoids interfere directly with NF-icB and AP-1 function through the physical 
interactions with the glucocorticoid receptor (Jonat et aL 1990; Schule et al. 1990, 
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Yang-Yen et al. 1990; Ray and Prefontaine 1994; Barries 1996; De Bosscher et al. 19971 
Liden et al. 1997), and up-regulate bcB synthesis (Auphan et al 1995). The interference 
with MF-icB function and the block of the JNK pathway by glucocorticoids is in apparent 
contradiction to the role of NF-icB and the JNK cascade in the EBV/CD40-L induced 
cell contact mediated signal. The mechanism of action of glucocorticoids in replacing 
the second signal is hence likely to be of a different nature than the EBV or CD40-L 
mechanism, such as through the direct transactivating potential of the glucocorticoid 
receptor on many genes (for review see McEwan et al. 1997). 
The human immunoglobulin heavy chain locus is composed of about I 100 kb of variable 
region gene segments upstream of 350 kb of constant gene segments arranged g, 8, y3,71, 
F, xV, (x 1, Py2,74, e, a2 (Hofker et aL 1989; Walter et al. 1990) (Fig. 1.5). The heavy chain 
components of IgM and IgD are produced by alternatively spliced transcripts initiating at the 
V region promoter upstream of the rearranged variable region. Immunoglobulin class 
switching to IgG, IgA, or IgE requires a DNA recombination event between a switch (S) 
region sequence upstream of the mu constant region and aS region upstream of the isotype 
to which switching is directed. 
Switch regions contain repeating pentameric units which may promote the pairing of the two 
switch regions undergoing recombination by enhancing homology between the two sequences 
(Fig. 4.5). Switch regions fall into two homology groups. Sg, SF-, and S(X form the first 
group, sharing considerable homology and containing the main pentameric units GAGCT 
and GGGCT (Mills el aL 1990). TheS71-4regions form the second group containing the 
main pentameric units GCAGG and CAGGG (Thienes and Gould unpublished 
observations). The role of the pentameric repeats and switch region topology in the 
mechanism of heavy chain recombination remains largely unknown. 
1.8 The regulation of transcription. 
Gene expression may be regulated at several levels: the activation of chromatin structure, 
initiation of transcription, processing of the transcript, mRNA stability, transport of the 
transcript to the cytoplasm, translation of niRNA. post-translatlonal modification, transport of 
the protein to the nucleus, and the stability of the protein. 
'24.2 
Eukaryotic genes typically have proximally located transcriptional control elements, 
comprising the promoter, and additional distal elements which regulate the chromosomal 
domain. Genes are regulated on the transcriptional level at the promoter by two types of 
factors. First, general factors bind to RNA polymerase to assemble the pre-initiation 
complex, which forins around the start site of transcription, and is required for the initiation of 
transcription (for transcription review, see Orphanides et al 1996, Roeder 1996, Lewin 
1997). Upstream factors, both inducible and constitutive, compose the second group and 
modulate the efficiency of initiation. 
Distal elements include enhancers and locus control regions (LCRs) which typically increase 
the likelihood of gene expression, silencers which repress expression, and insulators which 
linut control to an individual locus. Enhancer elements act to increase the activity of 
promoters at great distances from the start site of transcription (usually several kb from the 
promoter), can be located upstream, downstream or within the transcriptional unit, and 
function in either orientation relative to the start site of transcription. Enhancers potentiate 
activity from the promoter by acting to increase the probability of expression in a given cell, 
though not increasing the level of expression per cell (Martin et al. 1996). A locus control 
region (LCR), is often found at the border of a gene locus, affecting expression of the gene in 
a position independent and copy number dependent manner. The LCR is thought to act by 
exerting dominant transcriptional activating or inactivating functions over an entire chromatin 
domain by communication with enhancers and promoters and/or by modifications of 
chromatin accessibility (Martin et al. 1996). 
The transcriptional activity of genes is influenced by not only the availability of transcription 
factors, but also the access to chromatin for these factors. When the DNA template is 
wrapped around histone proteins to form nucleosomes, factor access is restricted. 
Acetylation of the core histones, causing destabilisation of nucleosomes , is associated with 
transcriptional activity (for review see Struhl 1998). Proteins associated with histone 
acetyltransferase and histone acetylase (deacetylase) activity have been shown to participate 
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acetyltransferase and acetylase activities described have been shown to be associated with the 
basal transcription machinery, as factors previously described as transcriptional coactivators 
and corepressors, respectively. The TAF130/250 histone acetyltransferase is a subunit of the 
MID complex, a basic component of the DNA polymerase II (Pol H) transcription 
machinery (Mizzen et aL 1996). The coactivator p300/CBP histone acetyltransferase is 
associated with the Pol H holoenzyme (Nakajima et al. 1997). 
One of the most intensively studied family of transcription factors associated with 
ac-Ityltransferase and acetylase activities are the nuclear-hormone receptors. The 
progesterone receptor (PR), glucocorticoid receptor (GR), estrogen receptor (ER), thyroid 
hormone receptor (TR), and the retinoic acid receptor (RXR) bind to the histone 
acetyltransferase steroid receptor coactivator-I (SRC-1) (Onate et al. 1995). Similarly, a 
second nuclear receptor coactivator, ACTR.., has also been shown to possess acetyltransferase 
activity (Chen et aL 1997). Both SRC- I and ACTR recruit the acetyltransferases CBP/P300 
and P/CAF thereby forming protein complex containing multiple histone acetyltransferases 
(Chen et al. 1997; Spencer et al. 1997). In the absence of hormone, TR and TR/RXR 
heterodimers bind corepressors which can be dissociated by thyroid hon-none in the presence 
of coactivators (Olson et al. 1998). Interaction of the corepressors silencing mediator of 
retinoic acid and thyroid hon-none receptor (SMRT) and nuclear receptor corepressor (N- 
CoR) with the nuclear receptor associates with mammalian Sin3a, which in turn recruits the 
histone deacetylase HDAC I to the receptor/corepressor complex (Alland et al. 1997; Nagy et 
al. 1997). 
1.9 The regulation of heavy chain recombination. 
Recombination in the heavy chain locus requires at least two locus control elements, the 
immunoglobulin JH-Cýt enhancer (Eýt) in the JH-Cg intron (Banedi et al. 1983; Gillies et al. 
1983; Mercola et al 1983), and the 31 immunoglobulin locus control region (LCR) 
downstream of the C(x gene in the mouse (Madisen and Groudine 1994), and both Ca 
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genes in the human (Nfills el aL 1997) Deletion of Eýt significantly reduces V region 
recombination (Chen el at 1993; Serwe and Sablitzky 1993), and recombination within the 
mu switch region (Gu et al. 1993). In Eýt deficient mice recombination occurs within and 
between downstream switch regions, though because recombination does not involve 
Sg, these are not productive switching events (Gu et al. 1993). Mutation of the 3' LCR 
affects recombination in the downstream switch regions (Cogne et at 1994), but does 
not affect variable region assembly or recombination within Sg. 
Prior to switch recombination, transcription occurs through the mu locus and within the 
constant region locus to which switching is directed (for review see Vercelli and Geha 1992, 
Coffman et al. 1993). In each case transcription (germline transcription) begins in a short 
exon (germline exon, I exon) upstream of the switch region and proceeds through the 
constant region (Fig 1.6). The germline exon contain translation stop codons in each reading 
frame and no protein products have been detected. Gem-dine transcription is a required event 
for switch recombination. Deletion of the Iyl or 1y2b exons and their promoters resulted in 
the inhibition of class switching to the corresponding genes (Jung ef al 1993; Zhang el al. 
1993). Potentially, one function of gen-rdine transcription could be to maintain or participate 
in the initiation of locus accessibility, either by the act of transcription itself, or by the 
associated activity of transcription factors involved in chromatin accessibility such as the 
histone acetyltransferase p300/CBP (Ogryzko et al. 1996). Some evidence suggests that 
gem-dine transcripts function in the mechanism of switch recombination. Conservation of the 
germline exon 3' splice donor sequence is required in addition to transcription for non-nal 
levels of switch recombination, suggesting that a correctly spliced germline transcript is 
required (Lorenz et at 1995). Additionally, transcripts from the murine Sa region form a 
strong tri-molecular complex with the switch region in vitro (Reaban et at 1994), 
suggesting they maintain accessibility to the recombination apparatus by disrupting the 
helix or by excluding nucleosomes from the switch region. The existence of trans- 
spliced germline transcripts also suggests a role of chimeric transcripts in the alignment 
of the two switch regions during recombination (Fujieda et at 1996). 
Gem-dine transcription in all the murine downstream loci except 71 are significantly reduced 
upon inactivation of the 3' LCF, suggesting that the LCR regulates germline 
transcription in addition to recombination. The presence of an enhancer immediately 
upstream of the GL-, yI exon (Xu and Stavnezer 1992), suggests the 
independence of 71 
germline transcription from the 3' LCR could be through the activity of this enhancer. 
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Figure 1.6. The mechanism of heavy chain recombination. (A) Prior to heavy chain 
switching, transcription occurs initiating at germline (1) exons in the heavy chain locus 
upstream of the mu switch region (Sg), and after IL-4 stimulation, from IE. Transcription 
proceeds through the respective constant region, producing a germline transcript (B-E). (G) 
In the presence of CD40 engagement on the B cell, recombination between SP and Sc can 
occur allowing production of a VDJ containing IgE transcript (H, ý, and protein (0. 
n8 
Stimulation of B cells through the cell contact mediated signal for switching, CD40 
engagement, may work in part through the activation of the 3' LCR. CD40 engagement 
causes up regulation of 3' LCR activity (Grant et al, 1996). Consequently, many of the 
transcription factors known to be activated by the JNK cascade after CD40 engagement are 
also involved in the regulation of the LCF, including NF-kB, AP- 1, and Elf- 1, (Grant et al. 
1995; Linderson et al. 1997). 
The transcription factors NF-icB and BSAP and C/EBP have been found to participate in the 
regulation of many of the germline gene promoters and elements characterised in the 
immunoglobulinCH locus, suggesting a co-ordinated regulation of the region. NF-ICB is 
involved in regulation of the 3' LCF, and the germline gene promoter for murine epsilon 
(Delphin and Stavnezer 1995). C/EBP family members are involved in the regulation of 
the E and 'y I germline genes (Lundgren et al. 1994; Delphin and Stavnezer 1995). The B 
cell-specific transcription factor (BSAP/PAX-5) is involved regulation of the 3' LCR and 
the F, germline gene (Singh and Birshtein 1993; Neurath et al. 1994; Michaelson el al. 
1996). BSAP has also been shown to bind at multiple sites within the murine IgH locus, 
including the region 5' of Sy2a, a segment downstream of Ca, at two sites upstream of 
Ca, and in Sýt (Waters et aL 1989; Liao et aL 1992; Xu et aL 1992). The existence of 
multiple binding sites for NF-icB, C/EBP, and BSAP raises the possibility that these 
factors mediate physical interactions between the LCR and the germline gene promoter 
elements. NF-iCB has been shown to physically interact with Ets family members in the 
activation of the HIV enhancer in T cells (Bassuk et al. 1997) and with the Ets family 
member Elf-I in the activation of the interleukin 2 receptor alpha-chain gene (John et al 
1995). NF--KB also physically interacts with the bZIP region of several C/EBP family 
members (Stein et aL 1993). The role of several Ets proteins in the regulation of the 3' 
LCR (Grant et al. 1995; Linderson et al. 1997), and of C/EBP factors in the regulation of 
the e-germline gene (Delphin and Stavnezer 1995), suggests that NF-KB may also 
interact with these factors in the immunoglobulin locus. BSAP has been shown to 
physically interact with octamer binding proteins in its repression of the 3' LCR (Singh 
and Birshtein 1996), to block the binding of the Ets family member NF-ccP during this 
repression, and to recruit Ets family members to the early B-cell-specific mb- I promoter 
(Fitzsimmons et al 1996). The potential of physical interactions between NF-KB, C/EBP, 
BSAP and Ets famýily members supports the idea that these factors aid in the communication 
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of the 3' LCR with the germline promoters by protein-protein interactions. A better 
understanding of the regulation of F--germline transcription may allow the design of new 
anti-allergy strategies to control this important step in the mechanism of heavy chain 
switching to IgE. 
1.10 The glucocorticoid potentiation of IgE secretion. 
Glucocorticoids are used extensively to control the symptoms of allergy through their anti- 
inflammatory effects (for review see Schleirner 1996; Schwiebert et al. 1996). Endogenous 
glucocorticoids are secreted from the adrenal gland and attenuate both allergic inflammation 
as well as the general inflanu-natory response (Wilckens and De Rjjk 1997). A variety of 
mechanisms of action are proposed to account for the activity of glucocorticolds on allergy. 
One mechanism suggests glucocorticoids inhibit inflammatory cell rnigration, potentially 
through an effect on the synthesis of cytokines that control the expression of adhesion 
molecules on endothelial cells, or through an affect on inflammatory cell activation. 
Glucocorticoids inhibit the secretion of the cytokines IL-4, IL-5, IL-8, EL-10, EL-12, UL-13, 
RANTES, and GM-CSF from epithelial cells and peripheral blood mononuclear cells (Sousa 
et al. 1993; Kwon et al. 1994; Kwon ef al. 1995; Brattsand and Linden 1996; Elenkov el al. 
1996; Ghaffar et & 1997). Suppression of the type 2 cytokines EL-4 and EL- 13 is thought to 
reduce rhinitis in pan through an inhibition of localised immunoglobulin isotype switching to 
IgE, as evidenced by a reduction in the expression of the gem-dine gene transcript for IgE in 
the nasal epithelium (Durham et aL 1997). 
Consistent with the effects on allergic symptoms, in vivo levels of allergen specific IgE 
decrease after steroid treatment (Crimi et al 1990; Naclerio et aL 1993). In contrast, total 
IgE levels are unchanged or are moderately increase after treatment with corticosteroids 
(Gunnar et al. 1970; Henderson et al. 1973; Posey et al. 1978; Settipane et aL 1978, Klebl et 
al. 1994; Zieg et al. 1994). In vitro, the effect of glucocorticoids on total IgE is more 
pronounced. Glucocorticoids significantly increase EL-4 induced total IgE levels in cultures 
of peripheral blood mononuclear cells (Wu et al. 199 1; Nusslein el al. 1994). Spontaneous 
IgE secretion is also increased by glucocorticoids in cultures of peripheral blood mononuclear 
cells (PBMQ in the absence of IIL-4 (Kimata et al. 1995; Hiratsuka el at 1996). 
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Little is known about the mechanism of the up regulation of IgE synthesis by glucocorticoids. 
The potentiation of IgE secretion from PBMC in vitro is monocyte dependent (Wu et al. 
1991). Enhancement still occurs when glucocorticoid is added as late as day 6 after initiation 
of the culture, suggesting it still acts at the EL4 independent stage of the IgE response. 
However, the potentiation of IgE synthesis in PBMC cultures may occur by a different 
mechanism than with purified B cell cultures. When glucocorticoid is added to purified B 
cells in the presence of IIL-4 it replaces the cell contact-mediated signal for class sWItching, 
and unlike its potentiation of IgE synthesis with PBMC, it is not monocyte dependent and 
requires glucocorticoid at the onset of culture (Jabara et aL 1991). More work is needed to 
elucidate the mechanism of the enhancement of IgE synthesis in PBMC, as a model of the 
events that occur in Wvo. 
1.11 Conclusions. 
Because of the central role of IgE and its high affinity receptor in allergy, a more clear 
understanding of the regulation of this ligand/receptor pair is needed to allow for the infori-ned 
design of new anti-allergy strategies. A better understanding of heavy chain recombination 
could also help to elucidate how switch region sequence, and the regulation of transcription 
and chromatin accessibility are involved in the mechanism of recombination. 
Chapter 3 describes the cloning and structure of the gene for the high affinity receptor for 
IgE. Sequence analysis of the upstream region of the gene for FczRI(x revealed a 
polymorphism that could be linked to allergy in the putative promoter region. In chapter 4 
the heavy chain recombination junction of the IgE secreting myeloma U266 is analysed. The 
sequence of the recombination junction was found to reveal a prior switching event to IgA 1. 
Recombination between the switch mu and switch alpha-I regions occurred at an areas of 
homology between Sýt and Sal. The germline gene transcript for IgE is cloned and 
characterised in chapter 5. The role of the B cell specIfic transcription factor 
BSAP/PAX-5 in the IL-4 and CD40 mediated up-regulation of F--germline transcription 
is demonstrated in chapter 6. In chapter 7, the mechanism of the glucocorticoid 
potentiation of IgE synthesis is investigated. IgE enhancement was 
found to occur only 
after 10 days of glucocorticoid addition in vitro. Gem-dine gene and productive epsilon 
transcription was not affected 4.5 days after glucocorticoid addition. 
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CHAPTER 2: Materials and Methods. 
2.1 END LABELLING. 
Kinasing: T4 polynucleotide kinasing was performed exactly as described by the 
Promega Biotec cycle sequencing protocol. 10 pMol oligonucleotide dried down to 
removed inhibitory NTi4+ residue, and resuspended in dH20. I 4L of T4 polynucleotide 
kinase buffer (Promega, Madison, WI), 3 gL 3000 ci/mMol (or 5 gL 5000 ci/mMol) 
Y 32p-ATP, :! ýl wk past activity date, 5 units of T4 polynucleotide kinase (Promega, 
5u/gL), were added in a final volume 10 gL. The reaction was incubated at 37'C for 45 
minutes, at 95'C for 5 minutes. The reaction was stored at -20'C. Typically, the kinased 
oligonucleotide was purified on 20% acrylamide gel (see 2.11 ACRYLAMIDE GEL 
ISOLATION); agarose leaves too much label contamination. 
3' End Filling: First, I pMoI of 3' ends was prepared, devoid of free nucleotides. 5 gL 
of IOX Promega, buffer D (150 mM NaCI), 2 gL 10 mM each dNTP except the 
nucleoticle to be labelled, 5 gL (X32p-dNTP (3000 ci/mMol, 10 gci/gL, :! ý2 weeks from 
activity date), 100 gg/m. L BSA, dH20to a total volume of 49.5 gL, and 0.4 gL Klenow 
polymerase (New England Biolabs, Beverly MA) were added to the DNA. The reaction 
was incubated at room temperature for 30 minutes, 2 gL 10 m. M unlabelled dNTP (same 
nucleotide as the labelled one) was added to chase, with 0.4 gL Klenow polymerase, and 
incubated at room temperature for 30 minutes. If needed, the DNA was purified on an 
acrylamide gel (see 2.11 ACRYLAMIDE GEL ISOLATION). 
2.2 T4 BLUNT ENDING 
I pMol of 5' or 3' overhang ends was mixed with 5 gL I OX polymerase buffer (or any 
restriction enzyme buffer), I gL 10 mM dNTPs, 100 gg/mL BSA, 2 units T4 polymerase 
(New England Biolabs, Beverly, MA), and dH20 to a total volume of 50 4L. The 
reaction was incubated at 12'C for 60 minutes, phenol extracted, and precipitated. 
li 
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2.3 PLASMID PREPARATION 
For restriction analysis, the Birnboim plasn-ýd DNA mini-preparation procedure was used 
[Birnboim, 1983 #477]. For DNA sequencing the Promega (Madison, WI) mini- 
preparation kit was used, exactly as described in the manufacturer's protocol except that 
RNase digestion containing 50 gg/mL RNase A was performed at the neutralisation step. 
Birnboim Plasmid Mini-Prep Method (adapted from Birnboim 1983): E. coli bacteria 
were inoculated into 1.75 m. L (or for 15 m. L, in parentheses) Terrific Broth (Sambrook et 
aL 1989) with 50 gg/mL ampicillin, and grown to full density or overnight. The culture 
was spun in an Eppendorf tube (Falcon 2057 or 14 mL, Becton Dickinson, San Jose, 
CA. ) to produce a cell pellet. The pellet was resuspended in 200 gL (1.6 m. L) of 
Solution 1 (50 mM glucose, 25 mM Tris pH 8,10 rnM EDTA). 400 gL (3.2mL) of 
fresh Solution 11 (0.2 N NaOH, 1% sodium dodecyl sulphate: NaOH added first and 
mixed) was added. 300 RL (2.4mL) of Solution 111 (14.7 g of KC1,5.75 rnL of glacial 
acetic acid, total volume of 50 mL) was added. The tube was spun for 5 minutes in a 
micro-centrifuge at 4'C, and the supernatant was retained. The supernatant was phenol 
extracted one time with 2 volumes phenol, one time with phenol/CHC13 (1: 1), and once 
with CHC13- One volume of ethanol was added, the precipitated was spun in a micro- 
centrifuge for 5 minutes, and the supernatant aspirated. The pellet was washed with cold 
70% ethanol and dried in a Speedvac. The pellet was resuspended in 100 gL l0m. M 
Tfis-HCl pH 8,0.1 mM EDTA (TE) with 50ýtg/ml, RNase A and stored at -20 C. If an 
RNA free preparation was required, the supernatant from step 6 was precipitated with 
ethanol, washed with 70% ethanol and resuspended in TE, and 50 ýtg/ml, RNase A was 
added. After 1-2 hour at 37'C the DNA was phenol extracted, chloroform extracted and 
lastly spun through a Sephadex G-50 column equilibrated in TE. 
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2.4 PREPARATION OF ssDNA FROM PHAGEMID (eg BLUESCRIPT) CLONES. 
A. Preparation of helper phage stock: 
Materials: Top agar consists of L broth with 0.7% agar (Sambrook el al. 1989). E 
coli BB4 was obtained from Stratagene (La Jolla, CA). Tetracycline 12.5 mg/mL 
(1000x) was dissolved in 50% ethanol. L plates consist of L broth with 1.5% agar. The 
helper phage stock was titred as described below every one or two months. 
Method: The rec+ fý bacteria strain BB4 was plated on selective media (tetracycline, 
12.5 gg/m. L) to ensure the presence of the f-factor. The bacteria was grown L broth 
(with tetracycline) overnight or to confluence. Top agar was melted and cooled to 42T. 
A dilution series of helper phage was prepared in L broth assuming the phage stock was 
10 10 plaque forming units (PFU) per rnL or less. 100 ýtL of bacteria was combined with 
a dilution of helper phage and 3 mL of top agar, and quickly poured on aL plate warmed 
to room temperature. The plate was incubated overnight at 37'C. 3 m. L of L broth was 
added to a plate that was confluent (no plaques visible) and was agitated on a shaker at 
room temperature for I hour. The L broth was collected with a pipette and the cells 
were spun out at 10,000 RPM for 10 minutes. The supernatant was incubated at 65'C 
for 10 minutes to kill the remaining bacteria. The phage stock was titred as described 
above and stored at 4'C. The titre was normally about 10'0 PFU/mL. 
B. Infection of bacteria with helper phage: 
Materials: Ampicillin 50 mg/mL (1000x) in dH20was filter sterilised. Kanamycin 100 
mg/mL (I 000x) in dH20was filter sterilised. Tetracycline 12.5 mg/mL (1000x) was 
dissolved in 50% ethanol. SOB or 2X-YT medium were prepared as described in 
Sambrook et al (1989). Helper phage M13KO7 was obtained from Promega (Madison, 
WI) or VCSM13 was obtained from Stratagene (La Jolla, CA). 
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Method: The phagemid was introduced into a rec+ 0- bacteria by transformation or by 
mating the f-factor from BB4 into a rec+ strain containing the phagemid. E. coli BB4 
was the simplest to use, as the f-factor can be selected for by growing in the presence of 
tetracycline. 
Mating protocol:. a) To mobilise the f-factor and phagemid into the same bacterial cell, 
both the strain containing the phagen-ýid, and BB4 were grown and to confluence. BB4 
was grown in the presence of 12.5 mg/mL tetracycline, and the phagemid containing 
strain with 50 gg/mL ampicillin. b) The residual antibiotics were washed from the 
bacteria by centrifuging the cells in a micro-centrifuge and resuspending them in a few 
m. L of L broth. A drop of each culture was combined together on aL plate (no 
antibiotics) and allowed to mate the bacteria for 4-6 hours at 37'C. c) The bacteria 
were inoculated with a bacterial loop on an L plate containing tetracycline and ampicillin 
to select for the f-factor and the phagemid, respectively. The plate was incubated less 
than 18 hours at 37T. The efficiency of mating can be as great as I in 10. 
From a plate containing a selection for both the phagemid and the f-factor, an overnight 
liquid culture was grown containing the antibiotics ampicillin and tetracycline. The 
antibiotics were washed from the medium, 200 [tL of the culture was inoculated into 5 
mL SOB or 2X-YT media without antibiotics, 150 ýtL of helper phage (5 x 109 PFU/mL 
or better) was added, and the culture was incubated with agitation for I hour at 37'C- 
After I hour 100 ýig/mL of kanamycin was added to select for infection by the helper 
phage, and the culture was incubated for a further 4-6 hours. 
Extraction of ssDNA from phage: 
Materials: 40% Polyethylene glycol (PEG) 8000,5 M sodium acetate pH 7, saturated 
ammonium acetate (=I 0 M) - 
Method: The cells from above were centrifuged at 10,000 RPM for 10 minutes. To the 
supernatant 1/9 of the volume of 5M NaOAc pH 7 and 1/9 of the volume of 40% PEG 
8000 were added and mixed thoroughly. The phage were precipitated for 15 minutes at 
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room temperature. The precipitate was centrifuged at 10,000 RPM for 10 minutes and 
the supernatant was withdrawn. The pellet was centrifuged again for 10 minutes and the 
remaining supernatant was removed . The pellet was usually barely visible. The pellet 
was resuspended in 200 ýtL of I OmM tris-HCI pH 8,0.1 mM EDTA (TE) by freeze/thaw 
cycles if necessary, but vortexing was avoided. The DNA was extracted with two 
volumes of phenol once, and two volumes of phenoUCHC13/1soamyl alcohol 25: 25: 1 
until only a small amount of debris remained at the interface and 0.25 volumes of 10 M 
ammonium acetate and 2.5 volumes of ethanol were added. The DNA was precipitated 
for 10 minutes on ice, spun in a tnicro-centrifuge for 30 minutes at 4'C, and the pellet 
was washed in 70% ethanol, dried and resuspended in 20 ýtL dH20. The DNA was 
stored at -20'C. The concentration was estimated using I ýtL of the DNA against 0.5 ýtg 
of ssDNA of known concentration on an agarose gel. 
2.5 GITC/PHENOL METHOD FOR THE EXTRACTION OF RNA. (modified 
from Chomczynski and Sacchi 1987) 
Solutions: Solution D: 4M guanidine isothiocyanate (GITC), 25 mm sodium citrate, 
pH 7,0.5% sodium lauryl sarcosinate, o. 1% Antifoam A (added fresh, I ýtL per I mL 
solution D), 0.7% 2-mercaptoethanol (added fresh, 7 ýtL per I mL solution D). To make 
solution D, GITC was dissolved at 50'C and sodium citrate and sodium lauryl 
sarcosinate were added This solution was stored at room temperature for months. 
Antifoam A and 2-mercaptoethanol were added on the day of the extraction. Milli-Q 
dH20was used as a source of RNase-free water, as diethyl pyrocarbonate (DEPQ 
treatment (Sambrook et al. 1989) reduces the template activity for enzymes. 10 M 
ammonium acetate ((NH4)20Ac) was made with RNase-free water. Phenol 
(AquaPhenol, Appligene, Illkirch, Fr) was equilibrated by mixing with an equal volume 
of water. 5: 1 Aquaphenol: CHC13/IAA was centrifuged to removed water and made 
fresh). 70% ethanol was made with RNase-free water. 
Materials: The following plastics were used without DEPC treatment: Prepackaged 
pipette tips (preferably filter tips), sterile screw-cap Eppendorf tubes (Scotlab, 
Coatbridge, Scotland), or others, except Sarstedt which break), and sterile disposable 
plastic tubes. 
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Method: (A) For 107 cells-. First, the cells were pelleted and supernatant was 
withdrawn. The cells were not washed and were frozen at -700C as a pellet. 0.4 mL of 
solution D (but no less than 4 volumes of the cell pellet with residual medium) was added 
to the cell pellet with aI mL syringe and a 26 gauge needle. The cells were immediately 
broken up by forcing the lysis solution and cells through the syringe repeatedly until the 
lysate was homogeneous. More solution D was added if the pellet was too viscous. 
Homogenization was continued an additional 10 times to shear the DNA. The lysate was 
transferred to an Eppendorf tube with 2 volumes of Aquaphenol/CHC13/IAA (5.1), 
mixed and cooled on ice for 15 minutes. The extraction was spun for 20 minutes at 4'C 
in a micro-centfifuge or at 10,000 RPM in a Sorvall. The aqueous phase was retained. 
If the interface was a large volume of the aqueous layer, it was back extracted by adding 
half the original volume of solution D to the remaining phenol/CHC13 and repeating step 
3. The aqueous phases were pooled from both extractions and extracted again with 
phenol/CHC13. The phenol/CHC13 extractions were repeated until only a fine layer of 
debris was left at the interface of the phases. The lysate was extracted once with 
CHC13/Iso amyl alcohol 25: 1.0.5 volumes of ethanol was added and the RNA was 
precipitated overnight at -20'C, or 30 minutes on ice if in a hurry. The precipitate was 
spun at 4'C for 30 minutes in a micro-centrifuge, or 10,000 RPM in a Sorvall, washed in 
ice cold 70% ethanol, and micro-centrifuged at 4'C for 10 minutes. The RNA was 
resuspended in 100 ýtl, dH20, if necessary by repeated cycles of freeze/thaw/vortex. The 
RNA was kept on ice when thawed. 0.25 volumes of (NH4)20Ac was added to the RNA 
and mixed, 2.5 volumes ethanol was added . snap-frozen on 
liquid N2, and left on ice for 
10 minutes. The precipitate was micro-centrifuged at 4'C for 30 minutes . The pellet 
was washed with ice cold 70% ethanol, micro-centrifuged for 10 minutes and then 
vacuum dried. The RNA was resuspended in dH20(about 100 ýtl, for 107 cells), and 
stored at -70 C. RNA concentration was estimated against a control of 
known 
concentration, by comparing the intensity of ribosomal bands after agarose gel 
electrophoresis in ix tris borate gel running buffer (TBE) in the presence of ethidium 
bromide. If no degradation occurred, the 28S ribosomal band was 2-3x the intensity of 
the 18S. If the 28S/18S ratio was less, then degradation occurred. The concentration of 
the control was determined by A26o as described in Sambrook et al (1989). 
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(B) For I cell to 5x 106 cells: The same method as described above was used except that 
E. coli Ribosomal RNA (#206 938, Boehringer Mannheim, Mannheim Germany) was 
added at 100 ýtg/mL and at least 0.1 mL of solution D was used. The concentration was 
estimated by probing for a control transcript such as P-actin and comparing this signal 
against that of an RNA preparation of known concentration. The RNA was resuspended 
in 20-100 ýtL of dH20- 
2.6 RNA EXTRACTION: CsCl/Tabletop Ultracentrifuge. 
Method: Less than 5XI08 cells were centrifuged at 1,200 RPM for 10 minutes, and not 
washed. 2.2 mL GITC lysis buffer (4 M GITC, 0.1 M Tris pH 7.5,1% P- 
mercaptoethanol, added just before use) was added to the cell pellet with a syringe 
containing a 25-27 gauge needle. The cells were homogenised quickly until the lysis was 
complete and continued for another 10 times. Sodium lauryl sarcosinate was added to a 
concentration of 0.5% (using a 10% solution). With a cut off P1000 tip, the lysate was 
carefully layered onto 0.83 mL of CsC1 solution (5.7 M CsCl, 10 MM EDTA pH 8) in a 
Beckman Polyallomer tube (no. 349623 Beckmann Instruments, Fullerton, CA). The 
gradient was centrifuged at 70,000 RPM for 3 hours in a TL100.3 rotor (Beckmann 
Instruments, Fullerton, CA). The lysate was aspirated to just below the top of the CsCl 
cushion. With a hot scalpel, or razor blade, the top was cut off of the tube just above the 
liquid level. The remaining solution was removed and washed with 80% ethanol. 100 
gL phenol/chloroform and 100 gL dH20 were added and the pellet was transferred to 
an Eppendorf tube. The RNA pellet was resuspended completely by repeated cycles of 
freezing, thawing, and vortexing. 0.25 volumes of saturated (10 M) NH40Ac was 
added and the RNA was spun in a micro-centrifuge. To the supernatant was added 2.5 
volumes of ethanol. The RNA was cooled in liquid N2, precipitated 10 minutes on ice, 
and spun for 30 minutes in a reffigerated micro-centrifuge. The pellet was washed with 
cold 80% ethanol, and resuspended in 50-400 ýtL dH20 by freeze/thaw/vortexing. 0.25 
volumes NH40Ac and 2.5 volumes ethanol, were added to the RNA, which was then 
cooled on liquid N2, micro-centrifuged, and washed. The tube was spun again for 1-2 
minutes and the last traces of ethanol were removed with a pipette tip. The pellet was 
Speedvac dried, resuspended it in dH20, and stored it at -800C. 
-I 
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2.7 SEMI-QUANTITATIVE RT-PCR. 
Materials: cDNA synthesis: Pre-packaged plastic tips and tubes, unopened chemicals 
and Milli-Q water were assumed to be RNase ftee, therefore diethyl pyrocarbonate 
(DEPQ treatment was not performed. 
Materials PCR: Filter pipette tips were used if possible to avoid cross contamination. 
cDNA synthesis: Less than 5 gg of RNA was brought to a volume of 10.2 ýtL with 
dH20. The RNA was kept on ice for only a few minutes before cDNA synthesis, to 
avoid degradation. The RNA was heated to 700C for 2 minutes and cooled on ice for I 
minute. 8.1 gL cDNA mix was added; per reaction: 4 gL 5X cDNA buffer (Gibco 
BRL/Amersham Life Sciences, Arlington Heights, IL), 1.6 gL 10 mM dNTPs, 0.5 gL 2 
gg/gL random 10 base oligonucleotides (10 mers), 2 gL 100 mM dithiothreitol 
(Gibco/BRL), 0.7 gL RNase inhibitor, I gL murine-Moloney leukaemia virus reverse 
transcriptase (M-MLV RT, Gibco/BRL #28025-013) and incubated 370C 60 minutes 
Oligonucleotide kinasing (as Promega cycle sequencing protocol): 10 PMOI 
oligonucleotide was dried down to removed inhibitory NH4+ residue and resuspended in 
dH20- I gL buffer (Promega, Madison, WI), 3 gL 3000 ci/mMol (or 5 gL 5000 
Ci/mMol), Y32p-ATP, 5 units T4 polynucleotide kinase (5 u/gL, Promega, Madison, WI) 
was added and the reaction was brought to a final volume of 10 gL with dH20. The 
reaction was incubated at 37'C for 45 minutes, and then 95'C for 5 minutes to denature 
the kinase. 
Polyrnerase chain reaction (PCR): A master mix was made of (per reaction) 14.05 ýLL 
dH20,2 ýtL I OX Buffer (including 15MM MgC12, Promega), 0.4 ýtL 10 mM dNTPS, 0.2 
gL 100 ýM oligonucleotide A, 0.2 gL 100 gM oligonucleotide B, 0.4 ýIL (or less) 
kinased oligonucleotide A or B, 0.1 gL polyoxyethylenesorbitan monolaurate (tween 20), 
mixed well, and 0.05 gL Taq polymerase (Promega 4.5 units/gL) was added. 18 ýtL of 
the master mixture was added per reaction and 2 gL (or less) cDNA. 3 drops (from a P- 
.1 
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1000) of mineral oil was added to each tube prior to PCR. After the PCR part of the 
reaction was run on a 4% polyacrylamide gel in IX Tris borate gel running buffer (TBE) 
and dried the gel before exposing. 
Quantitation: Quantitation was performed by a phosphor-imaging, using a GS525 
phosphoimager (Biorad, Hercules, CA. ), and integrating the digitised bands with 
Molecular analyst software. 
2.8 PRIMER EXTENSION. 
Materials: Milli-Q water, and pre-sterilised disposable plastics were assumed to be 
RNase free. Diethyl pyrocarbonate (DEPQ was not used, as it degrades template 
activity significantly. 10-50 gg CsCl isolated total RNA was used and checked on 
Northern gel for integrity. 
Method: An oligonucleotide kinased with >5000 Ci/rrMol t32p-ATP was purified on a 
Superfine Sephadex G-25 superfine column, made with a silanised Pasteur pipette. 50- 
100 ýtL fractions were taken, because the oligonucleotide and the unincorporated peaks 
travel very close together. For the annealing reaction, 1.5 gL I OX Annealing Buffer (1.5 
M KCI, 0.1 M Tris pH 8.3,10 mM EDTA), I gL Oligonucleotide (less than I pMol, but 
the quantity needs to be adjusted for each reaction), 12.5 gL RNA were added, and the 
reaction was incubated for 10 minutes at 65'C,, and 1.5 hour at the annealing 
temperature which was calculated as for PCR (T,, = 16.6Log[NaCl or KCI] 
0.41(%GC) + 81.5 - 675/length + IO'C). The reaction was cooled slowly (30-60 
minutes) to 37'C. 27.7 gL of extension mixture (per reaction) containing 16 gL dH20, 
0.125 gL IM Tris pH 8 (at room temperature), 0.625 gL, IM Tris pH 8.3 (at 42'Q 
0.4 5 gL, IM M902,0.45 gL 5 mg/mL actinomycin D, 50 gg/mL (in ethanol, 
Calbiochern La Jolla, CA), 2.25 gL each 100 mM dNTP (in dH20, Pharmacia), 0.563 
2M KCI and 0.45 ýtL 100 mM DTT were added. 2.3 ýtL M-MLV reverse 
transcriptase (Gibco BRL/Amersham Life Sciences, Arlington Heights, EL 28025-013) 
was added, and the reaction was incubated at 37'C for I hour. 6 gL 0.5 M EDTA, 100 
.9 
40 
gL TE and I gL 10 mg/mL Boiled RNase A was added, and the reaction was incubated 
at 37'C for 30 minutes. 38 gL saturated NH40Ac (=10 M) was added, the reaction was 
phenol/CHC13 extracted, and transferred to a silanised tube. 530 ýtL of ethanol was 
added and the precipitate was cooled on liquid N2, and the DNA was incubated on ice at 
least 15 minutes. The precipitate was micro-centrifuged at 4'C for 30 minutes, washed 
with 80% ethanol, and all the supernatant was withdrawn. The pellet was dried to 
completion in a Speedvac. 4-5 gL of formamide loading buffer was added to the pellet, 
it was heated at 95'C for 3 minutes, and run on a sequencing gel against a sequencing 
ladder as a marker, priming with the same end-labelled oligonucleotide. 
2.9 Sl NUCLEASE PROTECTION (Chapter 5). 
An SI probe was generated as follows: 2.5 ýtk[ of oligonucleotide Q 
CCATTTGGTGCCTGTGGATGGTGTG (227-251 of the human germline epsilon 
gene), was dried and resuspended it in 6.75 gL dH20,1.25 gL IOX T4 polynucleoticle 
kinase buffer (Promega Biotec, Madison, WI), 4 gL 3000 Ci/MMOI 
23 P-, yATP, 5 units of 
T4 polynucleotide kinase, incubated at 37'C for I hour, and 95'C for 5 minutes. Single 
stranded DNA from a 2.75 kb Kpn I-Hind III clone of the germline epsilon locus cloned 
into Bluescript was made by the "ssDNA preparation procedure" above. The 
"Sequenase" annealing procedure was followed to anneal the oligonucleotide to the 
template: 12 gL of 100 ng/mL of the 2.75 kb Kpn I-Hind III clone was added to 4 gL of 
the kinased oligonucleotide Q and 4 gL 5X "Sequenase" buffer (Amersham Life 
Sciences-USB, Arlington Heights, IL), heated to 70T for 2 minutes, and annealed by 
cooling to 35T for 30 minutes. 0.4 gL of a 10 mM mixture of dATP, dCTP, dGTP,, 
and dTTP was added to the annealing reaction along with 8 ýtL dH20, I ýtL 
0.1 M 
dithiothreitol, and 0.6 gL Sequenase T7 polymerase, and incubated at 37'C for 15 
minutes. I ýtL of BSA, 144 gL of dH20,20 gL of IOX Pst I buffer, and 40 units of Pst 
I was added to the reaction, and it was incubated for I hour at 37'C. The reaction was 
phenol extracted, and precipitated with 500 gL ethanol. The single stranded probe was 
isolated on a 4% polyacrylamide/urea sequencing gel. 
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5 gL (10 gg) of total RNA in from PBMC induced for 4 days with IL-4 was added to 5 
gL hybridisation buffer containing 20% polyethylene glycol 8000 80 MM piperazine-1,4- 
bis-(2-ethanesulfonic acid), 800 mM NaCl, 2 mM EDTA, and 1/80 th of the probe 
preparation. The samples were boiled for 10 minutes, and incubated at 701C for 30 
minutes. 300 gL of warm SI digestion buffer was added, containing 280 MM NaCl, 30 
mM NaOAc pH 4.8,4.5 mM ZnS04,20 gg/mL boiled calf thymus DNA, and 200 units 
SI nuclease (Boehringer Mannheim, Mannheim Germany). The reaction was incubated 
at 45'C for 30 minutes. 75 gL of termination buffer was added, containing 2.5 M 
NH4OAc,, 50 mM EDTA, and 170 ýtg/mL yeast tRNA (Boehringer Mannheim, 
Mannheim Germany). Two volumes of ethanol were added, the tube was cooled on 
liquid N2, and incubated on ice for 10 minutes. The precipitate was spun in a refrigerated 
micro-centrifuge for 90 minutes, washed 2 times in 80% ethanol, and dried completely in 
a Speedvac. The pellet was resuspended in 4 gL formamide loading buffer, denatured at 
95'C for 3 minutes, and loaded onto a 6% acrylamide/Urea sequencing gel. A 
sequencing ladder was used as a marker, with the same 3' end labelled oligonucleotide Q 
for the sequencing primer as for synthesis of the SI analysis probe. 
2.10 BACTERIAL COLONY PCR 
Colony isolation: A visible amount (o. 1 -1 ýtL) of a bacterial colony was picked from a 
plate with a Pipetteman. The colony was often several days old. The bacteria were 
added to 100 ýtL of TE in a micro-centrifuge tube. Often, 10-20 colonies were pooled 
into one tube. The suspension was vortexed, boiled for 5 minutes, cooled, micro- 
centrifuged briefly, vortexed again and micro-centrifuged for 30 sec in a micro-centrifuge 
to pellet the debris. 
A 
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PCR: 2 ýtL bacterial lysate was added to 18 gL of PCR mixture, composed of (per 
reaction) 15.05 ýtL dH20,2 ýtL I OX PCR buffer (containing 1.5mm MgC12, Promega, 
Madison, WI), 0.4 ýtL 10 mM dNTPs (mixture of all four), 0.2 ýtL 100 ýtM 
oligonucleotide A, 0.2 ýtL 100 ýtk[ oligonucleotide B, 0.1 ýtL Tween 20, and 0.05 4L 
Taq polymerase (Promega 4.5 U/ýtL). 3 drops (from a P-1000) of heavy paraffin oil was 
added to each tube. The PCR was cycled 30-40 times at 94'C for I minute, at the 
annealing temperature for I minute, and at 74'C for I minute. The annealing 
temperature was calculated as follows: (T. = 16.6Log[NaCl or KCI] + 0.41(%GC) + 
81.5 - 675/length +I O'C). 
2.11 ACRYLAMIDE GEL ISOLATION. 
A sample of DNA was on a non-denaturing acrylamide gel, using either 4 gg unlabelled 
or 0.5 ýtL end labelled low molecular weight marker (MspI Bluescript SK+) in 0.5X 
TBE (Sambrook et aL 1989). If the DNA was unlabelled, it was soaked in I gg/mL 
ethidium bromide for 20 minutes and the band was cut out on a UV box. If labelled, the 
gel was exposed a short time with autoradiography film. The bands were cut out , 
transferred to a screw-top Eppendorf tube, and macerated with a PION tip. The gel 
fragments were washed off the tip with 100-200 gL of TE, and the volume was adjusted 
to !ý 200 ýtL with TE, 100 gL saturated NH4OAc was added, and the tube was put on 
roller at 371C for 2 hour (or 4'C overnight). The gel debris was micro-centrifuged, the 
supernatant was transferred to a 1.5 mL Spin-x sterilisation filter (Cat#8160 Costar, 
Cambridge, MA), micro-centrifuged, and saved on ice. 200 ýtL of TE was added to the 
pellet, which was resuspended and put on a roller at 37'C for 2 hours. The gel 
fragments and buffer were transferred to the top of the previous Spin-x filter and spun 
again. The filtrate was transferred to a screw-top Eppendorf, 2 volumes ethanol was 
added, the precipitate was frozen on liquid N2, and incubated on ice for 10 minutes. The 
DNA was micro-centrifuged for 90 minutes at 4'C, washed with cold 80% ethanol, 
micro-centrifuged for 20 minutes, and completely dried in a Speedvac. 
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2.12 AGAROSE GEL ISOLATION. 
Typically, a low melting point agarose (Gibco/Amersham Life Sciences, Ajlington 
Heights, IL) gel was run in IX TBE, I gg/mL ethidium bromide (Sambrook el aL 1989) 
at a low voltage (in cold room if more than 1-2 hours). The band of interest was cut out 
of the gel and transferred to a screw-top Eppendorf tube. 100 ýtL of saturated NH4OAc 
was added, the isolate was diluted to 0.5% agarose with TE, heated at 700C for 5 
minutes, 2 volumes phenol were added, and the tube was micro-centrifuged for 5-10 
minutes at room temperature. The supernatant was transferred to a new tube, I volume 
phenol was added, and the extractions were repeated until no debris remained. 2 
volumes of phenol: CHC]3 isoamyl alcohol was added to the supernatant and the tube was 
micro-centrifuged. If necessary, the supernatant was concentrated by extracting it with 2 
volumes of 2-butanol serially until the volume was ! ý500 gL. The supernatant was 
extracted with 2 volumes CHC13: isoamyl alcohol (1: 24). 2 volumes of ethanol were 
added to the supernatant, which was frozen it on liquid N2, and micro-centrifuged for 90 
minutes at 4'C. The pellet was washed with cold 80% ethanol, micro-centrifuged for 20 
minutes, and completely dried in the Speedvac. 
2.13 BACTERIAL ELECTROPORATION. 
The bacterial electroporation method was followed exactly as described in the "Gene 
Pulser" (Biorad, Hercules, CA. ) protocol, using 0.2 mL cuvettes, and 50-100 ýtL cells 
either prepared in dH20instead of buffered solution, or purchased from Stratagene (La 
Jolla CA). 
A AM 
After electroporation, I mL of L broth (Sambrook et al. 1989) was added and the cells 
were shaken for 45 minutes. At least 200 gL of the cells were mixed on a 50 gg/mL 
ampicillin L plate with 50 gL of a 2% solution of 5-bromo-4-chloro-3-indoyl-p-D- 
galactoside (X-Gal) and 2 gL of I mg/mL isopropylthio-P-galactoside (IPTG), left to dry 
uncovered until liquid was adsorbed, then incubated inverted at 37T overnight. 
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2.14 LAMBDA LIBRARY SCREENING (Chapter 3). 
The FccRI(x gene was screened using aX EMBL-3 library (#HL1006d, Clonetech, Palo 
Alto, CA). The bacterial strain LE392 was used for screening the library. 
Approximately 5XI 04 phage were added to an overnight culture of LE392, incubated at 
370C for 20 minutes, and added to 3 mL 106 plaques were screened on 20 140 mm 
plates. Inserts were excised from vector with Sall. 
2.15 DNA FRAGMENT SIZE ESTBIATION (Chapter 3) 
A fl. 
Aner the DNA to be sized was run on an agarose gel alongside molecular weight 
markers) a standard curve was made by plotting the distance of the migration of the 
markers from the origin (well), on a semi-log graph, and fitting a straight line through 
them. After the distance of the migration of each unknown band was measured, the 
apparent molecular weight was read from the standard curve. 
2.16 GERMLINE TRANSCRIPT CLONING (Chapter 5). 
cDNA Synthesis: RNA was isolated as described in: 2.5 GITC/PHENOL METHOD 
FOR THE EXTRACTION OF RNA, from 107 PBMC induced for 5 days with IL-4. 
First and second strand cDNA was isolated with the Pharmacia cDNA synthesis kit 
(Amersharn Life Sciences, Arlington Heights, IL) from 0.5 ýtg of PBMC total RNA and 
5 gg of yeast tRNA (Boehringer Mannheim, Mannheim, Germany). The resulting S-300 
column effluent cDNA was treated with 3 units of T4 polymerase, heat inactivated at 
70'C for 5 minutes, and digested with 20 units of HincIl for 5 hours. The digested 
cDNA was phenol extracted and run over a S-300 column again for 2 minutes at 1500 
RPM. To a total volume of 50 gL of column effluent 2.5 gL of 10 mM ATP and 1000 
units of high concentration T4 ligase (New England Biolabs, Beverly MA) was added, 
and the reaction was incubated at 22'C for 10 hours. The recircularised cDNA was 
phenol extracted, ethanol precipitated, and resuspended 17 ýtL of dH20. 
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e Germline Transcript 5' End Cloning: 5 gL of the recircularised cDNA was added to 
a PCR reaction exactly as described in the "semi-quantitative RT-PCR" method above, 
with oligonucleotide H and oligonucleoticle F (Table 5.1) at 94'C 0.5 minutes, 65'C I 
minutes, 74'C I minutes for 40 cycles. The PCR reaction was digested with Ava I and 
Xba I and agarose gel isolated. 50% of the isolated PCR product was added with 20 ng 
of Ava I/Xba I digested (agarose gel isolated) Bluescript SK+ (Stratagene, La Jolla, 
CA), and ligated with 200 units of T4 ligase in a volume of 10 gL at 12'C overnight. E. 
coli were transformed by the "electroporation" method above with 30% of the ligation 
mixture. Transformants were screened by the "bacterial colony PCR" method above, 
and screened with oligonucleotide B (Table 5.1) and the M13 reverse oligonucleotide 
(New England Biolabs, Beverly MA). Positive transformants were sequenced by the 
"Sanger" method below. 
F_ Germline Transcript 3' End Cloning: 5 gL of the recircularised cDNA was added to 
a PCR reaction exactly as described in the "semi-quantitative RT-PCW' method above, 
with oligonucleotide G and oligonucleotide CF, 4 (Table 5.1) at 94'C 0.5 minutes, 65'C I 
minutes,, 74'C I minutes for 40 cycles. The PCR reaction was treated with T4 
polymerase as described in: 2.2 T4 BLUNT ENDING above, and agarose gel isolated. 
50% of the isolated PCR product was added with 20 ng of Eco RV digested (agarose gel 
isolated) Bluescript SK+ (Stratagene, La Jolla, CA), and ligated with 200 units of T4 
ligase in a volume of 10 ýtL at 20T for 6 hours. E. coli were transformed by the 
44 electroporation" method above with 30% of the ligation. Transformants were screened 
by the "bacterial colony PCR" method above, and screened with oligonucleotides CC4 
and either the M13 reverse, or -20 oligonucleotides (New England Biolabs, 
Beverly 
MA). Positive transformants were sequenced by the "Sanger" method below. 
2.17 SEQUENCING. 
Sanger et al (1977) Sequencing - The "Sanger" sequencing method was 
followed 
exactly as described in the "Sequenase" protocol (Amersham Life 
Sciences-USB, 
Arlington Heights, IL), except for the denaturation step for dsDNA. Denaturation was 
performed with 3 gg plasmid DNA, brought to a 16 ýtL total volume with 
dH20.4 RL 
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of IM NaOHJI mM EDTA was added to the DNA and mixed quickly. The reaction 
was incubated at 37'C for 10 minutes. 5 9L of saturated 1'ýý'40Ac was added to the 
denatured DNA, with 63 gL ethanol, and it was frozen on liquid N2, and incubated the 
reaction on ice for 10 minutes. The tube was micro-centrifuged for 30 minutes at 4 OC, 
washed with cold 80% ethanol, micro-centfifuged for 30 minutes at 4 'CI and completely 
dried in the Speedvac. 
Cycle Sequencing. The cycle sequencing protocol (Promega, Madison WI) was used 
exactly as described in the manufacturers' recommendation. 
Notes: Sequencing of the U266 splice junction (Chapter 4) was performed on ssDNA 
(see 2.4 PREPARATION OF ssDNA FROM PHAGEMID CLONES). Sequencing of 
the FcERI(x chain gene (Chapter 3) was performed directly on lambda phage DNA using 
the cycle sequencing protocol according to the protocol above. 
2.18 GERMLINE c PROMOTER REPORTER CONSTRUCTS: 
In order to obtain the human e germline (GL-e) promoter construct, a 423 bp fragment 
of the promoter, that ends 9 bp upstream of the splice site for C6, was inserted into the 
promoterless pGL3 basic vector (Promega, Madison, WI), that contains a luciferase (luc) 
reporter gene. The fragment was obtained by PCR amplification of genomic DNA from 
non-atopic human lymphocytes with Pfu DNA polymerase (Stratagene, La Jolla, CA) as 
follows: A forward primer 5'-CCTGGGAGTGAGTACAAGGTGAG, and as reverse 
primer 5'-GGTGGGCTGGGATACCTGAAG (nucleotide 25-47 and 667-687 of 
Genbank accession no. X56797) were added to 10 gg genomic DNA, 5% dimethyl 
sulfoxide, 6 units of PFU polymerase (exactly as described in manufacturers protocol) in 
a 100 gL total volume. The reaction was cycled 40 times at 95'C for I minute, 64'C for 
I minute, 72'C for I minute and agarose gel isolated. The PCR product was digested 
with Rsa I and Hae II, the 3' end was made blunt (see 2.2 T4 BLUNT ENDING), 
agarose gel purified, and ligated into the Smal site of pGL3, thus obtaining the F'-GL 
promoter construct. The insert and the junctions were sequenced by Sanger sequencing 
(Sanger et al. 1977) using the Sequenase version 2.0 kit (protocol (Amersham Life 
Sciences-USB Arlington Heights, IL). 
A 
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The deletion mutant lacking the BSAP binding site (BSAP del) was generated by PCR 
assembly of two fragments, using the F, GL promoter construct as the template for 
amplification. A 274 bp PCR product (BSAP Del 1) was obtained using as forward 
primer 5'-CACCCCATTTTTAGCTCCCAGGCTCCACTGC, that introduces a 27 bp 
deletion, and corresponds to nucleotide 94-151 in the human germline epsilon gene. The 
reverse primer was 5'-GCAGTTGCTCTCCAGCGGTTC (GL4 primer, Promega), that 
maps to position 146-165 in pGL3. Another PCR product of 357 bp (BSAP Del 2) was 
generated using as forward primer 5'-CTAGCAAATAGGCTGTCCC (RVpfimer3, 
Promega), that maps to position 4761-4780 in pGL3, and as reverse primer 5'- 
AGCTAAAAATGGGGTG that maps to position 94-109 in the human germline epsilon 
gene. The two PCR products were gel purified and combined into a PCR reaction using 
primers RVprimer3 and GL4, then digested with Kpn I and Hind III to generate a 470 bp 
fragment, and directionally cloned into Kpn I/Hind III digested pGL3. The BSAP mutl 
construct was generated using as a forward primer RVprimer3, and as a reverse primer 
5'-GGGAGCTCTTCCTCAG (nucleotide 117-132 in the human germline epsilon gene), 
where aG was replaced by aT as underlined in the sequence. The PCR product was 
digested with Kpn I and Sacl to generate a 312 bp fragment, and inserted into the 4923 
bp Kpn I/Sac I fragment of the GLF. promoter construct. The deletion and the mutation 
were confirmed by "Sanger sequence analysis"). All plasmids were prepared for 
transfection by 2 rounds of purification on CsCl density gradients. 
2.19 CELL CULTURE, CELL LINES. 
The B cell lines BL-2 (Gauchat et al. 1992), BJAB (Clements et al. 1975), and Namalwa 
(Middleton et al. 199 1), were cultured in Yssel's medium (without insulin and transferfin) 
(Yssel, et al 1984), supplemented with 10% foetal calf serum (FCS, Gibco/Amersham 
Life Sciences, Arlington Heights, IL) at 5% C02. The basophilic human cell line KU812 
(Kishi 1985) was cultured in RPMI medium supplemented with 10% FCS. 
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2.20 TRANSFECTIONS AND REPORTER ASSAYS. 
The Transfection method used below was exactly as described in Nelms (1990). 
GL-E Promoter analysis (Figs. 6.12,6.13): Log phase (=5xl 05 cells/mL, IOX106 total) 
BJAB, or BL-2 Lymphoblastoid B cells were washed once in phosphate buffered saline 
(PBS, Gibco/Amersharn Life Sciences, Arlington Heights, IL) and resuspended in 0.75 
mL TBS (for TBS, first two solutions were made: For solution A: 80 g/L NaCl, 3.8 gAL 
KCI, 2 g/L Na2UP04,30 g/L tris base, adjusted to pH 7.5 and filter sterilised. For 
solution B 15 g/L CaC12 and 10 gALMgC12, were filter sterilised. 10 mL of solution A 
was added to 89 mL of dH20 and I mL of solution B was added drop-wise with mixing. ) 
containing 10 gg reporter plasmid, 6 gg RSV-p-galactosidase control plasmid (Maggie 
Walmsley, London, UK), 4 gg RSV-Luciferase control plasmid (Gill May, London, UK), 
and 250 gL of 2 mg/mL diethylaminoethyl. cellulose (DEAE) dextran was added. 
Plasmids were prepared by two rounds of CsCl gradient purification. The transfection 
was incubated for 30 minutes at 370C. After transfection, the cells were diluted with 13 
mL of media, spun at 1,200 RPM for 5 minutes, split into 2 aliquots and cultured for 48 
hours in complete medium, in the presence or absence of IL-4 (100 U/mL) and anti- 
CD40 mAb 626.1 (5 ýtg/mL). Each transfection was performed in duplicate. Cell 
extracts were prepared, and luciferase activity determined according to the Luciferase 
Assay System (Promega) protocol. The same cell extracts were used to determine P- 
galactosidase (p-gal) activity using the chemiluminescent Galacto-Light kit (Tropix, 
Bedford, MA). All readings were taken using a Lumat Berthold 9501 luminometer 
(Berthold, Bad Wildbad, Germany. The results obtained for each transfection were 
normalised to p-gal activity. 
2.21 PBMC ISOLATION AND CELL CULTURE. 
PBMC were isolated from heparinised blood on ficoll gradients. Blood was drawn into a 
50 mL syringe, and immediately mixed with heparin. Blood was kept at room 
temperature until used. 12 mL of blood was diluted with 12 mL RPMI medium without 
FCSI carefully layered onto 12 mL of ficoll-hypaque (Pharmacia, Piscataway, NJ) and 
spun at 1600 RPM for 30 minutes, 22'C, without a brake. Aspirate top layer 
leaving 5 
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mL containing PBMC. The PBMC layer was carefully taken from the gradient with a 
pastette, avoiding ficoll layer and immediately mixed with 4 volumes of RPMI without 
FCS. The PBMC were next spun at 1500 RPM room temperature, 10 minutes and 
washed 2 more times in medium at 1200 RPM for 10 minutes. Stored on ice. 
Cultures were initiated at 1.5 X 106/ML in complete Yssel's medium (Yssel el al. 1984-, 
Claassen et aL 1990), supplemented with 10% FCS (Gibco/Amersham Life Sciences, 
Arlington Heights, IL). I mL of cells was cultured in a polystyrene round bottom 13 ML 
(Falcon #2059, Becton Dickinson, Franklin Lakes, NJ) or 0.4 m. L in a4m. L FACScan 
tube (Becton Dickinson, San Jose, CA. ) at 5%CO2. The cultures were not disturbed 
until 12-14 days later. Recombinant human IL-4 was a gift of DNAX (Palo Alto, CA, 
specific activity IxIO7 U/mg). Fluticasone, (a kind gift of Glaxo Welcome, Stevenage, 
UK), was dissolved at a concentration of 0.2 M in N, N-dimethyl-acetamide (Sigma, St. 
Louis, MO), and diluted appropriately in 0.9 M NaCl (physiological saline), 1% 
polyoxyethylenesorbitan monooleate (tween 80, Sigma, St. Louis, MO). IL-4 and 
fluticasone were added at the onset of culture. 
2.22 EMSA PROBES AND COMPETITORS 
The GL-F_ 80-184 EMSA probe (Fig. 6.4) was generated from a 106 bp Xma I-Bcl I 
fragment cleaved from the gel isolated 36/266 PCR product (Table 6.1), and end labelled 
with Klenow polymerase and OC32p-dCTP (see 2.1 END LABELLING) and isolated on 
a 6% non-denaturing polyacrylamide gel (see 2.11 ACRYLAMIDE GEL ISOLATION). 
The GL-F_ 42 base 36/78 probe was cleaved with Ymal from the 36/266 PCR product, 
end labelled with Klenow polymerase and (x32p-dCTP and isolated on a non-denaturing 
polyacrylamide get. The 104/191 and 104/139 probes (Table 6.1) were generated by 
first isolating (on a 6% and 10% non-denaturing polyacrylamide gel, respectively), a 
single stranded template generated by asymmetric PCR with the upper strand at I ýtM 
and the lower strand at 0.05 gM. The second strand was synthesised with sequencing 
Taq polymerase (Promega Biotec, Madison, WI) in the presence of unlabelled dATP, 
dGTP, dTTP and (2 gL/20 gL total volume) (x32p-dATP (10 ci/mL, 3000 ciJmMol), 





minutes, at 72T for 3 minutes, and chased with 0.4 gL unlabelled 10 mM dATP, and 
0.5 gL Taq 5 units/gL. The labelled probes were then isolated on a non-denaturing 
acrylamide gel (6% and 10%, respectively). 
Competition oligonucleotides were annealed in 100 mM NaCI, 10 MM Tris pH 8,0.1 
mM EDTA by heating to 95T 10 minutes and cooling slowly to the annealing 
temperature and incubating for I hour. Mutant BSAP competition oligonucleotides 
were generated by PCR by using the BSAPIXMUT and BSAP2XWT 
oligonucleotides. All probes and competitors were purified on polyacrylamide gels. 
2.23 NUCILYAR EXTRACIN AND ELECTROPHORETIC MOBIU[TY-SIH[Wr ASSAY. 
Nuclear extracts were prepared as follows: 2-3XI06 cells were washed 2 times in 
phosphate buffered saline (PBS), resuspended in 400 mL of buffer A (10 MM N-[2- 
hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid], 1.5 M-M MgCl2,10 m-M KCI, 0.5 MM 
dithiothreitol, with the protease inhibitors: 0.2 m. M phenylmethylsulphonyl flouride 
(PMSF), I mg/mL aprotinin, 3 mg/mL antipain, 3 mg/m_L pepstatin, 3 mg/mL leupeptin 
and the phosphatase inhibitors: I mM benzarnidine, I m. M ortho sodium vanadate, I MM 
sodium fluoride and 5 mM b-glycerol Phosphate) and incubated on ice for 10 minutes. 
NP-40 (0 003-0.01%) was added if the nuclei were not released within 10 minutes. The 
nuclei were sedimented in a micro-centrifuged for 12 seconds at 40C and then 
resuspended in 2 volumes of buffer C (20 rnM N-[2-hydroxyethyi]piperazine-N'-[2- 
ethanesulfonic acid], 25% glycerol, 1.5 M-M MgCl2 0.2 m. M EDTA, 0.5 mM 
dithiothreitol, with protease and phosphatase inhibitors. ). The total volume of the nuclei 
was measured and the nuclei were transferred to a new tube. Exactly I volume of buffer 
C containing 840 rnM NaCI was then added, and the nuclei were extracted for 20 
minutes on ice, with occasional mixing. The nuclei were sedimented at in a micro- 
centrifuge for 5 minutes at 4'C and the extracts were frozen on dry ice and stored at - 
70'C. Protein concentrations were determined by the BCA protein assay (Pierce, 
Rockford, IL). 
For EMSA, 5 mg of nuclear extract was added to 20 mL of binding buffer- 10 ni-M tris 
pH 8,0.5 mM MgC12, I n-LM EDTA, I mM dithiothreitol, with 5 mg polv(dl-dC)- 
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poly(dI-dQ (Pharmacia, Uppsala Sweden) and 5 fMoles of 32P-labelled probe in the 
presence or absence of competitors. NaCl and glycerol were adjusted to 0.1 M and 
10%, respectively. After incubation for 30 minutes on ice, the binding reactions were 
run on a 4% polyacrylamide gel in 50 MM tris, 50 mM boric acid, I mM EDTA pH 8, 
4% glycerol at 30 mA for 2-5 hours at 4'C. 
Supershifts were performed by preincubating the nuclear extracts in binding buffer with 
the appropriate antisera for 30 minutes on ice before adding the probe and competitors. 
2.24 IgE ENZYME-LINKED IMNIUNOABSORBENT ASSAY 
Materials: Coating antibodies consisted of fresh solution of 3 4g/mL each of Mouse 
IgG anti-human IgE mAb 7.12 and 4.14 (or 7.12 alone) (Macy et al. 1988) in 0.2 M 
carbonate buffer (3.73 g Na2CO3with 3.76 g NaHC03 to 400 mL, pH 9.8 with HO, 10 
gg/mL sodium azide). Nunc 96 well immunosorb plates (Nalge Nunc Intl, Rochester, 
NY). 
Method: Each well was coated with 50 gL the monoclonal antibodies 7.12 and 4.15, 
and incubated at 37'C for I hour (or room temp several hours or 4'C overnight). The 
plate was washed 2 times with Phosphate buffered saline (PBS). The wells were filled 
(=200 gL) with 2% non-fat dried skim milk (Marvel, UK), and incubated at 37'C for 30 
minutes to I hour (or room temperature for 2-3 hours). The plate was washed 3 times 
with PBS/0.05% Tween 20 (# P-1379, Sigma St. Louis, MO) and beat on towels. 50 ýtL 
supernatant (diluted in medium) to be analysed, or an IgE standard curve (11 2 fold 
dilutions from 100 ng/mL, throw away tip at each well) diluted in medium was added to 
the well. The plate was washed 4 times with PBS/Tween. The top layer antibody 
(1: 1000 of #P295, Dako, High Wycombe) was diluted in I% milk/PBS/Tween, 50 ýtL of 
the antibody was added per well and the plate was incubated at room temperature for 
several hours. The plate was washed 5 times with PBS/Tween, beat on a towel, washed 
IX, and beat again. To each well was added 50 gL of developing solution (20 MM citric 
acid, 50 mM NaBP04 pH 5,0.02% H202,4 mM o-phenylenediamine (OPD, 
P-9029, 
Sigma, St. Louis, MO), the OPD was dissolved in few drops methanol, the buffer and 
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H202were added, and it was used immediately). the plate was incubated at room 
temperature for at least 30 minutes or until the yellow colour developed. 50 ýtL 0.1 M 
H2SO4was added to each well to stop the reaction, and the absorbance was read at an 
optical density of 492. 
2.25 IMMUNOFLOURESCENT ANALYSIS OF CELL SURFACE ANTIGENS. 
Membrane staining was performed using a panel of B cell-specific mAbs and 
differentiation specific mAbs to phenotypically characterised B cell lines and primary B 
cells taken from tonsil. These included MEC-class 11 (RFDR2, y), CD19 (RFB9y), 
CD20-like (RFB7g), CD38 (RFIOy or g), CD21 (RFB6, y), kind gift of George Janossy 
(Royal Free Hospital, London, UK); CD23 (BU38, y), IgM (BUIy), from The Binding 
Site (Birminghaml UK); and CD40, kind gift of E. Clark (Seattle, WA). Isotype specific 
second layer antibodies conjugated to fluorescein isothiocyanate (FITC) or phycoerythrin 
(PE) were added. One or two colour immunofluorescence was detected using a 
FACscan (Becton Dickinson, San Jose, CA. ) and analysed using PC Lysis software. 
2.26 TRANSCRIPTION FACTOR BINDING SITE ANALYSIS. 
To find potential transcription factor binding sites, the Signal Scan suite of databases 
version 4.07 was used on the MRC-HGMP resource centre computer (Cambridge, UK). 
Signal Scan is a compilation of three databases (Prestridge 1991); TFD (Ghosh 1992), 
Transfact (Wingender 1988), and the Information Matrix Database Search (Chen el aL 
1995). Only factors considered potentially relevant to the expression of the FcF-Rl(x 




CHAPTER 3: Cloning of the Human IgE High Affinity Receptor (FcF-RI) Gene. 
3.1 INTRODUCTION 
The cDNA's for the high affinity receptor alpha chain have been cloned for the rat (Shimizu 
et aL 1988; Tepler et aL 1989), mouse (Ra et al. 1989), and human (Kochan ef al. 1988, 
Shimizu et al. 1988). The genes for the alpha chain have also been cloned for the rat (Tepler 
et al. 1989) and the mouse (Ye et al. 1992). Although the rat and mouse FCZRI(x 
polypeptide chains are only 70% identical, the nucleotide sequences are 84% identical in the 
coding region, and 92% in the 5' untranslated region. This suggests that although the protein 
has diverged between the rat and mouse, the DNA sequence, especially in the region of the 
promoter, has had pressure to remain evolutionarily conserved. Likewise, the regulation of 
the gene has also probably remained highly conserved between the rat and mouse. In 
contrast, the human FcF-Rl(x polypeptide chain is only 50% identical to the rodent, and 70% 
on the DNA level. Such divergence between the human and rodent on the nucleic acid level 
might suggest a divergence in regulation of the gene fi-om what is seen in the rodent. 
Likewise,, to understand the regulation of FcF-RI(x in the human, the gene was first cloned, 
and studied directly. 
Little is known about the regulation of the FceRI(x gene. IFN-gamma and alpha/beta have 
been shown to increase FcFRI(x mRNA levels in rat mast cell lines (Enciso et a[ 1996). 
FccRI levels on blood basophils has been shown to increase and decrease in a direct 
relationship with IgE levels (Lantz et al 1997; MacGlashan el al 1997; Yamaguchi ef aL 
1997). FceRI increases have been shown to be dependent on protein synthesis, but whether 
this regulation is on a transcriptional, translational, or post-translational level is not known. 
Genes are regulated on the transcriptional level at the promoter by two types of factors. First, 
general factors bind to RNA polymerase to assemble the pre-initiation complex, which 
forms 
around the start site of transcription, and is required for the i,, tiation of transcription 
(for 
transcription review, see Orphanides et al 1996; Roeder 1996, Lewin 1997). 
Upstream 
factors, both inducible and constitutive, compose the second group and modulate the 
efficiency of initiation. 
54 
The upstream region (Fig. 3.5) of the FcF-Rla gene contains sequence identity to the binding 
sites for the general transcription factors TFUD and TFII-I. Most genes, except rRNA, 
tRNA, 5SRNA and snRNA, are transcribed by RNA polymerase 11. The general factors that 
bind to polymerase 11 are termed TFIIX Of this group TFUD binds to the TATA box, which 
is positioned normally 30 bases upstream of the transcription start site (Nussinov 1992), and 
promotes the assembly of the pre-initiation complex. Overlapping with the transcription 
initiation site in an initiator sequence. TFH-I binds to the initiator, and to TRID, helping to 
position the start of transcription (Roy et al. 199 1; Roy et al. 1993 a). In promoters that lack 
a TATA box, TFUD binds at other less well defined sequences in a TFH-1 dependent manner. 
TFH-1 is immunologically related to the ubiquitous basic-helix-loop-helix (bHLH) protein 
family member upstream stimulatory factor (USF, Roy el al. 1991). bHLH proteins are 
upstream regulatory factors that bind the consensus E-box CANNTG. Two potential E- 
boxes are present in the upstream region. TFH-1 has been shown to interact co-operatively 
with USE, and another bHLH protein c-Myc (Roy et al. 1993b), in binding to both the E-box 
and the initiator element. TFIM and USF interact co-operatively at both the initiator element 
and the E-box. TFIM also interacts with c-Myc, a proto-oncogene expressed in most 
dividing cells (Zimmerman et aL 1986), interacting co-operatively at both the initiator element 
and the E-box (Roy el al. 1993b). However, in this case c-Myc Inhibits transcriPtion by 
preventing the interaction between TFIID,, TFH-I, and the promoter. Both cases present a 
mechanism of communication between upstream regulatory factors and the general 
transcription machinery. 
Several bHLH proteins potentially bind to the upstream sequences, including the ubiquitous 
c-Myc (Ayer and Eisenman 1993) and E2A (Visvader et al. 1991; Vierra et al. 
1994), the 
skeletal muscle specific MyoD (Goldhamer et al. 1992; Miner el al. 1992) and myogenin 
(Wright ef al. 1989), and AP-4 which is expressed in the myeloid 
lineage, among other cell 
types (Comb et at 1988; Men-nod ef at 1988; Gabuzda et al. 1989). 
Several other bHLH 
proteins are known to be expressed in the myeloid lineage 
including USF (Sirito et at 1994), 
Mxi I and Max (Zervos et al. 1993), Mad (Ayer and Eisenman 
1993), tal- I (Voronova and 
Lee 1994, Condorelli et al. 1997), MITF (Tsujimura ef al. 1996), ROX 
(Meroni ef al. 1997) 
and may bind to one or both of the E-boxes as well. 
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bHLH proteins contain a IFILH dimerisation domain which allows homodimers to form, and 
also heterodimers between members of the bULH family. Some family members, such as c- 
Myc and USF belong to a second class, the bHLH-zip proteins, and can form higher order 
multimers by addition of the leucine zipper domain (Beckmann and Kadesch 1991). 
Interaction between bHLH family members can aflow communication between regulatory 
elements within a promoter, and between a promoter and enhancer (Zimmerman el al. 1986; 
Roy el aL 199 1; Artandi et al. 1994). 
The upstream region of the mouse gene also contains a potential CCAAT box. When 
present, CCAAT boxes occur from 50 to 200 bases upstream of the transcription start site 
(Nussinov 1992). Nearby the homologous position in the human and rat to the mouse 
CCAAT box are sites for the CCAAT binding factors C/EBP (Johnson el al. 1987, Ron ef al. 
1990), and CTF/NF-I (Morgan el al. 1987; Paonessa et al. 1988; Abraham et al 1990; 
Graves et al. 1991). C/EBP is expressed ubiquitously (Landschulz el al. 1988; Wedel and 
Ziegler-Heitbrock 1995), and CTF/NF-I is expressed in myeloid, adipocyte and hepatocyte 
lineages (Bienz 1986; Jones et al. 1987). The activation domain of CTF/NFI and C/EBP 
interacts vAth TFHB, helping recruit it to the preinitiation complex m and Roeder 1994, (Ki - 
Nerlov and Ziff 1995). 
Also present is the potential binding site for LF-Al (Ammendola et al. 1990), a liver specific 
regulatory factor for the NF- I gene, and IINF-3 (Grange et al. 199 1), which has binding sites 
that overlap with C/EBP in the rat an-iinotransferase gene. BNF-3 belongs to the HNF-3/fork 
head family of transcription factors which share homology in the VAnged-helix DNA binding 
domain (Lai et al. 1993), is expressed in the bronchial epithelium, lung, liver, stomach, small 
intestine, embryonic notochord, floor plate, and gut (Ang and Rossant 1994; Kaestner el al, 
1994; Weinstein et aL 1994), and is involved in the inflammatory response in the lung (Chen 
and Liao 1993; Magdaleno et al. 1997). 
Three potential GATA binding sites are present in the upstream sequences. GATA family 
members GATA-1,2, and 3, are expressed in haernatopoetic cells, and bind to the consensus 
sequence A /TGATA A /G (Ko and Engel 1993; Merika and Orkin 1993). GATA- I binds to a 
site in the chicken beta-globin promoter that includes the canonical TATA box, and a site in 
the beta-globin enhancer. The enhancer GATA- I site can functionally replace the TATA box 
in the promoter. GATA- I interaction vvith the TATA box is required for enhancer dependent 
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transcriptional regulation (Fong and Emerson 1992), suggesting that GATA- I both aids in 
commurucation between an enhancer and promoter, and enables THID to be regulated by 
distal elements. 
At position -71, a polymorphism containing either aT or C, was found in the FCZRI(x gene at 
a potential GATA-1 binding site (Barnhart et al. 1989). This polymorphism has at least a 
sfight finkage to atopy (D. Fear, pers. comm. ). When aT is present at this position, two 
EMSA bands are seen, and only one is present in the C aflele. 
The sequences upstream of the coding region were analysed in luciferase reporter assays and 
were found to contain promoter activity in human basophils. 
3.2 RESULTS 
3.2.1 Cloning of the FeFRI(x gene 
Oligonucleotide sequences chosen to screen a genomic library were checked for potential 
cross hybridisation by searching against the Genbank/EMBL database of sequences 
(Wisconsin Package, Genetics Computer Group, Madison, WI). 
For the first screening, an oligonucleotide specific for exon 4 of the human cDNA (Kochan et 
al 1988; Shirnizu et al 1988), hFcFR131 (Table 3.1; Fig 3.1) was used to probe 106 plaques 
of a X-emb13 male human leukocyte genomic library (#HL1006d, Clonetech, Palo Mto, 
CA), infected into the K coli bacterial strain LE392. The library was composed of Mbo 
I partial digest of genornic DNA constructed to allow excision of the entire insert by a 
Sal I digest. Five potential clones were identified. Four of the five potential clones were 
confirmed by a secondary screening with an oligonucleotide specific for exon 5, hFczR132. 
The four clones, 3C, 17,22 and 28, contained inserts of approximately 15.9,15.8,15.7, and 
18.1 Kb, respectively (Fig. 3.2). Each clone was additionally confirmed 
by DNA sequencing 
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Intron sequences at the intron/exon border were identical to the rat, or mouse at 4 of the 8 
borders (Fig. 3.3). At 90%, similarity between the human and rodent intron/exon borders 
was higher than the 70% homology in the coding sequence, demonstrating the importance of 
sequence conservation to the splicing machinery. AR intronic sequence at the intron/exon 
border obeyed the GT ..... 
intron 
..... AG rule 
(for splicing review, see Padgett et aL 1986). 
Human 110 TCTTCGgtaagtagag/--intron 
11 1 illilli 11 
Mouse 83 TCATGTgtaagtacag/--intron 
lill 11111111111 
Rat 97 TCATATgtaagtacag/--intron 
Human 131 TAGCAGgtgagtcctc/--intron 
I IIIIIIIII 
Mouse 103 TGACAGgtgagtgagt/--intron 
I IIIIII III 
Rat 118 TAACAGgtaagtcctg/--intron 
Human 386 TCAGTGgtaagttcca/--intron 
1111 111111 
Mouse 362 CGCAAGgtacgttcca/--intron 
IIIIIIIIIIIIIII 
Rat 373 i(iCAAGgtacgttcca/--intron 
Human 644 TAAAAGgtgagttggt/--intron 
11111111 11111 1 
Mouse 617 TAAAAGgtaagttgat/--intron 
IIIIIIIIIIIIIIII 
















4--/tccactacagCT.. C. 652 




Figure 3.3. Sequence of Exon/intron borders. Uppercase, exon 
sequence, lowercase, intron sequence. Numbering refers to the human 
(Genbank: hsfceri), mouse (Genbank: musfcera), and rat (Genbank: 
ratmciaa) sequences. 
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The 5' untranslated region was sequenced to 349 nucleotides upstream from the transcniption 
start site, and showed a moderate, 75% identity to the mouse and rat. This region Is in 
agreement between all four clones, except for aC or T at nucleotide -71 (Fig. 3.4). 
Subsequent work by David Fear has shown this position corresponds to a polymorphisn-ý 
with a slight linkage to atopy. The presence of the C or T aliele was assayed in 15 atopIc and 
15 non-atopic individuals by sequencing. All 4 (2 homozygous and 2 heterozygous) of the 30 
individuals containing aC allele were non-atopic. 








44 GGAATCCCCT ACTCTACTGT GTGTAGCCTT 







ij intron A 
GGTAAGT 
FmRIa-C -A -G-AIQ IAT 
FcF-Rla-T . AGATAT 
GATA Consensus A/TG AT A At 
Figure 3.4. C/T pollymorphism in the 5' untranslated region. Above, 
location of the polymorphism (grey box) at position -71, the relative position 
of the rat, mouse and human transcription start sites, and the translation 
start site (black box). Below, comparison of the two polymorphic sequences 
with the GATA consensus, and the region of homology (grey box) between 
the consensus and the Fc. F-Rl(x sequences. 
3.2.2 Potential transcription factor binding sites 
A potential GATA- I binding site (Barnhart ef aL 1989) at the sequence AGATA (Fig. 3.4) Is 
present in the T allele at position -74, and in conforms to the GATA consensus WGATAR 
(Plumb et al. 1989,; Perkins el al. 1990; Yamamoto et aL 1990, Macleod and Plumb 199 1) at 
5 out of 6 positions. Although GATA- I has not been shown to bind here by EMSA analysis 
(D. Fear, pers. comm. ), two EMSA bands are seen with the T allele, and only one with the C 
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allele. In addition to the potential GATA-1 site at position -74 is a second site immediately 
adjacent at position -69 (Barnhart et aL 1989). The presence of two EMSA bands in the 
AGATA allele and one in the AGACA allele may correspond to occupancy of the two 
adjacent GATA sites in the T aflele, and only one in the C allele. 
Sequences 5' of the coding region were searched for homology to other known transcription 
factor binding sites to look for likely regulatory elements in the promoter (see in Materials 
and Methods, 2.26; Table 3.2; Fig. 3.5). Regions of interest correspond to potential binding 
sites of at least 6 bases in length, and representing factors likely to be present in myeloid cells. 
Other potential binding sites representing related factors overlapping or immediately adjacent 
to a region of interest were also noted. Some of the factors binding to overlapping or 
adjacent binding sites mentioned may not be expressed in the myeloid lineage, but indicate the 
potential presence of related factors that may be expressed in myeloid cells. 
In addition to the two partial WGATAR sites present at bases -74 and -69, and an additional 
GATA site confon-ning to the WGATAR consensus (Plumb et al. 1989; Perkins el al. 1990; 
Yamamoto et al. 1990; Macleod and Plumb 199 1) is present at - 122. 
Two E-box motifs (Blackwell and Weintraub 1990) occur at bases - 144 and -9 1. Both of the 
E-box motifs are immediately surrounded or overlap with several other potential binding sites. 
E-box motifs bind proteins of the basic-helix-loop-helix (bBLH) family. The distal E-box 
potentially binds the bl-ILH protein c-Myc (Suen and Hung 1991), and the proximal box 
potential-ly binds AP-4 (Comb et al. 1988; Mermod et al. 1988; Chu el al. 199 1). 
Additional b1HLH proteins potentially bind at sites overlapping and adjacent to the proximal 
E-box motif hnmediately adjacent to the proximal E-box is a potential binding site for the 
bI1LH protein myogenin (Baldwin and Burden 1989). Overlapping with both the proximal 
E-box and the myogenin site, are potential binding sites for two additional bHLH proteins 
MyoD (Rosenthal et al. 1990) and E2A (Xiao et al. 1987). The proximal E-box also 
overlaps with the potential binding site for the factor IUF- I (Shelton et al 1992; Bretherton- 
Watt et al. 1996), that is thought to be associated with the bHLH family member USF in the 
islet amyloid polypepticle (IAPP) promoter. 
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Human -349 ---------------------------- TATTCAGTAATTAGTTGCTGCT 
-328 
Human -327 GTTTTATTCTGCTCTCCCTTGCATCCCACTTTTCTAAGTTGTAAACTAAA 
-278 Rat -291 .... C ..... A. AG ... TC. TT. CT.. GTGG.. TC .... CTC ... TC... -242 Mouse -265 ------------------------------ G.. T ..... CTC ... TC... -245 
Human -277 TAGTTGTACACAGATTG-ACAGATTA --- AGAAAGGCTTGTGATTGTGC- -233 Rat -241 TC ... GG... G.. AC. TT.. CC ........... TC. ACA ... C. C ... T -195 Mouse -244 TC .... G.. TT.. A.. -T.. CC ... AGG.. G.. TC. ACA ... C-C ... T -196 
Human 232 TAGACCTATGCCTCTCTCTCACCAGATTCCAGGTGTATATGTGGAGGTGG 
- 183 Rat -194 ... G.. CT.. GT .... A. CT ......... T ....... C. GC.. A .... AC -146 Mouse -195 ...... CT.. GTC. CTG. CT. T ....... T ....... C. GC.. A .... AC -147 






-145 A.. C ---------- A.. A ..... G. C ... A.. 





Human -132 ATCCTGAAT TAAAGAAAGAAGCAAAACCAGGC AGCTGAIGý -03 
Rat -103 W.. CT. T.. .. 
GG 




... GC. -56 
GATA GATA 
Human -82 GGTTAACC CAGAAAACATTTCCTTCTGCTTTTTGGTTTTA i -33 








... CG ...... C. -6 




.... G ...... 
C. -6 
+1 +1 






AGCCTATA, 'T rTG CCTTAGATCTCTCCAGCACAGTAAGCACCAGGAGT 
T A A T TG TG G G c 
18 
43 ...... . ... ... . . .... .. ...... . - 
Mouse -5 ....... T.. C ...... A. JG .... T ...... 
T. A.. G 43 
TFII-l 
Met 
Human 19 CCATGAAGAA, CTCCTGCCATGGAATCCCCTACTCTACTGTGTGTA 68 
Rat 44 ACA. GG. C. - A. A --------- G. GGAT.. G. C. GG ..... 
CC. - 86 
Mouse 44 TGCA. GG. CG-i. TCA --------- G. AGGT.. G. C. AG ..... 
cc.. 86 
Figure 3.5. Location of potential transcription factor binding sites in the region upstream of 
the FceRla gene. The 5' regions of the human, rat and mouse genes are shown. Nucleotides of 
the rat and mouse genes similar to the human gene are represented as a period and gaps created 
for sequence alignment as a dash. Regions of homology to known transcription factor binding sites 
are boxed in the 5' regions of the human, rat, and mouse genes. An inverted repeat surrounding 
bases -141/-142 in the distal grouping of binding sites in the human, is marked with anTws. The start 
of translation, Met, is indicated in blue. The transcription start sites in the mouse and rat (blue 
arrow), and human (black arrow) are indicated. 
MyoDlmyugen, inM 
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Both E-box motifs also potentially bind the non-bBLH protein c-Myb (Sureau et al 1992) 
with the distal site a perfect match, and the proximal site slightly unfavoured for c-Myb at the 
G in position 3 (Deng et a[ 1996). 
In the mouse sequence a CCAAT box overlaps with the distal E-box. A number of factors 
that are known to bind the CCAAT box also have potential binding sites in or near the E- 
box/CCAAT box motif The CCAAT/enhancer-binding protein (C/EBP) family (Johnson et 
al. 1987; Landschulz el al. 1988; Brasier et al. 1990; Ron el al 1990; Ron et al. 1991, 
Brasier and Kumar 1994) and NF-I (Paonessa et al. 1988; Abraham et al 1990, Graves el al. 
1991) potentially bind sites overlapping or adjacent to the region that contains the CCAAT 
motif in the mouse. Both the C/EBP family and NF- I are known to bind to CCAAT boxes, 
as well as other sequences, though interestingly the corresponding human and rat regions do 
not contain a CCAAT motif LF-Al (Hardon et al 1988; Ammendola el al 1990) also binds 
in this region, and is known to regulate NF-1. BNF-3 (Grange el al. 1991), binds here as 
well, and is known to have a binding site that overlaps with various C/EBP sites in the rat 
tyrosine an-dnotransferase gene. 
Adding to the possibility that a regulatory element resides at the E-box/CCAAT motif, a 
perfect palindrome with 6 base arms is present overlapping the human E-box/CCAAT motif, 
with near perfect palindromes in the corresponding rat and mouse sequences. The 
palindrome is centred in the E-box, extending 4 bases beyond each side of the E-box. Many 
regulatory elements, including the E-box, are known to be composed of two half-sites, often 
present as a palindrome, and represent the binding of two half sites by a regulatory factor. 
No TATA box is found near to the mouse (Ye et aL 1992) rat (Tepler et aL 1989) and 
human (D. Fear, pers. comm. ) transcription start sites, suggesting a TATA-less promoter, 
though no multiple GC box is found, an element commonly present in TATA-less promoters. 
A potential TFUD site (Tamura et aL 1990), present in both TATA containing and 
TATA- 
less promoters (Roy et al. 1991; Roy et aL 1993a), is found near the start site 
in the human 
and rat sequences at position -24. A potential TFII-I binding site 
(Roy et aL 199 1), also used 
in TATA-less promoters (Roy et aL 1993b; Manzano-Winkler et aL 1996; 
Montano et al, 
1996), appears nearby the start sites at position - 13. 
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3.2.3 Promoter analysis 
Promoter fi7agrnents from the lambda clone X were identified and inserted Into the reporter 
plasrnid pGL2. Bg1 11 and Nco I were chosen as restriction site termini for the promoter 
fi-agments because both sites are near the 3' end of the first exon of the Fcf-RIOC gene (Fig 
3.7), insuring that all potential promoter sequences would be included in the expression 
constructs. Bg1 H and Nco I fragments fi7orn containing the putative promoter region were 
identified from clone 3C by a polymerase chain reaction (PCR) based method. Clone 3C was 
digested with Bg] H or Nco I and the fragments were isolated from an agarose gel (Fig. 3.6). 
Restriction fragments containing the putative promoter region were identified by PCR using 
the oligonucleotides 5ocR and 5FC (Fig. 3.6, Table 1). A 1.2 Kb Bgl 11 fragment and a 4.0 
kb Nco I fragment were identified to contain the putative promoter fragments. The Nco I 
fragment containing the putative FcF-Rl(x promoter, from -4000 to +45 was inserted into a 
reporter construct (Fig. 3.7) in both a forward and reverse orientation. Transient 
transfections were perfon-ned in the basophilic cell line KU812 (Kishi 1985). A 12 fold 
increase in expression from the putative promoter fragment was observed when compared to 
the same fragment in the reverse orientation (Table 3.3, and Fig. 3.8). Surpnsingly, when a 
shorter 1.25 kb Bgl H fragment was used, expression was greater in the reverse onentation. 
After 3 transfections, and confin-nation of the orientation by sequencing and restriction 
analysis, this result was reproducible. When both alleles of the two regions were re-cloned 
again, deleting all extra plasI-nid derived polylinker sequences generated during subcloning, 
the same result was observed (D. Fear, pers. comm. ). 
3.3 DISCUSSION 
The human FczRI(x gene displayed a moderate degree of homology to the mouse and rat 
genes in the 5' untranslated region (75%) and a high homology (90%), in the intron/exon 
borders. 
A polyrnorphism exists at nucleotide -71, either aC or aT occurring at this position, 
The C 
allele has been found to exist only in non-atopics, of 4 individuals in 30 
found to contain at 
least one C allele. Analysis of a larger sample size will be required to confirm that the 
polymorphism is linked to allergy. But as the C allele was not present in atopics, therefore the 


























Figure 3.6. Isolation of the FcF-Rl(x upstream sequences. (A), Preparative gel of the 
Bgl 11 and Nco I digests of RzRla clone 3C. 10 Bgl 11 and 7 Nco I bands (arrows) were 
isolated from the gel for identification by PCR and subcloning. The molecular weight 
marker (X Sty 1: X-C1857 cut with Sty 1) sizes are shown by the hohzontal lines. (B) PCR 
mediated identification of the FccRI(x upstream sequences using the oligos 5'CCR and 5FC 
(Table 3.1). The Bgl 11 fragment 3 and the Nco I fragment 6 were positive for the upstream 
sequences. (M), the molecular weight marker Blueschpt cut with Hpa 11. 
Bgl 11 x sty I Nco I 
Bgl 11 Bgl 11 Nco I 
123M45678M9 10 1234M567 
+41 Nco 
-12 Bgl I 
-1.2 kb Bgl I 



























C: 0) 0 







(1) -.:, X 
0 
















sU C: 0- 
3c-,, -C3 cc -I. - C: 
















Table 3.3. Promoter activity of 
the F(xR]cc upstream sequences. 
Construct 
Luciferase Activibl 
24 hr 48 hr 
PGL2 Ncol+ 0.026 0.110 
pGL2 Ncol- 0.006 0.007 
pGL2 Bglll+ 0.024 0.031 
pGL2 Bglll- 0.097 0.134 
pGL2 . 
005 0.05 
RSV Luc >90 >90 
a Absolute units of Luciferase, activity 
resulting from transient transfection of 
the 4.0 kb Nco I or BgI 11 promoter 
fragments were inserted into the 
reporter plasmid pGL2, in a forward or 
reverse odentation. Luciferase activity 
is compared to vector alone (pGL2) 
and an enhancer driven positive 
control (RSV-Lue). One 







Figure 3.8. Promoter activity of the F(xRl(x 
upstream sequences. Results of Table 3.3 
expressed in graphical format. 
a tAaP oA, I Lý, -. MetG] uAsp 
AiTGCAAGCTTGGCATTCCGGTAiCTGTTGGTAAAATGGAAGACI IAAGAAGATGGCT-C-CTG-CCATG G-GCCGGGAGC 
Nco I 
Figure 3.9. Sequence surrounding Wt codons in the luciferase reporter construct. 
Above, the amino acid sequence potentially added (blue) to the luciferase protein if the 
native methionine from the FceRla gene is used in the reporter construct instead of the 
methionine from the pGL2-luciferase gene. The pGL2-luciferase protein is shown in black. 
Centre, the nucleotide sequence of the 3' end of the FccRIct promoter fragment (cyan), 
fused to the polylinker sequences of pGEM-5Z (green), and pUC19 (red), and the pGL2- 
luciferase gene (magenta). The Nco I site (underlined) in the FcF-Rla gene Contains is at 
the end of fragment used for subcIoning into the reporter construct. 
ce 
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Subsequent to this work, Pang et al (1993) published the a sequence of the FcF-RI(x gene 
which was in agreement with ours at all positions. The sequence reported by Pang et al 
was the T allele in the polymorphism found in this chapter at position -71. 
The sequence TGATA at position -74 in the T allele is a potential GATA binding site. This 
sequence becomes TGACA in the C allele, and would likely reduce binding of GATA to the 
sequence. Although GATA has not been shown to bind to this sequence, EMSA analysis 
shows that two proteins of 50 and 100 kd bind here in the T allele, and only the 50 kd protein 
binds in the C allele. This pattern of binding could indicate that a protein binds to each of the 
two potential GATA sites surrounding the polymorphism. The fact that the 100 kd species 
could indicate binding of two identical 50 kd proteins also supports the idea that a protein 
binds to each GATA site. In addition to the two tandem GATA sites at -74 and -69 is 
another potential GATA site at position -122, that conforrns to the well known WGATAR 
consensus sequence. 
Two E-box motifs are present at bases -144 and -91. Multiple E-box elements are involved 
in the function of a number of regulatory elements; including the immunoglobulin enhancer 
(Ernst and Smale 1995), the immunoglobulin LCR (Meyer et al. 1995), and FHV- I (Ou et al. 
1994). b1HLH proteins bind to E-boxes, can form heterodimers with other family members, 
and may provide physical bridges between control regions, (Artandi et al. 1994; Ferre el al. 
1994). Either of the E-boxes may mediate interactions within the promoter, or with distant 
regulatory elements. Some of these interactions may be with the pre-initiation complex as is 
shown in associations between TFH-1 and c-Myc (Roy et al. 1993b) or USF (Roy et al 
199 1), affecting the efficiency of initiation. 
E-boxes mediate both positive and negative regulation (Ernst and Smale 1995). In the 
immunoglobulin enhancer, the E-boxes ýtE4 and ýtE5 mediate repression, whereas ýIE2 and 
gE3 are involved in activation. At least one bHLH protein potentially binding 
here, MyoD, 
mediates chromatin reconfiguration in skeletal muscle genes (Gerber et al 
1997), and is 
probably involved in transcriptional activation in part through this mechanism. 
Although 
MyoD is expressed in the myogenic lineage, other related bHLH proteins 
binding to this site, 
such as c-Myc, AP4 and E2A may perform the same 
function in myeloid cells. 
Transcriptional repression by at least one bHLH protein expressed in the myeloid 
lineage, 
MAD, is also mediated by chromatin reconfiguration through histone 
deacetylation (Laherty 
ei al 1997). 
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CHAPTER 4: Analysis Of Myeloma U266 Sývitch Recombination Junctions. 
4.1 INTRODUCTION 
During an immune reaction, antigen presenting cells display processed foreign antigen to B- 
lymphocytes in the lymph nodes (for review, see Kosco 1991; Neeýes and Momburg 1993). 
IgM beating B-cells recognise antigen in the context of class H MEC and the resting B-cell 
becomes activated. Activated B-cells can switch the heavy chain component of an antibody 
to a downstream isotype, thus changing the effector fanction of the antibody without 
changing the antigen specificity (Reviewed in Vercelli and Geha 1992; Coffman el al. 
1993). B-cell lines as well as B-cells isolated from peripheral blood, spleen and tonsil can be 
induced with combinations of lymphokines and ri-ýtogens to switch to IgG, IgE or IgA. In the 
human, primary B cells can be induced to switch to IgE and IgG4 in the presence of EL-4 and 
a second, cell contact mediated signal provided by activated T cells (Pene et al 1988; Vercelli 
el al. 1989; Gascan et al. 1991b), or granulocytic cells (Gauchat el al. 1993). The cell 
contact mediated signal can be mimicked by cross-linking CD40 on the surface of the B cell 
(Gascan el al. 199 1 a), or addition of Epstein-Barr virus (Jabara el al. 1990), which may use a 
similar pathway of signal transduction as CD40 (Mosialos et aL 1995). 
Leukaernic B-cell lines that express IgG, IgE or IgA show a deletion of the immunoglobulin 
heavy chain locus (for review, see Coffman et at 1993). Deletion events occur between 
switch regions, located 1-2 kb upstream of each immunoglobulin heavy chain (IgH) constant 
region locus except C8. Switch regions contain highly repeated DNA sequence elements, and 
show some homology to each other. During the proposed mechanism for deletional 
recombination (Honjo and Kataoka 1978; Jack et al. 1988), the association of two switch 
regions allows the looping out and ligation of the intervening DNA to forrn an 
extrachromosomal circle. 
Circular reciprocal recombination products have been isolated from B cells undergoing heavy 
chain svAtcIfing (Iwasato et aL 1990, Matsuoka et aL 1990, von Schwedler et aL 1990, 
Yoshida et aL 1990). Evidence for successive svAtching from ýt-q4--ýF- and 
g--xxI-->, y4--)e has been suggested from circular recombination products. Sy4/SF- and 
Socl/S-y4/SF- junctions have been cloned from circular reciprocal recombination products, 
suggesting that some cells giving rise IgE have previously switched to IgG4 or IgAl and 
IgG4 (Zhang et al. 1994). 
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In transgerk rnice, heavy chain recombination can occur between a M-ýt construct and the 
endogenous y-constant region on a different chromosome (Gerstein ef al. 1990). This 
suggests that switch recombination can occur between homologous chromosomes, though no 
evidence yet exists showing this happens in normal switching events. 
Recombination activity exists not only between, but also within switch regions. Deletions in 
the mu switch region have been found in subsequent switch junction analyses (Shapira et aL 
1991). Deletions in switch regions have been shown to occur after the initial recombination 
event (Zhang et al. 1995), and have been postulated to be involved in a mechanism of isotype 
stabilisation, by reducing the size of the switch region remaining. Deletions within the ýt 
switch region have also been found to occur prior to switching in Namalwa (Middleton et al. 
1991), a cell line that has not undergone a heavy chain switching event. Internal deletions in 
Sg also occur in mice deficient in switching (Cogne et at 1994), due to deletion of the 3'IgH 
enhancer, further suggesting that recombination activity exists in the mu switch region in the 
absence of switching. 
In chapter 4 the sequence of the switch recombination junction of the IgE secreting myeloma 
U266 (Nilsson et al. 1970; Nilsson 1971) is revealed. U266 appears to be the product of a 
sequential g-->(xl-->e series of switching events. In the mu and epsilon switch regions two 
prominent pentamers, GAGCT, and GGGCT, were demonstrated to be highly repeated on 
the top strand of each switch region, and are probably involved in the mechanism of 
recombination. 
4.2 RESULTS 
4.2.1 Sequence of the U266 recombination slvitchj unction. 
Our objective was to map the location of a g--->e recombination event 
by sequencing a switch 
recombination junction clone. We chose the IgE secreting myeloma 
U266 (Nilsson et aL 
1970; Nilsson 197 1) as a source of the SWSF- switch recombination product. 
The clone 
XP- 1.2 (Fig 4.1, Flanagan and Rabbitts 1982), originating from U266, contains a rearranged 
epsilon locus (Flanagan and Rabbitts 1982). Comparison of the restriction 
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XF-1.2 with that of the germline mu (Buluwela ef al. 1988), and epsilon (Max el al. 1982' 
Ueda et al. 1982; MIN el al. 1990) loci suggested that the svAtch recombination event 
occurred within a 0.6 kb PstI-KpnI fragment (Fig. 4.1). Both the Pstl-Ncol fragment, and a 
0.8 kb Pstl-Kpnl fi7agment were subcloned fi-om 41.2 into bluescript and sequenced. 
Sequencing from the 3' Pstl site in Sýt revealed a 252 base deletion from nucleotides 3781 - 
4033 of Sg (see box 1, Fig. 4.2). A second deletion of 1640 bases occurred in Sýt at 
nucleotides 4220-5860 (see box H, Fig. 4.2). Between the SpJSE recombination junction is a 
28 nucleotide ftagment originating from position 1265-1292 of Sal (see box M, Fig. 4.2). 
The presence of a Sal fragment between Sýt and Se in the region of the recombination join 
suggests that U266 switched to IgAl prior to the expression of IgE (Fig. 4.3Q. The svAtch 
recombination event to IgAl to IgE occurred at base 3173 of the germline epsilon sequence 
(see box IV, Fig. 4.2). 
Significant sequence homology exists between the switch regions that gave rise to the internal 
Sg deletions (bases 3781-4033 and 4220-5860), and the SWS(xI switch recombination event 
are (Table 4.1; Appendix 1-3). Because of the homology between the switch region 
sequences, it was not possible to detennine the exact location of the recombination events 
resulting in the Sg deletions and the g->(xl switching event. The homology between each 
switch region that underwent a deletion or switch recombination event suggests that semi- 
homologous pairing of switch regions contributes to the mechanism of switch recombination. 
Homology between Se and both Sg and Scc I was low (Table 4.1; Appendix 4), suggesting 
that although homology between switch regions may play a role in the mechanism of switch 
recombination, a high degree of homology is not a requirement. Subsequently published 
SýUSF- junctions (Shapira et al. 1992; Zhang et al. 1994) demonstrated homology at the site 
of recombination between Sg and Se in other switching events (Fig. 4.4). 
The deletion of Sg bases 3781-4033 and 4220-5860 could have occurred at any time In the 
sequence of switching events. Because of the high degree of 
homology with. in Sýt and 
between Sg and S(x, and the significantly lower homology between these regions and 
Se, the 









3571 'C'ATC, ' 
U266 CTTTCAGAAATGGACTCAGATGGGCAAAACTGACCTAAGCTGA 





Sýt CTGAGCTGAGCTGAACTGGGCTGAGTTGAACTGGGTT'uAGCTGAGCTGAGCTGAGCTGG,, 'iC TAAGTTGC A 3709 
I 
Sg GGCTGCGCTGAGCTGGGCTGGGCTGAGCTGGGCTAGGCTGGGCTGAGý'TGGG, -TGA' C 4032 
lill 1111 111 Hill 11 111111111 1111111 1 111111111111 
U266 CCAGGTGAGCTGAGCTGAGCTGGGCTTGGCTGCACTAAGCTGGGCTGAGCTGGGCAGubuiuuuuiGAGC 349 
Sýl CCAGGTGAGCTGAGCTGAGI. CTGGGCTTGf--ý, C TSC ACTA AG TtG), G ýG CTC, t 3779 
Sýt TAGGCTGGGCTGGGCTrýGGf,, TGAGOfýG, ýý'cýýý_'-! 4101 
U266 TAGGCTGGGCTGGGCTGGGCTGAGCGGGGCTGAGCGGGGCTGAGCTGAGCTAGGCTGGGCTGAGCGGGGC 419 
Sp I GAGCTGGGCTGGGCTGAGCTGGGCTGGGCTGGGCTGGGCTGAGCGGTCTAGC 3832 
Sg TGAGCTGAGCTAGGCTGGGCTGGGCTGGGCTGAGCCAAGCTGAACCGGC-TTGACiC ýTu -11 -CTGTC, -'TGGýCT 4171 
U266 TGAGCTGAGCTAGGCTGGGCTGGGCTGGGCTGAGCCAAGCTGAACCGGGTTGAGCGTGCTGTGCTGGGCT 489 
-"FGAU'C-FGAGCCAAGI-TGAGCTTAGCTGGGCTGA'uC-//-TT'. ý'ý,, 'ý"i'l. 'T(ýA(-, ýý, -IGG3ý-'I 1280 Sa I 4L Gt", G'(. 'CAAGC TAGG, 
U266 GAGCCAAGCTAGGCTGAGCTGAGCCAAGTTGACCTTAGCTGGGGTGAGTTGGGCTGGGCTGAGCTGGGCT 559 
SýL GAGCTGGGTTAAGCCGAGCTGGGTTGGGCTGGGCTGGGTTGGGCTGGGCTGAGCCGb bt5bu 
IV 
Sal AAGCTGGACCTGGCTGGGGTGAGCT 1305 
U266 AAGCTGGACCTGACTGTGATTTTGGGGGTACCTAGAGCAGACTTCAAGACCAAGCTAOCTGGGCTCCAG 629 
Se GGATACTGTGATTTTGGGGGTACCTAGAGCAGACTTCAAGA, 'CAAGCTAAACTGGGCTCCAG 3231 
U266 GGGCAGGATGGGCTGGG-ACTTGG-ACTCCAGGCCAGGGGCGAAGGGCCACGCTGTACAGACCGCAC-AT 696 
SE GG(iCAGGATGGGCTGGGGACTTGGGACTCCAGGCCAGGGGCGAAGGGCCACGCTGTACAGACCGCACTAT 3301 
U266 CTGGGCCAGGGTTCTGTGGTGGGAGGGACTGACTGCCTGGGGCATCAGGGCAAG-CTTTCCCGCC-TCCC 764 
III HIM 1111 
SF- CTGiý-, GCCAGGGTT(-, TGTo-GTGGGAGGGACTGACTGý^CTGGGGCATI, 'AGGGCAAGTCTT-CCCGCCCTCCý'- 3370 
U266 CTAGAGGTCAGGGGTGGGCAGAGCACCATGG 795 
SE CTAGAGGTCAGGGGTGGGCAGAGCACCATGG 3401 
Figure 4.2. Sequerwe of the U266 recombination junction. The sequence of the 
U266 switch 
recombination junction is shown next to regions with 
identity (red) to Sg, Sal, and SE. Boxes, recombination 
junctions. 






















Figure 4.3. Proposed switch recombination events in the U266 heavy chain locus. 
(A) the locabon of svAtch recombinabon events in U266 on the heavy chain locus map. (B- 
E) proposed switch recombinabon intermediates in U266. (1& B) delebon of Sj. 1 bases 
4220-5860. (2 & C) CWCO switching event; (3 & D) CcO/C. F- Switching event; (E) partial 
sequence of U266. Verfical bars, idenbty between adjacent sequences. Lower case 
letters, sequence of unknown origin. 
Table 4.1 Homology between switch 
Recombination Event 15' Switch 
ions surrounding sites of recombination. 
3' Switch 
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Sg Deletion 3781-4033 Sg 3598-3848 Sg 3851-4100 65% 




3554-7010 SO 591-2402 68% 
Sal --. >Sc Switch 
-- 
SO 1048-1607 Se 2929-3488 30% 
a Homology is shown between switch region sequences (5' Switch Region 3', Switch Region) proposed to pair prior to the recombination event. The location in the published sequence, of the switch regions compared is shown. 
1640 bp Deletion 
v 
U266 ... CTTAGCTGu-GgTGAGTTGGGCTGGGCTGAGCTGGGCTAAGCTGGACCTGACTGTGATTTT 2C4 ... GGGCTGAGCT'GGGCTGAtCTAcgC TGGaC TGAAC TGAGCAGAGC -FGAACCTAGCTGGGCT... A5-1 ... CTAACCTGGGCAGAGCTGAGCTGGGCTGAGCTAACCTGTGGCCTGGCCTCGGC ... A5-2 ... TGGCCTGGCCTCGGCGGaCTGGGCTGAGCAGGCCTGAGCAGG ... HJS6 ... CTGAGCTGGGCTGAGCTGGGCTGAAATGGGCTGAGGTGAGCTAG... HJS7-1 ... CTGCAGTAA-CTGGGCTGAGCTGGGCAGGGCTGGGCTGAaCTGAaCTGGGCTGGA ... HJS7-2 ... TTTCAGAAATGGACTCAGATGACCTGGCCTGAGTTCAGCagggcTGCGCTGAG ... SKS281 
... TGGGCTGAGCTGGGCAGGGCTGTCTACgC*TGGGCTGAACTGAGCAGAGCTGAACCTAGCT SKS282 
... TGAGTTGAACTGGGTTGAGCTGAACTGGGtTGAGCTGGGGAGGACT ... SKS283 
... TGGGCTGAGTTGAACTGGGTTGATGAACCTAGCTGGGCTGGGCTAAA ... SKS285 
... TTTCAGAAATGGACTCAGATGGGGGAGGACTAGGCTGGGTGAGTGAC ... SKS286 
... TTGAACTGGGTTGAGCTGAGCTGATTGAGATGGCTGGACTGAAATAA ... SKS287 
. .. GAGACAAAAGATGGAAGCCAGCCTAGGTTGGGCTGGGTTýGGCTAAA ... SKS288 
... AGCTGAGCTGAACTGGGCTGAGTTGAATGGAGCTGGGCTGAGCTGGCCTGGCCGGGCCTG ... 
pSC1.7-56 ... GGGTGATCTGAATTTAGCTGGGCTGAGCTGGGCTGAGCTGGGCTGAGCTGGGCTGAGCAAG 
pSC1.8-23 ... GGGCTGGGGTGATC TGAATTTAGCTGGGTTGAGCAGAGCTGGGCTGG... 
pSC1.8-10 ... AGCTGGGATGAGCTGGGCTGGGCTGAACTGTGCTGAGCAGGGCTGAGCTGAACTGGGCTG ... 
pSC1.7-12 ... GTTAGTCTGGGAAGCTGGGCTGGGTTGGGCTAGCTGGGCTGGGCTATACTfLELTTAGCT ... 
pSC1.7-6 ... GGGCTGGGGTGATCTGAATTTAGCTGGATTGAGCTGGCCTGGGCTGGGATGAAC ... 
pSC1.7-2 ... GGGCTGGGGTGATCTGAATTTAGC 
TGGGCTGGGCTGGGATGAACTGGAGGACATGGCA ... 
pSC1.7-1 ... CTAACCTGGGTTCAGCTGGCCTAGGTTGGGCTGGGATGAACTGGAGGACATGGCACTGGG ... 
pSC1.1-12 ... TTATCCTAAGCCCTAAGGTGGACTGAGCT, 
GGCCTGGGCTGGGATGAACTGGAGGACA... 
pSC1.1-7 ... CGGGTTTAGCTGAGTTGAGTGAGTGGACTGGGCTATACTGGGCTTAGCTGGGCTGGGCTG ... 
pSC1.1-4 ... GCTGTGTTGAGTGAGTGGACTGGGTAGAGGGGCTGTGCTGAACTATGCTGGGCTGGGCTA ... 
pSC1.7-4 ... GAGCAGGCCTTAAATTattgaactaaattGAGCTGGGTTGAACTGTGCTGAGCTGAGCTG ... 
Fibroblast ... C 
%GCTGGGCTGGGCTGGGTTCAGCTGAGCGGGGTT ... 
HJS102 ... TTGGCTGCACTAAGCTGGGCTGGGCTGGGCT--ii---A 
j, - -iý --, GTTCAGCTGAGCGGG ... 
Figure 4.4. Sequence of the switch recombination junctions. Recombination junctions 
from the IgE expressing plasmacytoma cell line U266, the IgE-expressing EBV lines 2C4, 
A5, HJS6, HJS7, the non-IgE expressing EBV line HJS102, and the fibroblast line 
SKS252 (Shapira et al. 1991; Mills et al. 1992; Shapira et al. 1992) (see Table 4.2 for 
locations). pSC1.1-4-pSC1.8-23 are DNA clones amplified by PCR from primary B cells 
induced with 11-4 and a-CD40 (Zhang et al. 1994). Green shows regions of 
homology 
between Sg and Se near the switch recombination junction. Sequence was identified as 
originating from the Sg region (red), Se (blue), either 
Sla or Se (green), Sal (purple) 
unknown (lower case black). The pentamers 
GAGCT and GGGCT are underlined. 
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Table 4.2. Locatinn-q nf _qwitt-h rcinnrnhinntimn oxiontca Clone Cell Type Location Sýt Location SF- Event Refe - rence 
U266 Myelonla 7219 3174 SPISF- (Shapira et al. 199 1: 
Mills et al. 1992) 
2C4 EBV line 4030 2405 Sýtlse (Mills et al. 1992) 75 
-I EBV line 4330 2743 SýUSF- (Shapira et al. 199 1) 
A5-2 EBV line 3778 2787 SýLISF- (Shapira eta/. 1991) 
HJS6 EBV line 3884 2535 SýL/SE (Shapira et al. 1991) 
HJS7-2 EBV line 35 92 1562 SýL/SF- (ShapIFaet al. 1991) 
HSJ7-1 EBV line 3782 2491 S[L/SE (Shapira et al. 199 1) 
pSCI. 1-12 Primary B 6946 1333 SýUSE (Zhang et al. 1994) 
pSC 1.1-32 Primary B - 1327 Sy4/S(x I/Sc (Zhang et al. 1994) 
pSC 1.1-35 Primary B - 1508 SE/Sy4 (Zhang et al. 1994) 
pSC 1.1-4 Primary B 6689 1265 SýUSF, (Zhang et al. 1994) 
pSC 1.1-40 Primary B - 1510 SF-/Sy4 (Zhang et al. 1994) 
pSC 1.1 -7 Primary B 6819 1258 SýUSF- (Zhang et al. 1994) 
pSC 1.2-65 Primary B - 1496 SE/Sy4 (Zhang, et al. 1994) 
pSC 1.5-1 Primary B - 1254 Sc/Sy4 (Zhang et al. 1994) 
pSC 1.5-8 Primary B - 1300 SF-/Sy4 (Zhang et al. 1994) 
pSC 1.6-5 Primary B - 1677 Se/Sy4 (Zhang et al. 1994) 
pSC 1.7-1 Primary B 6952 1974 Sýt/se (Zhang et al. 1994 
pSC 1.7-12 Primary B 6783 1901 SýUSE (Zhang et al. 1994) 
_ 
pSC 1.7-2 Primary B 6951 1760 SýUSF- (Zhang et al. 1994) 
_ pSC 1.7-22 Primary B - 1781 SF-/Sy4 (Zhang et al. 1994) 
pSC 1.7-4 Primary B 6659 1732 Sg/SE (Zhang et al. 1994) 
pSC 1.7-56 Primary B 3849 1759 SýL/Sy4/SF- (Zhang et al. 1994) 
pSC 1.7-6 Primary B 6938 1757 Sýt/sc (Zhang et al. 1994) 
pSC 1.7-67 Primary B - 2395 Se/Sy4 (Zhang et al. 1994) 
PS C 1.8 - 10 Primary B 6434 1783 SýUSF- (Zhang et al. 1994) 
pS C 1.8 -23 Primary B 6018 1758 Sýt/sc (Zhang et al. 1994) 
SKS281 Primary B 3771 2408 SýL/SE (Shapira et al. 1992) 
SKS282 Primary B 3682 2167 SýUSF- (Shapira et al. 1992) 
SKS283 Primary B 3678 2435 SýUSE (Shapira et al. 1992) 
SKS285 Primary B 3594 2181 SýUSE (Shapira et al. 1992) 
SKS286 Primary B 3685 3005 SýLISF- (Shapira et al. 1992) 
SKS287 Primary B 3478 1962 SýL/SF- (Shapira et al. 1992) 
SKS288 Primary B 3668 2150 Sg/SF- (Shapira et al. 1992) 
HJS102 EBV line None None None (Shapira et al. 1991) 
Locations in Sýt (Appendix 5) and SF- (Appendix 6). 
4.2.2 The presence of pentameric repeats in Sg and Se. 
The pentamers GAGCT and GGGCT are present near each switch recombination junction 
(Fig. 4.4; Appendix 5,6). The presence of the repeating pentarners corresponds to the 
location of switch recombination events in Sýt and Sc (Fig. 4.5-7). The pentamers 
GAGCT and GGGCT occur almost exclusively on the top strand, suggesting they may be 
involved in the mechanism of switching, possibly to aid in the semi-homologous pairing 
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Figure 4.5. Location of pentamers and switching events in the mu and epsilon 
switch regions. (A, C), Frequencies of the pentamer GAGCT in the upper strand (red), 
and lower strand (dark blue), and the pentamer GGGCT in the upper strand (green) and 
lower strand (light blue) of the mu and epsilon switch regions. The frequency of switching 
events (recombination events, black, see Table 4.2) is also shown, compared to the 
relative positions in the mu and epsilon locus (B, D). 
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4.3 DISCUSSION 
The myeloma U266 appears to be the product of a sequential switch from IgM--AgA I -ýIgE, 
leaving a 28 nucleotide S(x I fragment between the Sg and SF- recombination junctions. One 
further IgJ\4-AgAI--*IgE switching event has subsequently been published by Zhang et al 
(1994). Because IgA is not normally induced by events leading to the production of IgE, the 
progenitor cell for the he U266 may have initially responded to stimuli specific for switching 
to IgA, such as IIL-10 and TGF-P (van Vlasselaer et al. 1992; Fayette ef al. 1997). The 
U266 progenitor potentially later was exposed to Th. 2 cytokines, received the necessary 
and responded to the appropriate cell contact mediated signals for switching to IgE. The 
two switching events probably did not occur through a common set of stimuli since the 
stimuli inducing switching to IgA, such as TGF-P (Gauchat et aL 1990), inhibit 
switching to IgE. 
The location of the switch recombination events were within the SR Sal, and Se regions, like 
subsequently published switching events (Shapira et al 1991; Mills et aL 1992; Shapira et al 
1992; van der Stoep et aL 1994). Two deletion events occurred within SýL. Both the 
deletion events, and the Sýt-xxl switch recombination event occurred in areas of significant 
switch region homology. The high level of homology between the switch regions near a site 
of recombination further supports a model where serni-homologous pairing between switch 
regions is important to the mechanism of svvitch recombination. More recent reports have 
demonstrated that IgM->IgE recombination events also occur at regions of homology 
between Sýt and SF- (Shapira et aL 199 1; Mills et aL 1992, Shapira et al. 1992; van der Stoep 
el aL 1994). 
Switching to IgE has also been reported to occur via IgG4 (Mills et al. 1992; Zhang et 
al. 1994). Most of the switching events via IgG4 were detected by a polymerase chain 
reaction (PCR) strategy that is biased to select for the presence of the S74 containing 
switch circles (Zhang et al. 1994), and evidence from van der Stoep et al (1994) 
suggests that most switching events to IgE occur directly from IgN4-AgE. 
The repeating pentarnefic units GAGCT and GGGCT were present on the top strand in both 
the mu and epsilon switch regions. The presence of the pentarners on the top strand supports 
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a model that they help direct the alignment of the two switch regions prior to the 
recombination event by increasing the level of homology between the switch regions. The 
pentamers could also serve as binding sites for proteins involved in the association of the two 
switch regions, or for components of the recombination apparatus. 
An analysis of the location of recombination events reveals that most of the recorded events 
occur at both borders of the areas of pentameric repeats in the mu switch region, and at the 5' 
border of the Se repeats. The positioning of the recombination events at the border of the 
pentameric regions suggests that the structure of these regions could determine the 
general location of the recombination events. The role of the pentameric units could be 
to either aid in the positioning of recombination events by either directly interacting with 
the recombination apparatus, or by physically excluding recombination from the 
pentameric region, or by a combination of the two possibilities. 
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CHAPTER 5: Cloning and Characterisation of the F--Germline Transcript. 
5.1 INTRODUCTION 
Prior to heavy chain switcling the IgH constant region locus to which switching is directed 
becomes transcriptionally active (Stavnezer-Nordgren and Sirlin 1986; Lutzker and Alt 1988, 
Stavnezer et al. 1988; Berton et al. 1989; Esser and Radbruch 1989; Bottaro et al 1994) and 
its transcription is referred to as germline gene transcription. Several murine and human 
germline transcripts have been cloned, and share structural similarities (Reviewed in 
Vercelli and Geha 1992, Coffman el aL 1993). The germline gene transcripts initiate 
from TATA-less promoters within 2 Kb upstream of the switch region, and proceed 
through short exons (germline or IH exons) that are spliced to the first exon of theCH 
gene. Germline transcripts are not translated because of multiple stop codons present in 
the germline exon. The region containing the germline promoter and the IH exon is 
deleted during switch recombination. 
One theory for the role of germline transcription in heavy chain switching is that it directs 
switching by modulating the accessibility of a particular switch region to a common 
recombinase. Thus, the specificity of switching may be directed via the regulation of 
germline gene transcription. In vitro experiments also suggest that germline transcripts 
form tri-molecular complexes with the switch region and may be involved in the 
association of the two switch regions prior to recombination (Reaban et aL 1994; Fujieda 
et aL 1996). 
Germline transcription is a required event for switch recombination to occur. The 
importance of germline transcription in isotype switching is shown by gene knock-out 
experiments. Deletion of the IyI or Iy2b exons and their promoters resulted in the 
inhibition of class switching to the corresponding genes (Jung et al 1993; Zhang et aL 
1993). The loss of switching after deletion of the germline exon and promoter suggests 
that transcription in the switch region is necessary to target the appropriate switch region 
for recombination and switching. Transcription itself, although necessary, is not 
sufficient for switch recombination. An Eg. NH promoter cassette, containing no exon 
sequences, cannot restore normal levels of switch recombination when inserted in place of 
the F--germline gene promoter and exon (Bottaro et aL 1994). Furthermore, conservation of 
82 
the germline exon 3' splice donor sequence is required in addition to transcription for normal 
levels of switch recombination, suggesting that a correctly spliced germline transcript is 
required (Lorenz el al. 1995). 
With the essential role of germline transcription in switch recombination well established, it is 
therefore important to understand how the induction of germline transcription is 
regulated. Different cytokines specifically activate transcription at the appropriate 
germline promoter. In particular, EL-4 has been shown to induce F, germline transcripts 
in murine B cells (Rothman et al. 1990; Severinson et & 1990; Rothman et al. 199 1). 
The work in this chapter describes the cloning of the human germline gene transcript for the 
heavy chain gene of IgE. Additionally the F. germline gene transcription start sites were 
determined in primary B cells and B cell lines. A comparison of the genomic sequence 
between three individual people has revealed a polymorphism in the germline exon. 
5.2 RESULTS 
5.2.1 Structure of the F--germline gene transcript. 
To clone the cDNA for the F--gen-nline transcript, polymerase chain reaction (PCR) primers 
were designed near regions of homology between the human switch region sequence and the 
mouse germline-F- (GL-c) exon (Fig. 5.1). Homology between the mouse GL-E exon and a 
538 base segment upstream of the human epsilon switch region was 67%, and potentially 
contained the human GL-F, exon. 
RNA was isolated from PBMC incubated with IIL-4 for 5 days. Second strand cDNA was 
synthesised (see Materials and Methods 2.16) and used as a template for PCR using primers 
specific for the putative germline exon and CO, yielding a 1497 base product (Figs. 5.2,5.31 
Table 5.1). To clone the 5' end of the cDNA, circular PCR was performed on cDNA that 
was cleaved at a I-EncII site in the 3' end of CF-I and circularised to its 5' end. Primers 
specific for the germline exon, and the 3' end of eCHI were used to amplify a product across 
the 5' end of the gerrnline exon and the ligated ends of the cDNA circle. The PCR products 
were inserted into Bluescript and sequenced (Fig. 5.4; Table 5.2). 
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Human 1 GGATCCCCGGCTGCAGGACAGTGACCTGGGAGTGAGTACAAGGTGAGGCC 50 
III I1 1111 1 11 11 11 11 Hill 1 11 111 Hill 
House 214 GGACCTCAAGCTGAAAGATAATCACTTGTGAGTGGGCACCAGGGAAGGCC 263 
Human 51 AC ... CACTCAGGGTGCCAGCTCCAAGCGGGTCACAGGGACGAGGGCTGC 97 11 1 111 11 Hill 11 1111 111 
Mouse 264 ACTGTCCCTC. GCATGCCAGCTCCAAAGCTGATACAGGAACTAGGG. TGC 311 
Human 98 GGCCATCAGGAGGCCCTGCA.. CACACATCTGGGACACGCGCCCCGAGGG 145 
1 lill 11111111111 11 111111 11 11 
Mouse 312 CTCTATCA. GAGGCCCTGCAATGTCATATCTGG 
.......... CCCACAG 350 
Human 146 CCAGTTCACCTCAGTGCGCC. TCATTCTCCTGCACAWGCGCCCCCATC 194 
1 1111 11 lill 11 11111 11 11 11 11 
Mouse 351 GCTGTTCCTCTTTGTGCACCATTAATAACTTACAAAGTGACAGCCACA.. 398 
Human 195 CTTTCTTCACAAGGCTTTCGTGGAAGCAGAGGCGTCGATGCCCAGTACCC 244 
11 1 111111 111 lill I III 1 11 
Mouse 399 .. CTCCCCTGAAGGCTGCCAAAGGAACAGAAAAAGCAATGGCGAuuulUI 446 
Human 245 TCTCCCTTTCCCAGGCAACGGGACCCCAAGTTTGCTGAC. TGGGACCACC 293 
III I IIII 1 11 1111 11 11 111 11 
Mouse 447 AGTCCTGCCTCAGGGCAGTGACACTCCAAAGGGGCAGGCATGGTGACTGC 496 
Human 294 AAGC. CACGCATGCGTCAAGAGTAGAGTCCGGGACCTAGGC. AGGGGCCC 341 
1 11 111 1111 1111 111 11 11 111 11 111 1 11 
Mouse 497 ACGCACACACATG... CAAGGCTTTAATACGAGAGCTATGCAAGGAGACC 543 
Human 342 TGGCGTTGGGCCTGAGAGAGAAGAGAACCTCCCCAGCACT .... CGGTGT 387 
III III IIII IIIII III III IIIII 
Mouse 544 TGGGATCAGACGATGGAGAATAGAGAGCCTTGACCAGAGTGTGCAGGTGT 593 
H- 
Human 388 GCATCGGTAGTGAACCAGCCTCACCTGA. CCCCCGCTQTTGCTCAATCGA 436 
1 11 111 11 11111111111 lill lirl II I II I 
Mouse 594 GTCTC. CTAG. AAAGAGGCCTCACCTGAGACCCCACTGTGCCTTAGTCAA 641 
G 
Human 437 CTTCCCAAGAACAGAGAGAAAAGGGAACTTCCAG&GCGGCCCGGGCCTCC 486 
House 642 CTT. CCAAGAACAGAATCAAAAGGGAACTTCCAAGGCTGCTAAGG ... 
CC 687 
Human 487 TGGGGTTCCCACCCCATTTTTAGCTGMAGCACTGAGGCAGAGCTCCCCC 536 
Mouse 688 GGGGGTTCCCACCCCACTTTTAGCTGAGGGCACTGAGGCAGAGCGGCCCC 737 
Human 537 TA 538 
11 
Mouse 738 TA 739 
Figure 5.1. Homology between the sequences surrounding the mouse GL-e exon 
and the corresponding area upstream of the human switch region. The human (Mills 
et al. 1990) and mouse (Gerondakis 1990) sequences are compared. The mouse GL-C 
exon is shown in red. Arrows represent the position and orientation of the oligonudeotides 
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Table 5.1 Oligonucleoticles used in this study. 
-Oliclo ------- ..... 
§! ýquence Location 
Actin GAGCACAGAGC TCGCCTTTGC 267-288a 
Actin R GGATCTTCATGAGGTAGTCAGTCAGG 2242-2217a 
B TCTAGAGCTCACTAGTCACTCCATCGTCCACAGACTG 534-554 
b 
C ATCGATCTCGAGTCGACGCAAGCTGATGGTGGCATAGTGAC 458-481 
b 
C2 ATCGATCTCGAGTCGACAGAGTCACG GAG GTGGCATTG 325-347 
b 
CF-2.3 CGTCGCAGGACGACTGTAAG 613-633 
b 
CF-4 CGCTCGCTGGACGGTCTGTGAG 1408-1429 
b 
F CATCAGCTTGCTGACCGTCTCG 470-491 
b 
G CGAATTCCCAAGAACAGAGAGAAAAGGGAACTTCCAAGG 36-69 
b 
H ACTAGTCTAGACTTGGGAAGTCGATTGAGCAAC 22-43 
b 
Q CCATTTGGTGCCTGTGGATGGTGTG 227-251 
b 
Location in the a human P-actin gene (Nakajima-lijima et al. 1985), or the b F--germline gene 
transcript sequence (Fig. 5.4). 
A 






Figure 5.3. PCR amplification of F, -germline transcript cDNA. (A) Amplification of F-- 
germline transcript cDNA with primers G and CF-4 (Table 5.1). Markers, 
Hpall cut 
bluescript SK+. Media, PBMC cultured in media only for 3 days. IL-4, PBMC cultured in 
the presence of IL-4 for 3 days. Arrow, band excised for cloning. (B) Markers, 
Hpall cut 
bluescript SK+. Amplification using primers H and F, of the 5' end of F--germline 
transcript cDNA from PBMC induced for 3 days with IL-4 . Arrows 
indicate 3 regions of 
















































Figure 5.4. Sequence of the F- germline transcript. (A) Map of the epsilon locus in 
gennline configuration. (B) Sequence of the germline exon (red), and of the constant 
region exons (blue). Binding sites of the PCR primers (arrows) used to clone the Send (H, 
F), and the 3' end (G, Ce4) of the germline transcript. The stop codons (underlined), and 
the only ATG (black), are indicated. 
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Table 5.2. Location of F, -germline transcript cDNA 5'ends. 
L., Yl 
, 
2oe- LocationL' Clond" Location! ý 
1.4 1 2.7 1 
1.11 1 2.13 1 
1.12 1 1.22 3 
1.13 1 2.5 3 
1.14 1 2.6 3 
1.15 1 2.11 3 
1.16 1 2.12 3 
1.17 1 2.3 19 
1.18 1 2.4 20 
1.19 1 2.8 20 
1.21 1 2.9 20 
2.1 1 2.10 21/22 
ba 
5) ends of cDNAs cloned by circular'lPCR. 
Location in the germline transcript sequence (Fig. 5.4) 
The Cc exons of the germline transcript showed 100% identity to the published sequence 
(Flanagan and Rabbitts 1982). The sequence of the GL-F- exon was 98% similar to the 
published sequence upstream of Sc (Fig. 5.5; Mills et al. 1990), and situated about 500 bases 
upstream of the switch region (Fig. 4.5; Appendix 6). Each of the 4 clones sequenced were 
identical except for position 224, which had either an A or G and potentially represented a 
polymorphism. 
To confirm that a polymorphism exists at position 224, and determine the correct sequence 
for the GL-F- exon, we cloned genomic DNA for this region by PCR (Fig. 5.6; see Materials 
and Methods 2.18). Primers were chosen from the published genomic sequence 380 bp 
upstream of the germline exon, and 17 bp downstream of the exon. Nineteen clones were 
analysed from the DNA of 3 individuals (Table 5.3). The sequences agreed at all positions 
except for either aG or A at nt 604 of the genonuc sequence. Of the three individuals 
analysed, one was homozygous for the A allele, and two heterozygous. The sequence of the 
cDNA clones agreed 100% with either the A or G allele of the genorrfic DNA sequence. 
Similar to the germline transcripts previously reported for ýt, y2p, and F_ (Lennon and Perry 
1985; Lutzker and Alt 1988; Rothman et al. 1990), an in-frame AUG is not present in the 
germline exon. The only ATG found in the F--germline exon is translationally out of frame 
with the constant region (Fig. 5.4). In addition, stop codons are present in each reading frame 
in the gerrnline exon, consistent with the observation that germline transcripts are not 
translated. 
The intronic sequence at the intron/exon border of the F--gen-nllne exon (Figs. 5.4,5.6) obeys 
the GT ..... intron ..... 
AG rule (for splicing review, see Padgett et al. 1986). 
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38A CAGCCTCACCTGACCCCCGCTGTTGCTCAATCGACTTCCCAAGAACAGAG 452 
CDNA GAGCCTCACCTGACCCCCGCTGTTGCTCAATCGACTTCCCAAGAACAGAG 50 
38A AGAAAAGGGAACTTCCAGGGCGGCCCGGGCCTCCTGGGGTTCCCACCCCA 502 
CDNA AGAAAAGGGAACTTCCAGGGCGGCCCGGGCCTCCGGGGGTTCCCACCCCA 100 
38A TTTTTAGCTGAAAGCACTGAGGCAGAGCTCCCCCTACCCAGGCTCCACTG 552 
CDNA TTTTTAGCTGAAAGCACTGAGGCAGAGCTCCCCCTACCCAGGCTCCACTG 150 
38A CCCGGCACAGAAATAACAACCACGGTTACTGATCATCTGGGAGCTGTCCA 602 
cDNA CCCGGCACAGAAATAACAACCACGGTTACTGATCATCTGGGAGCTGTCCA 200 
38A GGAACCCGACA.. GAGCCGGA. GGGCCACA. CATCCACAGGCACCAAATG 648 
CDNA GGAACCCGACAGGGAGCCGGACGA-G'CCACACCATCCACAGGCACCAAATG 250 G 
38A GACGACCCGGCGCTTC 664 
cDNA GACGACCCGGCGCTTu 266 
Figure 5.5. Identity between the GL-e and published Sc sequences. The 
GL-e exon sequence (cDNA) is compared with the published genomic Se 
sequence from X done 38A (Mills et al. 1990). 
CCTGGGAGTGAGTACAAGGTGAGGCCACCACTCAGGGTGCCAGCTCCAAGCGGGTCACAGGGACGAGGGC 70 
TGCGGCCATCAGGAGGCCCTGCACACACATCTGGGACACGCGCCCCGAGGGCCAGTTCACCTCAGTGCGC 140 








Figure 5.6. Genomic sequence surrounding the GL-c exon. Red, GL-e exon; 
PCR primers, horizontal arrows. 
Table 5.3. Occurrence of the polymorphism at 
aNumb I er of PCR ge In-e ra I ted I clones 1, with the 
A or G allele sequence from the genomic 
DNA of three donors (1,3, and 6). 
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5.2.2 E-germline transcript expression. 
Expression of the F, -germline gene transcript was investigated in cultures of PBMC and in 
the B lymphoma line Namalwa (Middleton et al. 1991). PBMC were induced with fL-4 
over a 13 day period and assayed at 12 hours, 1,2,3,5,7,9,11, and 13 days for both 
secreted IgE by enzyme-linked immunoabsorbent assay (ELISA), and the E-germllne 
gene transcript by PCR (Fig. 5.7). Secreted IgE became detectable at day 5 in PBMC, 
and reached a maximum at day 9 of culture with IIL-4. Germline transcript levels were 
detectable by RT-PCR as early as 12 hours after IIL-4 addition, and reached a maximum 
at day 3 after IL-4 addition, supporting the model that the induction of germline 
transcription precedes switching. e-GLT were also detectable, at lower levels, without 
added IL-4 during a shorter time period between 3 and 9 days of culture. The 
expression of germline transcripts without added IL-4 is presumably due to production 
of type 2 cytokines by T cells activated during or prior to the initiation of the culture. 
The B cell line Namalwa also induced the expression of the &GLT after treatment with 
IL-4 over an 8 day period, with the expression again undetectable 22 days after IL-4 
addition, showing that an IL-4 stimulus is required for the maintenance of germline 
transcription. After 22 days of culture, all of the EL-4 activity was presumably degraded. 
Germline transcription was also detected in an IL-4 induced EBV B cell line (A5), in 
Tonsil cells induced with IL-4, but not with the IgE secreting plasmacytoma U266 
(Nilsson et aL 1970). The lack of F--GLT expression in the cell line U266 agrees with 
other reports (Gauchat el aL 1990), and is presumably due to the fact that heavy chain 
recombination occurred on both chromosomes, deleting the F, -germline exon. 
5.2.3 Location of E-germline transcript start sites. 
To find the transcription start site, SI protection was perfon-ned on RNA isolated from EL-4 
treated PBMC and primer extension was perfon-ned on the EBV-negative Burkitt lymphoma 
B cell fines, BJAB (Clements et al. 1975) and BL-2 (Gauchat et al. 1992). SI protection 
involves hybridisation of a single stranded DNA probe, 32p_labelled at its 5' end, and 
complementary to a mRNA of interest. The probe is hybridised to total RNA and the single 
stranded ends of the hybrid are digested with SI nuclease, leaving a probe corresponding in 
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acrylamide gel and sized against a DNA sequencing ladder. Primer extension is performed by 
hybridising a short fragment of complementary DNA to the RNA and extending the fragment 
by a DNA synthesis reaction off the 5' end of the RNA with reverse transcriptase. The 
primer extension products are also sized on a denaturing acrylamýide gel. BJAB was induced 
with 11L-4 alone, whereas BL-2 was induced with both EL-4 and O(-CD40. A probe from 
(392 to -25 1) was used for SI analysis of PBMC RNA (Fig. 5.9). Signals equivalent between 
the uninduced and IL-4 induced lanes were considered to be due to background, and 
disregarded. In PBMC, multiple start sites were found by SI analysis at positions -35, -21, 
53,108., 119,132,141,166,170, and 190 (Figs. 5.9,5.10). Consistent with the presence of 
multiple start sites, no TATA box is found in the upstream sequences. Promoters with 
multiple start sites commonly lack a TATA element (Benoist and Chambon 1981). The 
previously cloned gem-dine transcripts for g, y2b, ande also possessed multiple start sites and 
lacked a TATA box (Lennon and Perry 1985; Lutzker and Alt 1988, Rothman ef al. 1990). 
Primer extension was initiated from an oligonucleotide probe at positions 251 to 227. 
Multiple start sites were also found in the B cell lines BJAB and BL-2 by primer extension at 
positions 21-25,30,81,102,106,110,140,14 1, and 157 (Figs. 5.8,5.10). Some of the 
transcription start sites in PBMC generally agree with those in the cell lines BJAB and BL-2, 
namely positions 140/141,53/57, and 102/108. The differences between the start sites 
determ-ined in PBMC and the cell lines could be due to the influence of the activation or 
differentiation state each cell line is arrested in on the presence of various transcription factors 
that affect transcriptional initiation. Differences in the levels of some of the transcription 
factors in the cell lines could cause changes in the position of initiation events from those 
present in PBMC. Gauchat el al (1990) also reported multiple transcription start sites in IL-4 
stimulated PBMC for the GL-F, transcript (Fig. 5.10, green arrows). The start sites 
determýined for PBMC in this chapter agreed within 3 bp to the start sites reported by 
Gauchat et al (1990) . 
One site determined for PBMC in this chapter at base 119 was not 
found in Gauchat el al, though this was a minor start site not confin-ned in the cell lines BJAB 
and BL-2. Because a shorter probe was used by Gauchat et al, containing a 5' terminus at 
base 77 of the GL-E promoter sequence, sites 5' of base 77 could not be compared. The 3' 
ten-ninus of the transcription start site region reported in this chapter, agreed exactly with 


































Figure 5.8. Primer extension analysis ofe-germline transcript start sites in the B- 
lymphoblastic line BJAB. (A) Sequence ladder (G, A, T, C), using oligo Q as a 
sequencing primer. (BJAB, BJAB+IL-4), primer extension analysis of BJAB cells with, and 
without added IL-4, using oligo Q as a primer. The arrow indicates the start site induced in 
BJAB cells with IL-4 at position 157. (B) (G, A, T, C), Sequence ladder using oligo STFR 
as a primer. (BJAB, BJAB+IL4), Primer extension analysis of BJAB with, and without 
added IL-4, using oligo STFR as a primer. The arrows indicate the start sites induced in 
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Figure 5.9. SI nuclease mapping of the E-germfine transcript start sites in the 13- 
lymphoblastic lines BJAB and BL-2, and PBMC. (A) Sequence ladder (G, A, T, C), using oligo 
STFR as a sequencing primer., Primer extension analysis of BJAB cells with and without added IL-4 
(BJAB, BJAB+IL-4), using oligo STFR as a primer. Primer extension analysis of BL-2 cells with, and 
without added IL-4 and ocCD40 antibody (BL-2, BL-2+IL-4+(xCD40), using oligo STFR as a primer. 
The arrows indicate the start sites induced in BJAB and BL-2 cells with IL-4 at positions 21-25,30, 
81,102,106,110, and 140. (B) (Marker), Hpall cut pBluescript SK+, sequence ladder (G, A, T, C), 
using oligo Q as a sequencing primer. S1 protection analysis of PBMC with, and without added IL-4 
(PBMC, PBMC+IL4). The arrows indicate the start sites induced in PBMC with IL-4 at positions -35, 












ý cDNA done 5'ends ý SI analysis ý Primer extension ý Gauchat et al (1990) 
Figure 5.10. Location of transcription start sites for the germline transcript 
Red sequence, germline sequence, black, genomic sequence. Black arrows, start 
sites determined by S1 nuclease protection with RNA from 11-4 induced PBMC. Blue 
arrows, start site determined by primer extension using the cell lines BJAB and BL-2 
induced with IL4 and IL4+(x-CD40, respectively. Q, the oligonucleotide used for 
primer extension, and to construct the S1 probe (see materials and methods). Red 
arrows, location of the cDNA 5' ends detected by PCR (Table 5.2, Fig. 5.4). Green 
arrows, start sites determined by Gauchat et al (1990). 
5.3 DtSCUSSION 
The germfine, transcript for IgE was cloned from IIL-4 treated PBMC. Transcription initiated 
about 500 bases upstream of SF. at multiple sites in a region of about 220 bp in primary cells 
and in the B cell lines BJAB and BL-2. The location of the all of the multiple initiation sites 
presented in Gauchat et al (1990) agreed with the start sites presented in this chapter. No 
TATA box is present immediately upstream of the gem-dine exon, consistent YAth the 
observation that promoters which possess multiple initiation sites commonly lack a TATA 
element. 
The F, -germline gene transcript was expressed as early as 12 hours after IL-4 addition, 
and reached a maximum at day 3 after ILA addition, supporting the model that the 
induction of gem-dine transcription precedes switching. F, -GLT were also detectable 
without added IILA during a shorter time period between 3 and 9 days of culture. The 
expression of germline transcripts without added IL-4 is presumably due to production 
of type 2 cytokines by T cells activated during or prior to the initiation of the culture. F, - 
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germline gene transcripts were also expressed after IL-4 induction in the B cell line 
Namalwa over an 8 day period, with the expression again undetectable 22 days after IL-4 
addition, showing that a continuous IL-4 stimulus is required for germline transcription. 
A polymorphism exists at base 224 of the cDNA sequence with either an A or G at this 
position. Three individuals were analysed for the presence of this polymorphism. Two 
individuals were heterozygous for the polymorphism and one was homozygous for the A 
allele. No linkage is known between the polymorphism and atopy. The polymorphism is 34 
bases downstream of the 33-most transcription initiation site and is unlikely to affect the 
regulation of transcription (Figs. 5.6,6.1 B). Because the gern-dine transcript may physically 
interact with the recombination apparatus, or form a tri-molecular complex with the switch 
regions, a polymorphism in the gem-dine exon could destabilise these interactions, and affect 
the level of switching. 
Like all other gerrrdine transcripts characterised, the F- gem-dine exon contains stop codons in 
each translational reading frame and does not possess an AUG codon in frame vvith the 
constant region, consistent with the conclusion that no translation of gem-dine transcripts 
occurs. 
The sequence of the e-gern-dine exon agrees with Gauchat et al (1990) except at positions 
467 and 641 (Fig 5.6), containing aC and T instead of aG and T, respectively at these 
positions, in disagreement with both Mills et a] (1990) and the sequence presented here. 
Also, the designation of the gen-nline exon in Gauchat et al excluded one base at the 3' end of 
the exon which forms the first base of the epsilon constant region. The expression kinetics for 
the F--GLT in PBMC, presented in Gauchat el al, agree with the results presented here 
except that the maximum for transcription levels was later, at about 9 days after IL-4 
addition, though transcription controls were not used in Gauchat et al, so accurate judgement 
of their transcription levels was not possible. 
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CHAPTER 6: Role of BSAP/PAX-5 in the Regulation of F, --Germline Transcription. 
6.1 INTRODUCTION 
Isotype switching results from a DNA recombination event that juxtaposes different 
downstream CH genes to the expressed VDJ gene segment, thus changing the effector 
function but not the specificity of the antibody molecule. Isotype switching is not a 
random event, but is directed by cytokines in conjunction with the regulation of B cell 
proliferation and differentiation (Coffman et aL 1993). Cytokine-dependent induction of 
isotype switching to a particular CH gene almost invariably correlates with the 
transcriptional activation of the same gene in germline configuration. Several murine and 
human germline transcripts have been cloned, and share structural similarities (for review 
see Vercelli and Geha 1992; Coffman et aL 1993). Germline transcripts initiate from 
TATA-less promoters a few kilobases upstream of the switch region, and proceed 
through short exons (germline or IH exons) that are spliced to the first exon of the CH 
gene. The region containing the germline promoter and the IH exon is deleted during 
switch recombination. 
Germline transcription is thought to direct switching by modulating the accessibility of a 
particular switch region to a common recombinase. The importance of germline 
transcription in the regulation of isotype switching has been demonstrated by gene 
knock-out experiments. Deletion of the lyl (Jung et aL 1993) or F(2b (Zhang et al. 
1993) exons and their promoter resulted in the inhibition of class switching to the 
corresponding genes, suggesting that transcription in the switch region is necessary to 
target the appropriate switch region for recombination and switching. Therefore, 
it is 
important to understand how germline transcription is regulated. 
Different cytokines specifically activate transcription at the appropriate germline 
promoter. In particular, IL-4 has been demonstrated to induce F--germline transcrIpts 
in 
murine (Rothman el aL 1990, Severinson et aL 1990; Rothman el aL 1991), and 
human 
(Gauchat el aL 1990, Jabara el aL 1990) B cells. IL-4-dependent F--germline 
transcription in B cells is strongly up-regulated upon CD40 engagement (Jabara el al. 
1990; Shapira et aL 1992). This transcriptional effect of CD40 may be critical 
for 
switching (Warren and Berton 1995), because optimal levels of transcription through the 
switch region may be required to target recombination. 
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Several cis-acting elements have been characterised which regulate EL-4-induced E- 
germline transcription. A highly conserved DNA region 5' to the major initiation sites 
for murine germline-c RNA has been demonstrated to contain an IL-4-responsive 
element that binds three transcription factors: a member of the Signal Transducer and 
Activator of Transcription (STAT) family, Stat6, one or more members of the 
CCAAT/enhancer-binding protein (C/EBP) family, and Nuclear factor-kappa B (NF- 
KB)/p50 (Delphin and Stavnezer 1995, see also Fig. 6.2). Mutation of any of the binding 
sites for these factors abolished or reduced the IL-4 inducibility of the murineF--promoter 
(Delphin and Stavnezer 1995). A binding site for Stat6 has also been identified in the 
human e-germline promoter (Kohler and Rieber 1993; Albrecht et al. 1994; Fenghao et 
aL 1995). 
A region in the murine E-germline promoter 3' to the Stat6 element binds a constitutively 
expressed transcription factor, B cell lineage- specific activator protein (BSAP, Pax-5) 
(Liao et aL 1994). BSAP belongs to the Pax gene family of homeodomain transcription 
factors, and is the mammalian homologue of the sea urchin tissue-specific transcription 
activator protein, a regulator of late histone genes. BSAP is expressed in pre-B and 
mature B lymphocytes, but not in terminally differentiated plasma cells (Adams el aL 
1992). BSAP knock-out mice exhibit a complete block of early B cell differentiation at 
the pro-preBI stage (Urbanek et aL 1994), and are significantly reduced in V-DJ 
recombination (Nutt et aL 1997). Binding sites for BSAP have been identified in the 
promoter of several B cell-specific genes, such as CD19 (Kozmik et aL 1992), X5, 
VpreB I (Okabe et aL 19 92), XBP I (Reimold et aL 1996), the tyrosine kinase blk 
(Zwollo and Desiderio 1994), and the germline gene exons and switch regions of the IgH 
genes R, 7 1, y2, F-, a (Waters et al. 1989; Liao et aL 1992; Xu et aL 1992; Liao et al. 
1994). BSAP has also been demonstrated to positively regulate the CD19 gene, the B- 
cell receptor component Ig-alpha (mb-1) and the transcription factors N-myc and LEF-1 
(Kozmik et aL 1992; Nutt el aL 1998). BSAP negatively regulates the XBP I promoter 
(Reimold et aL 1996), and the gene coding for the cell surface protein PD- I (Nutt et al. 
1998). Interestingly, BSAP positively regulates the Ig 3' a enhancer HS4 (Michaelson el 
al. 1996), but has a negative effect on the Ig 3' a enhancer HS 1,2 (Singh and Birshtein 
1993; Neurath et aL 1994) Negative regulation of the Ig 3' a enhancer HS 1,2 seems to 
be due to the ability of BSAP to suppress binding of the Ets family member NF-(xP, a 
protein that positively controls enhancer activity and heavy chain transcription (Neurath 
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et al. 1995). BSAP interacts with the POU domain of octamer binding proteins to 
mediate its repression of the 3' enhancer (Singh and Birshtein 1996). In addition to the 
suggested interaction with NF-(xP and octamer binding proteins, BSAP has been 
demonstrated to participate in other protein-protein interactions, including its facilitation of 
the binding of proteins of the Ets proto-oncogene family to the early B-cell-specific mb- I 
promoter (Fitzsimmons et al. 1996). Further evidence for the role of BSAP in recruiting 
other transcription factors to regulatory regions was demonstrated by the reconstitution 
of mb-I and LEF-I activity in BSAP deficient pre-BI cells by the BSAP paired domain 
polypeptide lacking any transactivation function (Nutt et aL 1998). 
BSAP has also been demonstrated to be involved in the control of cell proliferation in 
mouse B cells (Wakatsuki et al. 1994). Furthermore, =2% of non-Hodgkin lymphomas 
are generated by translocation of the BSAP gene near the Eýt enhancer (Busslinger et aL 
1996). BSAP may be important for switching not only through the regulation of genes 
in the immunoglobulin locus, but also through the control of cellular proliferation. 
Through the use of DNA synthesis inhibitors, proliferation has been shown to be 
important for yl-germline transcription and switching (Lundgren et al. 1995). In 
addition, Ets family members have been implicated in the cell cycle specific control of 
yI -germline transcription. 
Of the factors known to bind the P--germline transcript promoter in mice and humans, 
BSAP represents the only B cell specific factor. As the only B cell specific factor, BSAP 
may be responsible for the cell type specificity of F--germline transcription. Conflicting 
reports exist though, about the role of BSAP in the regulation of F--germline transcription 
in murine B cells. Deletion of the BSAP binding site abrogated induction of F--germline 
promoter activity in murine B cells stimulated with IL-4 + LPS (Liao et al. 1994). 
Activity was restored by the introduction of a BSAP binding site from the sea urchin 
histone gene H2A-2.2 (Liao et aL 1994). In contrast, deletions in the BSAP binding 
region were unable to affect the IL-4-dependent inducibility of the promoter in the 
absence of LPS (Delphin and Stavnezer 1995). In this chapter, the role of BSAP in the 
transcriptional regulation of the E-germline promoter in human B cells was investigated. 
BSAP was found to bind the human Fgermline promoter, and to be essential for both the 




6.2.1 Characterisation of cell lines to be used for transcription factor analysis. 
The human B cell lines BJAB and BL-2 were chosen as candidates for studying the 
regulation of F--germline transcription. BJAB and BL-2 have not undergone a heavy 
chain switching event and are EBNA-negative. EBV-encoded proteins provide B cells 
with signals that trigger IgE switching (Thyphronitis et al. 1989; Jabara et al. 1990), 
through a pathway shared at least in part with the CD40 signaling route (Cheng et al. 
1995; Mosialos et al. 1995). EBV positive cell lines were therefore avoided because of 
the potential difficulties in the interpretation of experimental results. BJAB and BL-2 
were assayed by semi quantitative reverse transcriptase-polymerase chain reaction (RT- 
PCR) for the expression of F--germline transcripts upon IL-4 stimulation. Figure 6.1 
illustrates that BJAB and BL-2 cells expressed E-germline transcripts following a 48 hr 
incubation with EL-4 (100 U/mL). In the cell line BL-2, F, -germline transcript levels were 
significantly lower than BJAB in the presence of IL-4 alone, and were normally not 
detectable. In the presence of (x-CD40 (5 [tg/mL) and IL-4, F--germline transcript levels 
in BL-2 were enhanced at least 5 fold over EL-4 alone. F--germline transcription was not 
induced by (x-CD40 mAb alone in the cell line BL-2 (Fig. 6.1, right panel). Germline 
transcript levels were quantified by densitometery and normalised to levels of the 
glyceraldehyde-3 -phosphate dehydrogenase (GAPDH) gene to control for errors in 
loading. 
Next, EMSA was used to identify B cell specific proteins that bind to the germline 
transcript promoter. To test that the EMSA was functioning in our system, an EL-4 
induced signal corresponding to STAT6 (Fenghao et al. 1995) was assayed from EL-4 
induced BJAB cells. A probe that spans the STAT6 site (nucleotides 36-78 in Fig. 6.2B) 
was used for EMSA analysis. As early as 5 hours after addition of IL-4, a signal was 
substantially enhanced (Fig. 6.3) in nuclear extracts from cells induced with EL-4 and EL- 
4/(x-CD40. The EL-4 induced complex was present up to 48 hours after EL-4 addition. 
The presence of an EL-4 induced complex binding to the STAT6 site strongly suggests 
that the EMSA correctly detected nuclear proteins that bind to the F--germline promoter. 
Table 6.1 
Name 
Oligonucleotides used in this study. 
Primer Pair (upper strand, lower strand) Sizea 
100 
T--b Reference/Accessbn 
F--GLT GACGGGCCACACCATCCACAGGCACCAAATGGACGAC409 65C Fig. 5AM220-256 
CAGGACGACTGTAAGATCTTCACG Fig. 5.4 nt 606-629 
GAPDH GGGAAGGTGAAGGTCGGAGTC 438 580C M33197 nt 64-84 CTGATGATCTTGAGGCTGTTG M33197 nt 483-503 
104/139 TTAGCTGAAAGCACTGAGGCAGAG 36 57"C Fig. 5.4 nt 104-127 GGGTAGGGGGAGCTCT Fig. 5.4 nt 124-139 
104/191 TTAGCTGAAAGCACTGAGGCAGAG 89 60"C Fig. 5.4 nt 104-127 
CCCAGATGATCAGTAACCGTG Fig. 5.4 nt 171-191 
36/266 229 670C Fig. 5.4 nt 36-69 
CCATTTGGTGCCTGTGGATGGTGTG Fig. 5.4 nt 227-266 
H2A2.2 TGTGACGCAGCGGTGGGTGACGAC 24 (Barberis et al. 1989) 
GTCGTCACCCACCGCTGCGTCACA 
NF-HB GATCAGAATTGTGAAGCGTGACCA 24 (Liao et al. 1992) 
TGGTCACGCTTCACAATTCTGATC 
COUP TCGACTCTATGGTGTCAAAGGTCAAACTTCTGAC 34 (Wang et al. 1987) 
CTCAGAAGTTTGACCTTTGACACCATAGAGTCGA 
TRE CGATCGTGCGGTCACGTCCCTGATCTTACCTTTCCA 36 (Orchard et al. 1990) 
TGGAAAGGTAAGATCAGGGACGTGACCGcAcGATCG 
BSAP1XMut TTAGCTGAAAGCACTGAGGAAGAG 89 50'C Fig. 5.4 nt 104-127 
CCCAGATGATCAGTAACCGTG Fig. 5.4 nt 171-191 
BSAP2XMut TTAGCTGAAAGCACTGAGTAAGAG 89 500C Fig. 5.4 nt 104-127 
CCCAGATGATCAGTAACCGTG Fig. 5.4 nt 171-191 
F--GLTREP CCTGGGAGTGAGTACAAGGTGAG 663 640C X56797 nt 25-47 
GGTGGGCTGGGATACCTGAAG X56797nt 667-687 
REP1XMUT CTAGCAAATAGGCTGTCCC 379 50'C Promega 
RVpHmer, 3 
GGGAGCTCTTCCTCAG Fig. 5.4 nt 117-132 
BSAP Dell CACCCCATTTTTAGCTCCCAGGCTCCACTGC 274 47C Fig. 6.213 nt 94-151 
GCAGTTGCTCTCCAGCGGTTC Promega GL4 
BSAP De12 CTAGCAAATAGGCTGTCCC 379 50'C Promega 
RVprimer3 
AGCTAAAAATGGGGTG Fig. 6.21B nt 94-109 












Figure 6.1. IL-4 induces e-germline transcripts in human lymphoblastoid B cells. Levels 
of RNA for e-germline transciipts induced by IL-4 and (x-CD40 in BL-2 and BJAB cells assessed 
by semiquanfitative RT-PCR. RT-PCR was proven to give reproducible results after repeated 
experiments, and required fewer cells and reagents than Northern analysis or RNase 
protection. e-germline transcripts were amplified by primers corresponding to the 3' end of 
human IF- and the 5' end of CF-2 (F--GLT, upper and lower respectively, Table 6.1). 
Glyceraldehyde-3-phosphate dehydrogenase, GAPDH. 
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Figure 6.2. Map of the human germline-c gene. (A) Restjiction map of the unrearranged C. F- 
locus, with the Ic exon and the F, constant region. (B) The genomic sequence surrounding the 
gen-nline-F- promoter. Transcription factors known to bind in the human, STAT6, and regions 
homologous to the mouse C/EBP, NF-icB, BSAP, and HIVIG-I(Y), and, are boxed. Position 1 
corresponds to the start of the longest cDNA done obtained in chapter 5 (nucleotide 405 in 
Genbank accession no. X56797). Black and grey sequence indicate bases homologous and 
not homologous, respectively to the mouse IF- region. The end of the IF- exon is marked by an 
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6.2.2 BSAP/PAX-5 binds to the c-GLT promoter. 
In order to assess whether BSAP binds to the human F--germline promoter, EMSA 
analysis was performed using a probe (nucleotides 80-184 in Figure 6.2B) that spans the 
region homologous to the murine BSAP binding site. Figure 6.4 demonstrates that 
nuclear extracts from unstimulated BJAB cells contain a protein that retards the 
migration of the BSAP probe. The formation of the DNA-protein complex was 
specifically competed by an oligonucleotide containing a BSAP site located upstream of 
the murine S72a region, previously named B-lineage-specific nuclear factor that binds to 
Ig H gene segments (NF-HB), and by a BSAP site in the sea urchin histone H2A-2.2 
promoter. Oligonucleotides containing the binding sites for the unrelated transcription 
factors COUP (Wang et al. 1987) and TRE (Orchard et al. 1990) did not compete the 
putative BSAP complex. The putative BSAP complex also was found in the B cell line 
BL-2 (Fig. 6.5). Consistent with the B cell specificity of BSAP expression (Adams et al. 
1992), the BSAP complex was undetectable in nuclear extracts from Jurkat T cells (Fig. 
6.5). 
To determine if BSAP was present in the complex that binds to the BSAP probe, we 
tested the effect of (x-BSAP antisera in EMSA. Figure 6.6 shows that an antiserum 
against the C-terminal region of BSAP (aa 189-391) supershifted the BSAP complex, 
whereas an antiserum against the DNA binding domain of BSAP (aa 17-145) blocked the 
formation of the complex. In contrast, an antiserum against an unrelated transcription 
factor (HOXB3) had no affect on the binding of BSAP. These results combine to 
demonstrate that BSAP binds to the human F--germline promoter ill vitro. The possibility 
remains that other proteins may participate in the EMSA complex, and may also be 
involved in the regulation of F, -germline transcription. 
BSAP activity in splenic murine B cells has been shown to be up-regulated by 
proliferative stimuli (mitogens, cross-linking of sIgD or CD40) (Wakatsuki et al. 1994), 
and down-regulated by OX40 ligand cross-linking (Stuber el aL 1995). We therefore 
investigated whether stimulation with IL-4 and/or (x-CD40 mAb could modulate BSAP 
activity in human lymphoblastoid cells. The EMSA analysis in Figure 6.7 indicates that 
IL-4 and (x-CD40 stimuli do not cause significant changes in BSAP levels in nuclear 
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Figure 6.4. BSAP binds to the human F-- 
germline promoter. EMSA performed 
using a probe from 80-184 and nuclear 
extracts from unstimulated BJAB cells. 
The competing double-stranded 
oligonucleotides (100-fold molar excess) 
for the sea urchin H2A2.2 and murine NF- 
HB BSAP binding sites, and the unrelated 
transcription factors COUP, and TRE 
(Table 6.1), identify a putative BSAP 
complex (arrow). 
Figure 6.5. The putative BSAP complex 
is present in the B cell lines BJAB and 
BL-2 but not the T cell line Jurkat. 
EMSA with a probe from nucleotides 104- 
139 and extracts from BL-2, BJAB, and 
Jurkat. Competitors for the BSAP NF-HB 
site and the unrelated transcription factor 
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Figure 6.6. (x-BSAP antibodies confirm the identity of the putative BSAP complex. 
EMSA using nuclear extracts from unstimulated BJAB cells and a probe (nucleotides 104-139) 
that spans the BSAP binding site in the F--gerTnline promoter. Rabbit antibodies specific for the 
paired (DNA binding) domain of BSAP (aal7-145) disrupt binding of BSAP (left arrow) to the 
probe. Antibodies specific the C-terminal region of the protein (aal89-391) supershift the 






Figure 6.7. BSAP activity is not regulated by IL-4 or (x-CD40 stimuli. EMSA analysis of BL-2 
cells induced with IL-4, cc-CD40, or both, using a probe from nudeobdesl 04-139. Arrow, locabon of 
the BSAP complex 
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6.2.3 An invariant C in the BSAP consensus sequence is essential for binding. 
To determine if BSAP is essential for c-germline transcription, we first searched for a 
mutation that could interfere with its binding to the Ic promoter. Of all known BSAP 
binding sites, only the C at position 8 of the core motif is invariant (Fig. 6.8). A point 
mutation (C --- ýA) at the invariant C residue in a sea urchin H2A-2.2 BSAP site has been 
demonstrated to be sufficient to strongly impair the binding of murine BSAP in EMSA 
(Singh and Birshtein 1993; Liao et al. 1994). We tested whether an oligonucleotide 
containing the human Ic BSAP site with the C-ýA mutation could compete binding of 
human BSAP to an unmutated probe. Figure 6.9 illustrates that introduction of the 
C-->A mutation reduced competition by approximately 5-fold compared with the 
unmutated competitor, over a 10-IOOX excess range. AG residue one base 5' to the 
invariant C is conserved among many of the BSAP binding sites (Fig. 6.8). When the 
conserved G residue was mutated to aT in addition to the C-4A mutation, no further 
reduction in competition was observed. Thus, the invariant C in the BSAP site is 
important for in vitro DNA/protein interactions. 
A 
Site 1 2 3 4 5 6 17 q 9j 0 11 Reference 
NFHB (core B) T G T G A A GýC G? T G (Liao et al. 1992) 
NFHB (core 1) T G T G A AIG C T T A (Liao et al. 1992) 
S[t 96 G C T G - A GT G A (Xu et al. 1992) 
Ig J chain G T C T T T CC G T (Rinkenberger et al. 1996) 
(xS-1 A G T G T A A A G (Waters et al. 1989) 
H2A-2.2 T G T G A C 
I 
A G C (Barberis et al. 1989) 
Larndba 5 A G T C A G 
I 
A G A (Okabe et al. 1992) 
Murine Ic A C T G A G A G A (Rothman et al. 199 1) 
CD1 9 site 1 A G A C A CC A T G (Kozmik et al. 1992) 
VpreB1 T C T G G CC A T G (Okabe et al. 1992) 
Consensus D N H B D NSU D D N 
B BSAP Core 
Hufflan ACCCCATTTTTAGCTPAAAGCACTGAGGCAGAGCTCCCCC ACCCAGGCTCCA 147 
Mouse ACCCCACTTTTAGCTGAUbbUAUIUAU, "RUA'ULiCUCCUi'AGGTACIAUL; AI -8 
Figure 6.8. BSAP binding sites. (A) BSAP core motifs (updated from Neurath et al. 1994). 
Dark grey box, the C present in all BSAP sites, and the G present in 7 of 10 motifs, chosen for 
point mutation. (B) Comparison of the human and mouse (Rothman et al. 1990) sequences 
surrounding the BSAP core motif (open box). Light grey, the additional 27 base deletion used 















100 X Excess 
4- 4- 
I - 
300 X Excess 
lw AN t» 
%*, " woo**, *,, w- 
q6 0 to@ "0 
r. 
Figure 6.9. The invariant C in the BSAP binding site is essential for DNA/protein interactions. 
EMSA using BJAB nuclear extracts incubated wM a wild-type BSAP probe (104-191, Fig. 6.213). 
The BSAP complex (arrow) is competed much less efficiently by both the mutant than the wild-type 
sites. All competitors used the same fragment (104-191) as the probe, mutated at the C or G (Fig. 
6.8). The mut 1 competitor contains a C--->A mutation at the invariant C in the BSAP binding site. 
MLA 2 contains both a C-4A and a G--->T mutation. Competitors were added at 10-, 30-, and 100- 




6.2.4 BSAP up-regulates the IL-4 and CD40 induction of F_-GLT. 
In order to functionally characterise the role of BSAP in the regulation of human E- 
germline transcription, reporter assays were performed using constructs that contain the 
human F--germline promoter, with or without mutations in the BSAP binding site (Fig. 
6.10). As a source of the promoter fragment, genomic DNA was amplified by 
polymerase chain reaction (PCR) using the F--GLTREP primer pair (see Materials and 
Methods 2.18; Table 6.1). The human GL-F- promoter construct contained a 423 bp Rsa 
I-Hae H fragment of the amplified promoter region (bases - 118 to 259, Fig. 6.2B) 
inserted into the promoterless pGL3 luc vector, and was confirmed by sequencing. 
Because a polymorphism exists in the GL-F- promoter at position 224 (Figs. 5.6,6.2B), 
the IL-4 inducibility of the promoter constructs corresponding to both alleles was first 
compared in reporter assays. The two reporter constructs were transiently transfected at 
three DNA concentrations (30,10, and 2.5 ýtg) into the cell line BJAB. After 
transfection, the cells were divided into aliquots, and incubated in the presence or 
absence of EL-4. Luciferase activity was assessed 48 hours later. A P-gal control 
plasmid was cotransfected with the reporter construct to normalise for transfection 
efficiency. In duplicate experiments, the mean level of expression in the presence of EL- 
4 varied from 2.0 to 3.4 fold over medium alone, but no relationship was seen between 
the polymorphism and differences in reporter activity (Fig. 6.11). The G allele at 




Figure 6.10. GIL-F, Reporter constructs. The 423 base wild type germline promoter/exon Rsa I- 
Hae 11 fragment (bases -118 to 259) inserted into the Sma I site of pGL3. The BSAP mutabons 
mut 1, mut 2, and the 27 base deletion were introduced into the parent pGL3-mLAabons mut 1, mut 
2, and the 27 base deletion were introduced into the parent pGL3-GL. E luciferase reporter vector. 
expression of the luc constructs was inducible at higher and more consistent levels in BL- 
2 than in BJAJ3 cells (Figs. 6.12,6.13a). BL-2 cells were therefore used for this set of 
studies. The BSAP mut I and BSAP del constructs contained, respectively, the C--->A 
mutation at nucleotide 123 (Fig. 6.8), and an additional 27 bp deletion encompassing the 
BSAP binding site (nucleotide 110-136). BSAP mut I was obtained by PCR 
amplification of the GL-F- reporter construct (G allele) with the REP I XMUT primer pair 
(see Materials and Methods 2.16; Table 6.1), after which a 312 bp Kpn I-Sac I fragment 
of the amplification product was replaced for the corresponding Kpn I-Sac I fragment of 
the GL-F, reporter construct (Fig. 6.10). The BSAP del construct was obtained by 
amplification of the GL-e reporter construct insert in two half fragments with the BSAP 
Del I and BSAP Del 2 primer pairs (see Materials and Methods 2.16; Table 6.1). The 
two amplification products were then joined in a further PCR reaction with primers GL4 
and Rvprimer3, and inserted into the pGL3 reporter vector as a 470 bp Kpn I-Hind III 
fragment (Fig. 6.10). BL-2 cells were transfected with the mut 1, BSAP del, and wild 
type promoter reporter constructs and with the reporter vector only (pGL3) as a 
negative control. After transfection, the cells were divided into aliquots, and incubated 
in the presence or absence of IL-4 and (X-CD40 mAb. Figure 6.13a demonstrates that 
IL-4 stimulation of BL-2 cells transfected with the GL construct resulted in a 4.9-fold 
induction of luciferase activity. (x-CD40 mAb strongly (14.9-fold) up-regulated 
transcription driven by the e-germline promoter when added in combination with EL-4, 
but only slightly (1.6X) up-regulated transcription if added alone. The introduction of 
the C--ýA mutation in the BSAP binding site (BSAP mut 1) reduced the EL-4 inducibility 
of the promoter by >50%, and the response to the combination of EL-4 and the (x-CD40 
mAb by 65%. The deletion of the entire BSAP binding site (BSAP del) had comparable 
effects to the C-->A point mutation. Notably, the deletion and the mutation introduced in 
the BSAP site did not affect the basal expression of the reporter constructs in BL-2 cells 
(Fig. 6.13B). These results indicate that BSAP up-regulates both the EL-4-dependent 











Figure 6.11. Affect of AIG pollyrnorphism on reporter activity. Compadson of Reporter activity 
from both A and G alleles at position 224 (224 A, 224 G) in the G L-c promoter construct (Fig. 6.10). 
E3JAB cells were transiently transfected \Mth three different amounts of each construct; 30,10, and 
2.5 gg. Vector only (pGL3) was used as a negative control. Results represent the mean of 













Figure 6.12. Results of reporter assays with F--germline promoter luc constructs in 
BJAB cells. BAB cells were transiently transfected using Diethylaminoethyl cellulose 
(DEAE)-dextran, and split into aliquots that were incubated in the presence or absence of IL-4 
(100 U/ml-) and a-CD40 mAb (5 [tg/mL). Luciferase activity was assessed 48 hr later. (A) 
Fold induction with IL-4, (over medium alone) of the wild type GL-F, reporter (GLT promoter, 
Fig. 6.10) or the pGL3 vector only. Results are the mean and standard error of three 
experiments. (B) Fold induction in the presence of IL-4, (xCD40, or IL-4/(xCD40. Results are 
the mean of two experiments. A Vgalactosidase control plasmid was cotransfected with the 
reporter construct, to normalise for transfection efficiency. A fold induction of 1.0 is equivalent 
to the expression level of the F--germline promoter reporter construct in the presence of 
medium alone. 
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pGL3 Promoter mut 1 BSAP del 
Figure 6.13. Results of reporter assays with e-germline promoter luc constructs in BL-2 
cells. BL-2 cells were transiently transfected using DEAE-dextran, and split into aliquots that were 
incubated in the presence or absence of IL-4 (100 U/mL) and (X-CD40 mAb (5 Pg/mL). 
Luciferase activity was assessed 48 hr later. A P-galactosidase control plasmid was cotransfected 
with the reporter construct, to normalise for transfection efficiency. Values obtained from mock 
transfections were subtracted as background. (A) fold induction of luciferase activity with IL-4, (x- 
CD40 and IL-4/(Y-CD40 over medium alone. (B) Effect of the mutations on basal luciferase activity 
(no inducing agent), expressed in relative luciferase units (RILU). 
6.3 DISCUSSION 
Pax-5/BSAP is aB cell specific protein involved in the expression of a number of genes 
restricted to B cells, including CD19, ; 0, VpreB I, XBP 1, the tyrosine kinase blk, and 
the germline gene exons and switch regions of the IgH genes ýt, y I, y2,6, cc. As the only 
known B cell specific protein that interacts with the GL-F- promoter it may represent a 
key regulatory factor that restricts the cell type expression of the germline transcript to B 
cells. 
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The results in this chapter demonstrate that BSAP binds to the germline transcript 
promoter at a region homologous to the proposed murine BSAp element in EMSA. 
Antisera specific to the human BSAP C terminal region supershifts the EMSA band, and 
antisera specific to the DNA binding region blocks binding, identifying the protein as 
BSAP. A mutation at a C, invariant in all known BSAP binding sites, destroys the 
binding of BSAP in EMSA. The invariant C nucleotide is also necessary for the binding 
and transcriptional activation of the H2A2.2 promoter by BSAP in the sea urchin. 
The germline transcript exon and 5' sequences were inserted into a luciferase reporter 
construct and introduced into BL-2 cells. Reporter activity was induced 4.9 fold with 
IIL-4 and 15 fold with IL-4/(x-CD40. Mutation of aC at a position invariant in all BSAP 
sites reduced IL-4 induction by 50% and IL-4/(x-CD40 induction by 65%. Elimination 
of the entire BSAP site with a 27 base deletion had essentially the same effect on 
reporter activity as the point mutation at the invariant C. The additive effect of the 
mutations on reporter activity induced by IL-4 and (x-CD40 suggests that BSAP not only 
plays a role in the mechanism of IL-4 induction of e-germline transcription, but also in 
the (x-CD40 mediated up-regulation of transcription. Mutations in the BSAP binding 
site did not appreciably affect basal reporter activity suggesting that the role of BSAP in 
germline transcription is restricted to the up-regulation of transcription. As BSAP 
expression was unaffected by induction of BJAB cells with IL-4 and (X-CD40, it is 
unlikely that the results seen in the reporter assays are influenced by the effect of the 
inducing agents on BSAP levels. The 50% and 65% reduction in the levels of U'4 and 
IL-4/(xCD40 induced reporter activity, respectively, indicates that although BSAP is 
involved in the regulation of F, -GLT, other factors function to initiate transcription in the 
reporter construct, though at a lower level of efficiency. A 65% reduction in germline 
transcription could markedly affect the level of switch recombination if a high level of & 
GLT may be required to maintain a chromatin environment appropriate for 
recombination. In vivo, in the presence of distal regulatory elements such as the 
immunoglobulin 3'-LCF, the effect of the BSAP mutation may be greater, since the 
reporter constructs could lack factors involved in communication between the GL-F, 
promoter and the LCR. Also, the lack of an appropriate chromatin environment in the 
reporter construct could affect some of the interactions required for the complete role of 
BSAP in &GLT. 
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EL-4 strongly induced F--germline transcription in BJAB cells, whereas IL-4 alone 
normally induced little or no transcription in BL-2 cells. (X-CD40 was required in 
combination with EL-4 to induce levels of germline transcription in BL-2 comparable to 
BJAB with 11L-4 alone. In contrast, EL-4 alone mediated a strong induction of reporter 
activity in BL-2 cells (compare Figs. 6.1 to 6.13). One possible explanation for the high 
level of IL-4 induced reporter activity in BL-2 relative to endogenous germline 
transcription, is that the construct lacks negative elements which repress transcription 
from the endogenous gene in the absence of CD40 engagement. Derepression of the 
endogenous locus may require CD40 engagement, possibly mediated through the 
immunoglobulin 3' enhancer. The immunoglobulin 3' enhancer is known to be required 
for e-germline transcription and switching in the mouse (Cogne el aL 1994). In BL-2 
cells the 3' enhancer may be in a repressed state, exerting a repressive influence on the 
endogenous GL-promoter. As CD40 engagement is known to up-regulate the 3' 
enhancer (Grant et aL 1996), it could up-regulate expression of the endogenous germline 
transcript in BL-2 cells through activation of the enhancer. Conversely, BJAB cells 
could contain the 3' enhancer in a constitutively activated state enabling high level 
expression of the germline transcript after induction with IL-4 alone. In the absence of 
the repressive influence of the 3' enhancer on the reporter construct in BL-2 cells, fL-4 
could induce high levels of promoter activity without CD40 engagement. The 3 fold 
enhancement of reporter activity in the presence of (x-CD40 over IL-4 alone could 
involve a pathway independent of the 3' enhancer, such as through the activation of NF- 
'KB (Francis et aL 1995). 
Recent work reported by Albrecht et al (1996), concluded that BSAP was not involved 
in the IL-4 induced activation of human F--gern-dine gene transcription. Several 
differences in the experimental procedures of these authors from those used in this 
chapter could explain their different conclusions. In Albrecht el al the human Birkitt's 
lymphoma line DG75, and the murine B cell lymphoma M12.4.1 were used. The 
differentiation state of the cell lines used could have been before or after that needed to 
respond appropriately to transactivation by BSAP. Also, the mouse cell line used may 
not respond to BSAP or other factors necessary for transactivation of BSAP in the 
human expression construct, due to differences between the compliment of human and 
mouse transcription factors or their binding site affinities. The reporter constructs 
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contained promoter fragments that were 48 nucleotides shorter at the 3' end and 141 
nucleotides at the 5' end. The regions absent in the constructs used by Albrecht et al 
(1996) could contain regulatory elements for factors needed to interact with BSAP. 
Also, a clone of the germline exon was used (Albrecht et aL 1994) that contains 
numerous differences in sequence from the genomic sequence determined in chapter 5 
(Fig. 5.6), which could disrupt the binding of factors needed to interact with BSAP. 
Additionally, the reporter vector used by Albrecht el al, pGL2, is known contain 
sequences that target the luciferase protein to peroxisomes, that could affect expression 
levels through toxic effects (Groskreutz el aL 1995). The later pGL3 series of reporter 
vectors used in this chapter overcame this problem. 
BSAP clearly plays a role in the transcriptional up-regulation of F--germline transcription 
through up-regulate binding site in the promoter. BSAP may also regulate germline 
transcription through interaction with the 3' enhancer and the control of proliferation. 
BSAP may mediate some of these functions through interactions with other proteins 
involved in GL-e transcription and switching, e. g. interaction with Ets family members in 
the mb-I promoter and octamer binding proteins in the 3' enhancer. Given the 
interaction of BSAP with Ets family members in the mb-I promoter and its potential 
interaction with the Ets family member N-F-ocP in the immunoglobulin 3' enhancer, the 
possibility exists that BSAP may mediate communication between the germline promoter 
and the enhancer through BSAP-Ets interactions. Several Ets family members are 
known to bind the 3 1) enhancer (Grant el aL 1995; Linderson el aL 1997), any one of 
which could mediate BSAP-Ets interactions with the F--germline promoter. Corcoran, et 
al (1998) have also suggested a role for BSAP in the mediation of chromatin structure 
and germline gene transcription in the immunoglobulin heavy chain variable region gene 
segments. Mice lacking the alpha-chain of the interleukin-7 receptor are progressively 
impaired with distance, in V segment recombination and germline gene transcription. 
Coincident with the impairment in recombination is a decrease in BSAP expression, 
suggesting a role of BSAP in V region chromatin structure through its activity on the 
immunoglobulin LCR. 
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CHAPTER 7: Mechanism of the Enhancement of IgE Synthesis by Glucocorticoids. 
7.1 INTRODUCTION 
The association of high serum levels of IgE with allergic disease is well accepted (Leung 
1993). Similarly, levels of allergen specific IgE increase in allergic rhinitics during exposure 
to allergen. Corticosteroids are the primary treatment for the symptoms of rhinitis, but the 
exact mechanism(s) of their action are largely unknown (for review see Schleimer 1996, 
Schwiebert et aL 1996). 
Glucocorticoid treatment has been shown to diminish the seasonal rise in levels of allergen 
specific IgE (Crimi et aL 1990; Naclerio et al. 1993). In the local environment, B cells in the 
nasal mucosa of rhinitics increase their expression of IgE mRNA after allergen challenge, and 
this increase is inhibited by topical glucocorticoid (Durham el al. 1997). Total serum IgE 
levels, conversely are unchanged or increase moderately after glucocorticoid treatment 
(Gunnar et al. 1970; Henderson et al 1973; Posey et at 1978; Settipane el aL 1978; Klebl et 
al. 1994; Zieg et aL 1994). Furthermore studies have demonstrated that the effect of 
glucocorticoids on total IgE is more pronounced iii vitro. Glucocorticoids significantly 
increase EL-4 induced total IgE levels in cultures of peripheral blood mononuclear cells (Wu 
et al. 199 1; Nusslein el al. 1994). 
Little is known about the mechanism of the up regulation of IgE synthesis by glucocorticoids. 
IgE germline transcription occurs as soon as 12 hours after IL-4 addition, a functional epsilon 
transcript is produced after heavy chain gene recombination at 4-6 days, and secreted IgE 
appears at =8 days. Enhancement still occurs when glucocorticoid is added as late as day 6 
after initiation of the culture (Wu et aL 1991), suggesting it still acts at the IL-4 independent 
stage of the IgE response. Also, spontaneous IgE secretion is increased by glucocorticoids in 
cultures of peripheral blood mononuclear cells in the absence of EL-4 (Kimata et al. 1995, 
I-Eratsuka el al 1996). Pre-stimulation of PBMC with glucocorticoid prior to addition of EL- 
4 was also sufficient to enhance IgE synthesis (Fischer and Konig 1990). The in vitro 
potentiation of IL-4 induced IgE secretion by glucocorticoids is monocyte dependent (Wu el 
al 1991). The enhancement activity of glucocorticoids therefore is not dependent on IL-4 
and acts in a time independent manner in the first 6 days of culture. In purified B cell cultures 
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hydrocortisone act as a co-stimulatory signal to induce switching to IgE in the presence of UL- 
4 (Jabara et al. 1991, Jabara et aL 1993). In the presence of EL-4, hydrocortisone up- 
regulated the level of F, -gem-dine transcription 2 fold in purified B cell cultures and induced 
production of the VDJ-containing Ce transcript. The potentiation of IgE synthesis in PBMC 
cultures may occur by a different mechanism than with purified B cell cultures. When 
glucocorticoid is added to purified B cells in the presence of EL-4 it appears to replace the cell 
contact-mediated signal for class svvitching, and unlike its effect on the potentiation of IgE 
synthesis in PBMC, it is not monocyte dependent but requires glucocorticoid at the onset of 
culture (Jabara el aL 199 1; Jabara et aL 1993). 
FczRII plays a central role in IgE regulation. Similar to IgE, serum levels of FcFRII also 
increase in relation to atopy. Glucocorticoids down-regulate the unstimulated and EL-4 
induced expression of membrane and secreted FczRII from PBMC, B cells (Fischer and 
Konig 1990; Wu et al. 199 1; Paterson et al. 1994), monocytes, and eosinophils (Kawabe el 
aL 1991), iii vitro. This suppression of FcFRII expression is blocked by EBV and CD40 
engagement (Katira et aL 1993, Paterson et al. 1994). 
Glucocorticoids cause an increase in the apoptosis of B cells (Holder el al. 1992, Merino 
et al. 1994), T cells (Perandones el aL 1993), and eosinophils (Matsukura et aL 1997), 
and rescues neutrophils from apoptosis (Cox 1995; Kato et aL 1995). Recombinant 
soluble FceRII rescues germinal B cells from apoptosis (Bonnefoy et aL 1993), but 
membrane CD23 cross-linking induces apoptosis in resting B cells (Campbell et aL 1997). 
High levels of FcP-RII suppress IgE synthesis, potentially through apoptosis or effects on 
B cell differentiation (Cho et aL 1997). 
Glucocorticoids inhibit many cytokines in peripheral blood mononuclear cells, including 
IL-2, IL-3, IL-4, IL-5, IL-10, IL-12 and interferon-gamma (IFN-y) (Brinkmann and 
Kristofic 1995; Barnes 1996, Brattsand and Linden 1996; Elenkov ef al. 1996). Both 
IFN-'y and IL-12 inhibit IL-4 induced IgE synthesis in PBMC (Pene el aL 1988, Kiniwa 
et aL 1992), most likely through their ability to induce uncommitted T helper cells to a 
THI phenotype. 
119 
The activity of glucocorticoids in allergy are reminiscent of those of the steroid hormone 
vitamin D3. Vitamin D3 inhibits IgE-mediated biphasic cutaneous reactions (Katayama et 
al. 1996). Like glucocorticoids vitamin D3 suppresses Fcf-R-11 expression (Fargeas el al. 
1990; Boltz-Nitulescu el al. 1995). Vitamin D3 also inhibits NF-icB activity (Yu et aL 
1995). Vitamin D3 inhibits the expression of all three subtypes of major histocompatability 
complex class-11 antigens on monocytes (HLA-DR, -DP and -DQ) as well as the accessory 
activity of monocytes in promoting T cell activation, and IL-4 addition reverts these effects 
(Rigby and Waugh 1992; Xu et aL 1993). The similarities between the activities of 
glucocorticoids and vitamin D3 raise the possibility that both steroid hon-nones share some of 
the same mechanisms of action. 
The apparent contradiction between the up-regulation of IgE levels by glucocorticoids with 
the beneficial effects of these drugs on allergic symptoms warrants further investigation. 
Knowledge of the mechanism of the enhancement of IgE synthesis by glucocorticoids could 
help to reduce this potential antagonism to the efficacy of this drug in the treatment of allergic 
symptoms. Knowledge of the mechanism of glucocorticoid potentiation of IgE levels could 
also help to further elucidate the IgE regulatory network, Because the glucocorticoid 
hydrocortisone provides a co-stimulatory signal with EL-4 to induce genýnline and productive 
epsilon transcription and switching to IgE in purified B cells, the possibility that in PBMC, 
glucocorticoids also enhance these transcription events and the level of heavy chain switching 
to IgE is investigated in this chapter. 
7.2 RESULTS 
7.2.1 Fluticasone potentiates IgE secretion in vitro. 
Several possibilities were explored to elucidate the mechanism of the glucocorticold 
potentiation. The glucocorticoid fluticasone 17-propionate was used for these studies. 
Initially, if the effect of fluticasone on the gerraline gene and productive transcript levels for 
IgE was investigated. If fluticasone acts at a point before or during heavy chain 
switching then GL-F, transcript levels are expected to be greater in the presence of 
fluticasone. However, if fluticasone acts to up-regulate productive (VDJ-CF, ) 
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transcription, or at a point in the mechanism of heavy chain switching after the induction 
of germline transcription, VDJ-CF, transcript levels should be greater in the presence of 
fluticasone. If fluticasone does not up-regulate productive (VDJ-CE) transcription, then 
it could act by up-regulating the secretion of IgE or by affecting the ratio of secreted vs 
membrane bound IgE levels. 
Atopic patients were screened for the fluticasone experiments by two criterion. 1) A2 
year history of hay fever. 2) A positive allergic skin prick test (greater than 5 mm weal) 
to Timothy grass pollen extract (PhIeumpratentase, Soluprick, ALK, Denmark). PBMC 
were isolated from the venous blood of three atopic volunteers, and incubated with and 
without EL-4, and various concentrations of fluticasone 17-propionate. Parallel cultures were 
harvested at 4.5 days for RNA analysis, when both the gen-riline and productive transcripts 
are present, and 14 days for measurement of secreted immunoglobulin, when secreted IgE 
levels are at a maximum. 
IgE was induced in the presence of EL-4 alone in PBMC from two of the three atopic donors 
(TW and SD, Figs. 7.1 A and 7.1 B), and in the third (NP), IgE was below the level of 
detection (Fig. 7.1 Q. Fluticasone enhanced the level of IgE secreted from donors SD and 
TW at concentrations from 10-6M to 10-12 M, and 10 -6 to I 0-'OM respectively, with a 
maximum enhancement of --5 fold over EL-4 alone in both donors. PBMC from NP, which 
produced no detectable IgE with EL-4 alone (Fig. 7.1 Q, secreted IgE with addition of I 0-6M 
to 10-9M fluticasone at levels reaching a maximum similar to the donors SD and TW. 
Secreted IgE was not detected in the presence of fluticasone alone except in the case of TW, 
which produced a moderate amount of IgE at 10-7 and 10-'OM fluticasone (Fig. 7.1A). 
Induction of IgE in the absence of EL-4 in this case was probably due to the production of 
high endogenous levels of EL-4 from a greater than non-nal level of preactivated mononuclear 
cells. Spontaneous production of IgE occurs occasionally in some cultures, and could be due 
to the immunological status of the donor at the time of the experiment. When the protein 
synthesis inhibitor emetine (5 gg/mL) was added at the onset of culture, no IgE was 
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Figure 7.1. Fluticasone potentiates IL-4 induced IgE synthesis. ELISA analysis of secreted 
IgE levels from cultures of PBMC incubated 14 days with or without IL-4 and flubcasone. PBMC 
were isolated from (A) Steve Durham (SD), (B) Timothy Whitfield (TW), and (C) Nick Powel 
(NP). 
I -)-) 
7.2.2 GL-F, and VDJ-CF- transcript levels were not increased by fluticasone early in the 
culture period. 
RNA was extracted from par"el cultures induced for 4.5 days, and levels of the E-gerMline 
transcript, VDJ-Ce, and the secreted form of Ce were determined by reverse transcr&iptase- 
polymerase chain reaction (RT-PCR). The transcript levels of each assay were normalised to 
glyceraldehyde-3 -phosphate dehydrogenase (GAPDH) to adjust for loading error. Since 
GAPDH is expressed in all cell types present in the culture, we adjusted the GAPDH to 
account for the percentage of cells represented by B cell types, e. g 40% B cells represents 
40% of the total GAPDH value. An adjustment for the B cell percentage allows changes in 
the populations of the different cell types in the PBMC sample to be taken into account, due 
to the affects of the inducing agents on proliferation or cell death. An increase of e germline 
transcript levels of 0.5 to 2.5 fold occurred in the presence of fluticasone and IIL-4 (Fig 7.2), 
compared to IIL-4 alone. When the PBMC were analysed by FACS at day 6 and 7 (Fig. 7.5), 
we discovered that the percentage of B cells present in the total population increased about 2 
fold in the presence of fluticasone and IIL-4, when compared to IIL-4 alone. If the fold 
increase of F_-GLT measured by RT-PCR was corrected by the change in the B cell 
contribution (two-fold increase in the B cell percentage seen in Figure 7.5A and 7.5B) to the 
GAPDH level, gen-nline-c transcript levels per cell do not appreciably increase. At the same 
time, VDJ-CF- transcript levels increased 1.7 to 3 fold compared to EL-4 alone (Fig. 7.3). 
Again, if the levels of the VDJ-CF- transcript are corrected by the change in the B cell 
contribution,, the increase is not reflected on a per B cell basis. Even if the correction for the 
change in B cell percentages were not made for the e-GLT and the VDJ-Ce levels, the 0.5 
to 3 fold increase in transcript levels would not reflect the greater than 450 fold 
enhancement by fluticasone of secreted IgE from the NP induction. 
Although the levels of germline and productive transcripts did not change appreciably after 
glucocorticoid treatment, the increase in secreted IgE could be caused by a shift from the 
expression of the membrane to the secreted form of IgE. An increase in the ratio of secreted 
to membrane IgE levels could occur without changing the level of total IgE mRNA. To test 
the possibility that fluticasone caused a shift in the ratio of secreted to membrane epsilon 
transcripts, while not affecting total VDJ-CF- or GL-F, transcript levels, secreted CF- containing 
transcript levels were also measured. Secreted CF- containing transcript levels increased up to 
only 1.0 to 1.6 fold over IIL-4 alone (Fig. 7.4), without adjusting for an increase in the B cell 
percentage, strongly suggesting that fluticasone did not shift the ratio of mRNA isoforms to 
secreted IgE. 
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Table 7.1 Oligonucleotides used in this study. 





Classic (F--Secreted) CCCCACTGCACAGCTGGATG 
GCGGTCCACGACCAAGACCAG 




396 620C Fig. 5.7 nt 220-256 
Fig. 5.7 nt 611-634 
381 62'C (Tomlinson et al. 1996) 
Fig. 5.7 nt 611-634 
404 64'C (Zhang et al. 1994) 
J00222 nt 2434-2454 
346 64"C (Zhang et al. 1994) 
J00222 nt 2434-2454 
438 58'C M33197 nt 64-84 
M33197 nt 483-503 
'Size of PCR product. 'Annealing temperature used for PCR amplification. 
a) c 
0 
Figure 7.2. Effect of fluticasone on IL-4 induced F--Germline gene transcript levels. 
RT- 
PCR analysis of PBMC incubated with IL-4 and 10-7 or 10-81VI fluticasone, using PCR primers 
specific for the F--GLT (Table 7.1). Fold enhancement by fluticasone compared to 
IL-4 alone 
is shown. Results are quantified using phosphoirnagery. NP, Nick Powell; 
SD, Steve 
Durham; TW, Timothy Whitfield. 
lo-I'm 10-Im lo-I'm 10-Im lo-I'm 10-Im 













Figure 7.3. Effect of fluticasone on IL-4 induced VDJ-Ce transcript levels. RT-PCR 
analysis of PBMC incubated with IL-4 and 10-7 or 10-8M fluticasone, using PCR primers 
specific for the VDJ-CF- transcript (Table 7.1). Fold enhancement byfluticasone compared 
to IL-4 alone is shown. Results are quantified using phosphoimagery. NP, NickPowell, 











Figure 7.4. Effect of fluticasone on secreted/membrane epsilon transcript ratios. 
RT-PCR analysis of PBMC incubated with IL-4 and 10-7 or 10 -8 M fluticasone, using 
oligonucleotides specific for the two main secreted epsilon mRNAs. Both the classic and 
M2" primer pairs detect mRNAs that encode secreted epsilon isoforms (Table 7.1). Fold 
enhancement by fluticasone compared to IL-4 alone is shown. Results are quantified 
using phosphoimagery. NP, Nick Powell; SD, Steve Durham; TW, Timothy Whitfield. 
io-Im io-Im io-Im io-Im 10-8m io-Im 
TW TW SD SD NP NP 
lem lem lem lem ialm 107 
7m 
SID SID TW TW SID SID 

































CD19 CD20 CD40 Igm IgD 
CD3 CD38 CLASS 11 
CD3 CD38 CLASS 11 
Figure 7.5. B cell percentage rises after fluticasone treatment. FACS analysis of cells 
harvested at (A) day 6, or (B) day 7, stained with a panel of B cell specific antibodies, 
against CD19, CD20, CD40, IgM, and IgD; the T cell specific antibody against CD3, MHC 
class 11, or the antibodies against B cells + activated T cells, CD38. (A) Donor OMK, A 
Rachel Mallalien 
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7.2.3 The in iitro potentiation of IgE by fluticasone occurs after 10 days. 
Since fluticasone is not reqwred before day 6 of culture, the time at which fluticasone caused 
an increase in IgE levels over EL4 alone was determined. PBMC from an allergic donor 
(SD) were incubated with EL4 and fluticasone for 6,8,10,12, and 15 days, and assayed for 
secreted IgE-. A slight but measurable level of IgE was detected at 6 days of culture in the 
presence of 1IL4 (Fig 7.6). At 6 days IgE levels in the presence of UL-4 and fluticasone were 
near background. At day 8 IgE production increased in the presence of 11-4, and tL4 with 
the lowest concentration of fluticasone (10-'M), but was lower at the highest level of 
fluticasone (I O-7M). Secreted IgE appeared to reach the same level between EL4, and EL4 
with fluticasone at day 10. Interestingly, at day 12 and 15, IgE produced by IL-4 treated 
cultures appeared not to change from day 10, but in the presence of fluticasone IgE levels 








rý2vs in Cdture 
Figure 7.6. Fluticasone potentiation occurs late in culture. ELISA analysis of secreted 
IgE levels from cultures of PBMC incubated for 6-15 days with or without 
IL-4 and 
flubcasone. All cultures were performed in triplicate, and IgE levels are expressed with 
standard error. Donor, Steve Durham. 




Fluticasone potentiated U, -4 induced IgE synthesis at least 5 fold in cultures of PBMC. 
Epsilon gem-dine gene transcript levels were not significantly increased at day 4.5 of culture in 
the presence of fluticasone. Gem-dine transcription is expected to be at a maximum at 4.5 
days, and is a required event immediately prior to switching. The lack of an effect on 
gen-rdine transcription suggests the enhancement of IgE synthesis was not the result of an 
increase in heavy chain switching. VDJ-Ce gern-fline transcript levels did not increase 
significantly at day 4.5 of culture supporting the conclusion that switching is not affected 
by fluticasone. Also, the ratio of membrane to secreted IgE rnRNA did not change at 
day 4.5. This excluded the possibility that although total IgE remains constant, a 
reduction in the membrane form and increase in the secreted form of IgE niRNA caused 
the increase in secreted IgE. The possibility remains that VDJ-CF- transcription or the 
secreted to membrane ratio increases at a time later than 4.5 days, due to events caused 
by an effect on cell differentiation induced by fluticasone. 
If the potentiation of IgE synthesis by glucocorticoid does not occur until after 10 days 
of culture, as was revealed in these experiments, a comparison of GL-F- and VDJ-CF- 
transcription at days 4.5,10, and 15, in the presence and absence of glucocorticoids 
could reveal an effect on transcription at later time points. The ability of glucocorticolds 
to co-stimulate e-germline transcription and switching to IgE in purified B cell cultures 
(Jabara et aL 1993) suggests that an effect on transcription should be seen also in 
PBMC, though potentially at later time points than were tested. 
The effect of glucocorticoids could cause a prolonged period of competency for 
switching. If the period of switching was extended, the level of epsilon mRNAs may not 
increase until later in the culture period, after the 4.5 day time point assayed in this 
chapter. Also, glucocorticoids might induce switching through a differentiation event 
that occurs later than the events induced by IL-4 alone. Glucocorticoids could induce 
IgE synthesis through a mechanism independent of the IL-4/CD40/CD40-ligand 
mediated mechanism occurring in the presence of IL-4 alone. The initial levels of 
IgE 
produced starting at day 8 of culture could be induced by IL-4/CD40/CD40-ligand 
dependent mechanism both in the presence and absence of glucocorticoids. After Day 
10 
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the effects of glucocorticoids may cause an additional cellular differentiation event that 
co-stimulates switching to IgE at a later time than in the presence of IL-4 alone. Tile 
later, glucocorticoid induced differentiation event, could occur through the same 
mechanism as for the induction of switching in purified B cells by hydrocortisone and IL- 
4. Additional work is needed to determine if glucocorticoids mediate a previously un- 
described co-stimulatory mechanism for switching to IgE. 
To determine whether the effects of fluticasone occur though an up-regulation of 
switching, an increase in the number of cells expressing IgE can be determined by an 
enzyme-linked immunospot assay (Czerkinsky el al. 1983). An increase in switching to 
IgE would result in a greater number of cells expressing IgE, conversely, if fluticasone 
increases the level of productive epsilon transcription, translation, secretion, or a change 
in the membrane to secreted IgE ratio, the number of IgE expressing cells would be 
unchanged. 
Differences in the stage at which glucocorticoid is required, and the dependence on 
monocytes for purified B cell cultures compared to PBMC, have suggested that 
glucocorticoids have a different mechanism of action in the two cell populations. 
Though, the requirement of glucocorticoid at the onset of culture for switching to IgE in 
purified B cell cultures (Jabara el al. 1993), and not until day 6 in PBMC (Wu el al. 
1991), could simply reflect the absence of differentiation signals in purified B cell 
populations which are necessary for switching, and are provided by accessory cells 
present in PBMC. In purified B cell cultures, glucocorticoids may provide differentiation 
signals which replace the need for the accessory cells present in PBMC. The difference 
in the requirement for monocytes between purified B cell cultures and PBMC could 
reflect differences in experimental technique, as monocytes are difficult to separate from 
other cell types. Hence, it is possible that monocytes were present in the purified B cell 
cultures of Jabara et al (1993). 
The requirement of monocytes for enhancement of IgE secretion by PBMC suggests 
that cytokines which inhibit IL-4 induced IgE secretion are produced by monocytes or 
macrophages. IL-12 and IFN-, y, produced by macrophages are down-regulated by 
glucocorticoids, and could be a mechanism for IgE enhancement by fluticasone. 
Although IL-4, added exogeriously during the glucocorticold potentiation experiments, 
--1 
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also favours the development of a THI response, inhibiting the production of both IFN--ý 
from T cells and macrophages and IL- 12 from macrophages (Belardelli 1995, Romagnani 
1995; Trinchieri 1995; de Waal Malefyt 1997), fluticasone could inhibit levels of these 
cytokines at later times in culture, when the IL-4 has degraded, and account for the late 
enhancement of IgE secretion. Studies neutralising antibodies against IIL- 12 and IFN-y 
could help to explore this possibility. 
The potentiation of IgE synthesis could also occur through an effect on the efficiency of 
translation or secretion. Interleukin-6 is well known to increase immunoglobulin 
secretion, though dexamethasone causes a suppression of the activity of IL-6 on 
secretion (Shiao el aL 1996), suggesting that IL-6 is probably not involved in the 
glucocorticoid potentiation of IgE secretion. A post-transcriptional mechanism would 
not explain the ability of glucocorticoids to act as a co-stimulus for switching to IgE in 
purified B cells, unless this activity is through a different mechanism than for its 
potentiation of IgE secretion in PBMC. 
Glucocorticoids are known to down-regulate surface CD23 expression on B cells, monocytes 
and eosinophils. As membrane CD23 on B cells mediates a negative feedback loop for IgE 
synthesis, a down regulation of surface CD23 by fluticasone could enhance IgE levels. 
Inhibition of the negative feedback loop could occur at a stage after heavy chain 
switching to IgE through an effect on B cell differentiation, or directly on the efficiency 
of translation or immunoglobulin secretion. To determine if glucocorticoids act by 
interfering with the negative feedback route, inhibitors of the CD23-IgE interaction could be 
used to min-i=ic the effect of glucocorticoid addition. 
7.4 CONCLUSIONS 
, The absence of an effect at day 4.5 on F- germ-line and VDJ-F- transcript levels by 
fluticasone indicates that potentiation of IgE synthesis does not occur by an enhancement 
of switch recombination through the well characterised IL-4 and CD40 induced 
pathways. Glucocorticolds may act to potentiate IL-4 dependent IgE secretion by acting 
as a co-stimulus for heavy chain switching through a mechanism other than the IL-4 and 
CD40 induced pathways at stages later than were tested on day 4.5. Analysis of F-- 
I)o 
gern-Aine and VDJ-CF- transcription at later time points could reveal this possibility. The 
discovery that an enhancement of IgE synthesis does not occur until after 10 days of 
culture suggests that glucocorticoids could act through a novel mechanism for the up- 
regulation of IgE synthesis. Further work could reveal that the glucocorticoid receptor 
has an effect on the stabilisation of an accessible chromatin structure in the switch region 
or variable region promoter past day 4.5, through an enhanced recruitment of 
acetyltransferase proteins to the epsilon locus. 
The use of an enzyme-linked immunospot assay can help to determine whether the 
effects of fluticasone occur though an up-regulation of switching. Glucocorticoids may 
also act through inhibition of a negative feedback loop by the down-regulation of CD2_) 
expression. Neutralising antibodies against EL-12 and IFN-7, could help to determine if 
the down-regulation of these cytokines on macrophages by glucocorticoids is responsible 
for the potentiation of IgE synthesis. The effect of fluticasone could also be mediated 
through the involvement of the glucocorticoid receptor in the regulation one of the many 
genes it controls, as well as through the direct inhibition of transcription factors involved in 
immune function such as NF--KB or AP- 1. 
Several possibilities could explain the mechanism for glucocorticold potentiation of IgE 
secretion. The mechanism could cause increases in germline and productive mRNAs at 
later time points than were examined in this chapter, or the increases could be through an 
effect on translation or immunoglobulin secretion. 
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CONCLUSIONS 
IgE and its high affinity receptor perform a central role in the regulation of the allergic 
response. Consequently, a knowledge of the regulation of both genes will aid in an 
understanding of the development of atopy and aid in the design of new strategies against 
allergy. 
The gene for the high affinity receptor alpha chain was cloned, and a polymorphism was found 
in the upstream region sequences. Analysis of the genomic DNA of 30 individuals revealed a 
potential link between the polymorphism and allergy. An analysis of a larger sample size will 
be required to confirm that the polymorphism is linked to allergy. The mutation in the 
promoter region could either increase the chance of developing atopy, through an increase in 
receptor levels, or it could cause an greater severity of allergic symptoms in an individual. If 
the link to allergy is proven for this polymorphism, factors that bind to this site should be 
studied for their role in the regulation of FceRI(x and also for the development of new anti- 
allergy strategies. Several strong homologies to known transcription factor binding sites were 
discovered in the putative FcF-Rl(x promoter element, including two strong E boxes, and a two 
GATA sites, including one potential GATA site that overlaps with the polymorphism. An 
analysis of the potential role of these sites in regulation of the FccRI(x gene will be important 
to understand the factors that regulate the allergic response, and to help reveal other key 
markers linked to atopy. 
The sequence of the heavy chain switch recombination junction of the IgE secretino 
plasmacytoma line U266 revealed a successive switching from IgM->IgAl->IgE. The 
significance of a prior switching event to aI for allergy is not known. IgA has not been shown 
to be involved in the allergic response, but the expression of IgA on the mucus epithelium of 
the digestive and respiratory tracts is correlates with the location that allergen is encountered 
and raises the possibility of localised switching to IgE. Further work should concentrate on 
the possibility that a successive series of switching events from IgM->IgAl-->IgE occurs in the 
local environment of the nasal or bronchial epithelium. 
Recombination between ýt and (x I occurred at short areas of homology between the respective 
switch regions in U266. Subsequent reports have Indicated that recombination between Sýt 
and Sc also normally occurs at short regions of homology, supporting the theory that homology 
between switch regions may have a role in the mechanism of switch recombination. 
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In each case recombination occurred at regions of repeating pentameric units that characterise 
switch region topology. The pentameric units were found to occur in a strand specific 
manner, suggesting a role for these elements in the mechanism of switch recombination, 
possibly for the alignment of two switch regions prior to recombination. Further insights into 
the role of switch region structure in the mechanism of switch recombination could allow a 
better understanding of a potentially unique recombination system, and aid in the design of 
inhibitors of switching to IgE. 
As it is potentially important to the mechanism of switch recombination, the E-germline gene 
transcript was cloned, and its regulation was investigated. Expression of the GL-F- transcript 
preceded the appearance of IgE in IL-4 induced peripheral blood mononuclear cells, 
supporting the theory that germline transcription precedes switch recombination. The B cell 
specific factor BSA-P/PAX-5 was demonstrated to mediate both IL-4 and CD40 dependent 
up-regulation of F--germline gene transcription. As the only B cell specific factor known to 
bind the GL-F_ promoter, BSAP/PAX-5 is potentially responsible for the B cell restricted 
expression of the F--germline gene transcript. BSAP is also involved in the regulation of the 3' 
immunoglobulin locus control region, and the regulation of at least one other germline gene. 
BSAP is known to participate in several protein-protein interactions, and has therefore been 
shown to be a candidate to mediate communication between the 3' LCR and the GL-C 
promoter. Further work on the role of BSAP in the regulation of the tissue specificity of E- 
germline gene transcription could help to elucidate the regulation of the immunoglobulin heavy 
chain locus. The identification of BSAP as potentially responsible for the tissue specificity of 
GL-F- transcription could help to target a key event in switching to IgE for anti-allergy 
strategies. 
Further work on the role of the F--GLT, and the structure of the switch region in the 
mechanism of switching could also help to clarify the role of transcription and chromatin 
structure in recombination. 
The mechanism of the potentiation of IL-4 induced IgE synthesis by glucocorticolds in PBMC' 
was investigated. The enhancement of IgE secretion by glucocorticoid was found to occur 
after 10 days of culture. Surprisingly, no effect on germline gene or productive epsilon 
transcription was found at day 4.5, as was expected from previous work on purified B cells. 
The lack of an effect at day 4.5 demonstrates that the mechanism of the enhancement of IgE 
synthesis could occur by a different mechanism than that mediating EL-4/CD40 stimulation of 
switching to IgE, acting later in the culture period, possibly through an effect on B cell 
differentiation. An analysis germline and productive epsilon transcription at later times after 
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the addition of IL-4 could reveal a later acting mechanism for inducing switching to IgE by 
, glucocorticoids than by IL-4/CD40 stimulation. Further work on the glucocorticoid 
, 
enhancement of IL-4 induced IgE secretion could reveal a novel co-stimulus for switching to 
ý 
IgE. 
As glucocorticoids are known to down-regulate CD23 expression, and CD23 has been shown 
to mediate the induction of apoptosis in B cells, the down-regulation of CD23 by 
glucocorticolds could lead to the reduction of CD23 induced B cell apoptosis, and therefore 
, an increase in IgE accumulation in culture due to the extended survival of IgE producing cells. 
CD23 also mediates the negative regulation of IgE synthesis and its down-regulation by 
glucocorticoids could cause an increase in IgE synthesis by the inhibition of this negative 
control route. The potential role of CD23 down-regulation in the potentiation of IgE 
synthesis requires further investigation. 
The potential involvement of the JNK signalling cascade in the mechanism of glucocorticoid 
enhancement of IgE secretion is intriguing. CD40 and EBV both signal through the JNK 
cascade, and corticosteroid appears to co-stimulate IgE synthesis with EL-4 in purified B cells 
replacing the need for a co-stimulus from EBV or CD40. Surprisingly, glucocorticoids have 
been demonstrated to block induction of the JNK cascade. Also, the down-regulation of 
FcF_RlI by glucocorticoids is blocked by EBV and CD40 engagement. The effect of CD40 
engagement, EBV, and inhibitors of the JNK cascade need to be tested for their effect on the 
glucocorticoid enhancement of IgE synthesis. 
The potential role of histone acetylation of the immunoglobulin locus in the mechanism of the 
glucocorticoid up-regulation of IgE synthesis requires investigation and could help to explain a 
novel IgE regulatory route. 
Through the discovery of a polymorphism in the FccRI(x promoter region and the 
identification of a factor, BSAP, potentially responsible for the tissue specific regulation of c- 
germline transcription, two new targets for anti-allergy strategies have been proposed. The 
advances to the regulation of the FcF-Rl(x and the germline e genes described in this thesis have 
helped to elucidate two important control points in the regulation of IgE levels. The 
demonstration of late potentiation of IgE synthesis by glucocorticoids, and a IgM-4lgAl-->IgE 
localised switching programme have proposed two novel mechanisms by which IgE levels are 
regulated. 
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SR CTGGGCTGGGCTGAGCTGGGCTGAGCTGGGCTGAGCAAGGCTAGGCTGAGCTGGGCTGAGCTGAGCTGGG 3921 
111 11 111111 1 1111 111111111 111 111111 11 
sg CT GAGCCTAAGCTGAG CC. TAG AC TAAC AG GC TGAACTGGGCT G AGC TGAGCTGAAC TGGGCTGAGTTGAA 3668 
SýL CTGAGCAAGGCTAGGCTGAGCTGAGCTGAGCTGGGCTGCGCTGAGCTGGGCTGGGCTGCGCTGAGCTGGG 3991 
III I 111 11111111111111 111 1 111 1 11 11 lill 1111 1111 111 11 
SR CTGGGTTGAGCTGAGCTGAGCTGAGCTGGGCTAAGTTGCACC-AGGTGAGCTGAGCTGAGCTGGGCTTGG 3738 
SR CTGGGCTGAGCTGGGCTAGGCTGGGCTGAGCTGGGCTGAGCTAGGCTGGGCTGGGCTGGGCTGAGCGGGG 4061 
111 11 111111111 1111111 1 1111111111111 11111111111111 lill 11 111 
SR CTGCACTAAGCTGGGCTGAGCTGGGCAGGGCTGGGCTGAGCTGAGCTGGGCTGGGCTGAGCTGGGCTGGG 3808 
SR CTGAGCGGG-CTGAGCTGAGCTAGGCTGGGCTGAGCGGGG 4100 
111 11 11 HIM IIIIII 
Sýt CTGGGCTGGGCTGAGCGG'ILIAbL(ibbCTGAGCTGAGLi(3 Jb4b 
Appendix 1. Homology within the g switch region. Sg sequences are aligned to show 
homologous pairing leading to the proposed Sg deletion event from nucleotides 3781- 
4033. Sequence of the Sg regions with identity to the U266 switch recombination join is 
shown in red. 
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Sý ATGGACTCAGATGGCTAAACTGAGCCTAAGCTGAGCCTAGACTAACAGGCT W CTGGGCTGAGCTGAGC 3650 
11 111 11 11 1111111 11 1111111 11 
Sý TGATTTGGGCTGGGTTGAGCAWU; I LiGGCTGAGCCGGGTTGAGCTGAGCTGAACCAGGATGAGCTGGGC 5290 
Sýt TGAACTGGGCTGAGTTGAACTGGGTTGAGCTGAGCTGAGCTGAGCTGGGCTAAGTTGCACCAGG-TGAGC 3719 
III 111 1111 1 11 111 11 1 11 111 11 11 
Spi TGAGCTGAGCTGGGCTGGGTGGTCCAG[iL I GGGC I GACCTGGACCAGGCTGGGCCAGGATTGAGCTGGGC 5360 
Sýl TGAGCTGAGCTGGGCTTGGCTGCACTAAGCTGGGCTGAGCTGGGCAGGGCTGGGCTGAGCTGAGCTGGGC 3789 
1 111 HIM III 1111 11 1 11 111 1111111 1111111111 111111 HIM 
Sg TAAGCCGAGCTGAGCTGAGCTGAGCTGGGATGATCTGGGCTGGGCTGGGCTGGGCTAAGCTGACCTGGGC 5430 
Sg TGGGCTGAGCTGGGCTGGGCTGGGCTGGGCTGAGCGGTCTAGCGGGCTGAGCTGAGCTGAGGCTGGGCTG 3859 
1111111 111 1111 1111 1111 11 111 11 1111 111 11 1111 111 
Sg TGGGCTGGGCTAAGCTGAGCTGAGCTGAGTTAAGCTAAGCTGAG--CTGAACTGGGCCTGTGCTGAGCTA 5498 
Sý GGCTGAGCTGGGCTGAGCTGGGCTGAGCAAGGCTAGGCTGAGCTGGGCTGAGCTGAGCTGGGCTGAGCAA 3929 
sp LiGCTGGGCTGGGCTGAGCTGGGCTGGGCTGGGCTGAGCCAGATTGTGCCTGGCTGAACTGAGCTGGGCTA 5568 
SýL GGCTAGGCTGAGCTGAGCTGAGCTGGGCTGCGCTGAGCTGGGCTGGGCTGCGCTGAGCTGGGCTGGGCTG 3999 
III IIII IIIIIIIII 1111 1111 1111 1111 1 1111 1 111111111 11 11 111 
Sýt AGCTGAGCTGGGCTGAGCTGGGCTGAGCTGAGCTGGGCTGAGTGGGGCGGGGCTGAGCTGAGCCGGACTG 5638 
sg AGCTGGGCTAGGCTGGGCTGAGCTGGGCTGAGCTAGGCTGGGCTGGGCTGGGCTGAGCGGGGCTGAGCGG 4069 
11111111 lill 11111111 11111 11 1111111111 11111111 11 1 1111111 1 
sg LiGCTGGGCTGGGCTCAGCTGAGCTAAGCTGAACTGGGCTGGGCTGAACTGGGCTGGGCTGAGCTGAGCTG 5708 
SR G-CTGAGCTGAGCTAGGCTGGGCTGAGCGGGGCTGAGCTGAGCTAGGCTGGGCTGGGCTGGGCTGAGCCA 4138 
III lill III 11111111 11 1 11111111 11 111111111 11111111 1 
Sp AACTGGGCTGGGCTGAACTGGGCTGGGCTGAGCTGAGCTTGGATGAGCTGGGCTGAACTGGGCTGGGTTG 5778 
S9 AGCTGAACCGGGTTGAGC-GTGCTGTGCTGGGCTGAGCCAAGCTAGGCTGAGCTGAGCCAAGTTGAGCTT 4207 
IIIII I III IIII 1 11 111 111 11 111 1111 11 1111 11 11 11 
S9 AGCTGGGCTGGGCTGAGTTGAGCCAGACTGATCTGGGCTGAGCCGAGCTGGGTTAAGCCGAGCTGGGTTG 5848 
Sil AGCTGGGCTGAGCTAACCTGGGCAGGGCTGAGCTGGGCTGAGCTAACCTGGACTGGGCTGAGCTAACCTG 4277 
IIIIIIIII II IIIIII I II I 11111 11 111 1 111 1111 111 111 1 111 
Sg (iGCTGGGCTGGGTTGGGCTGGGCTGAGCCGGACTGGGTTGGGCTGAGCTGAGCTGGACTGGGCTGAGCTG 5918 
SýL GGCAGAGCTGAGCTGGGCTGAGCTAACCTGGGCTGGGCT&AGCTAACCTGGGCTGGCGTCAGCTCAGCTG 4347 
11 1 111 Hill IIIIIII I III II IIII IIIIIIIII I IIIII IIII 
Sýt AGCTGGTCTGGGCTGG-CTGAGCTGAGCTGTAGTTGAAGCCGCTAGGCTGGGCTGGGCTGAGCTGGGCTG 5987 
sg ACGTACGCTGGGCTGGGCTGGGCTGAGCCGAGCTGAACTGGGCTWCAGGCTGTGTCGGGCT&AGCCAA 4417 
11 1111 11 1 11 1111111 1 lill 11 11 1111 11 111 
S9 AACTGGGCTGAGCGGACGTGAGCTGAGCTGGGCTGGGTTGAGCAGAGCTGGGGGCTGAGCTGbbLibbbL 6057 
Sg GCTGGGCCGAGCTCA 4432 
Sg TGGGCTGAGTTMGC 6072 
ADDendix 2. Hornolociv within the g switch region. Sg sequences are aligned to show 
homologous pairing leading to the proposed Sg deletion event from nudeobdes 422G-5860. 
Sequence of the Sg regions with identity to the U266 switch recombination join is shown 
in red. 
136 
Sýl CATGACAACTCCATCCAGCTTTCAGAAATGGACTCAGATGGCTAAACTGAGCCTAAGCTGAGCCTAGACT 3623 
IIIIII IIII HIM III 
Sal GCTGTGCTGlLiLlWkUUILiLiLiLibUULIUAULIGAGCTGGGCTGGGCTGAGCTGAGCTGGGCTGGACTGG 660 
Sýt AACAGGCTGAACTGGGCTGAGCTGAGCTGAACTGGGCTGAGTTGAACTGGGTTGAGCTGAGCTGAGCTGA 3693 
Sa I GCTGGGATGAGCTGGGCTGGGCTGGGCTGAGCTGGGCTGAGCTGGGCTGGGCTGAGCTGAGCTGAGCTGG 730 
Sýt GCTGGGCTAAGTTGCACCAGG-TGAGCTGAGCTGAGCTGGGCTTGGCTGCACTAAGCTGGGCTGAGCTGG 3762 
11111111 1 11 1 11 11 1111 lill 11111111 Hill 11 1 11111111111 1 
Sal LiCTGGGCTGGGATGAGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGGCTGGGC TGGGTTGGGCTGAGC TAG 800 
SýL GCAGGGCTGGGCTGAGCTGAGCTGGGCTGGGCTGAGCTGGGCTGGGCTGGGCTGGGCTGAGCGGTCTAGC 3832 
I IIIIII IIIIIIIII IIII Hill III IIIIIIIII IIIIIII III III 
Sal ACTGGGCTGAGCTGAGCTGGGCTGAGCTGGACTGGGCTGGGCTGAGCTGGGCCGGGGCGGATTGGGCCGG 870 
Sg GGGCTGAGCTGAGCTGAGGCTGGGCTGGGCTGAGCTGGGCTGAGCTGGGCTGAGCAAGGCTAGGCTGAGC 3902 
III1 11 1 1111 11 111111111 11 11 1 lill 1111111 
Sal (iCCCGGGCGGACTGGGCGGGCCGAGCGGGCCGGGGCGGGCTGAGCGGGTCTAGACTGGGCTGAGCTGAGC 940 
SýL TGGGCTGAGCTGAGCTGGGCTGAGCAAGGCTAGGCTGAGCTGAGCTGAGCTGGGCTGCGCTGAGCTGGGC 3972 
Soci TGGGNTGGGCTGGGCTTGGACGAGCTGGGCTGCCCTGGGTTGAGCTGAGCTGAGCTGAGCTGGGCTGGCC 1010 
Sýl TGGGCTGCGCTGAGCTGGGCTGGGCTGAGCTGGGCTAGGCTGGGCTGAGCTGGGCTGAGCTAGGCTGGGC 4042 
11 1111 1111 111 1111111111 11111111 1111 11 11111111111 11 11 11 11 
Sal TGAGCTGGGCTGGGCTAGGCTGGGCTGGGCTGGGCTGGGCTTGGACGAGCTGGGCTGCCCTGGGTTGAGC 1080 
Sýt TGGGCTGGGCTGAGCGGGGCTGAGCGGGCTGAGCTGAGCTAGGCTGGGCTGAGCGGGGCTGAGCTGAGCT 4112 
11 lill IIIIIII IIIIII II1 11 1111 111 11 1111111111 1 111 1111 111 
Sal TGAGCTGAGCTGAGCTGGGCTGGGTGAGCTGGGCTGGGCTGGGTTGGGCTGAGCTAGACTGGGCTGGGCT 1150 
Sýt AGGCTGGGCTGGGCTGGGCTGAGCCAAGCTG. AAý', CGGGTTGAGC-GTGCTGTGCTGGGCTGAGCCAAGCT 4181 
IIIII IIIIIIII IIII I IIII I 111111 11 1 111 11111111111 111 
Sal GGGCTGAGCTGGGCTAAGCTGGACTGGGCTGGGCTGGGTTGGGCTGAACTGGGCTGGGCTGAGTTGGGCT 1220 
delefion, nt 4220-5860 
sg AGGCTGAGCTGAGCCAAG*TTGAGCTTAGC'TGGGCTGAGTTGGGCTGGGCTGAGCCC6ACTGGGTTGGGCT 5892 
IIII IIIIIII IIIII III 111111111111 11 1 1111111111 11 11 1 111 1 
Sal GAGCTGGGCTGAGCTGAGTTGGGCTGAGCTGGGCTGAGCTGAGTTGGGCTGAGCTGGGCTAAGCTGGACC 1290 
Sg GAGCTGAGCTGGACTGGGCTGAGCTGAGCTGGTCTGGGCTGG-CTGAGCTGAGCTGTAGTTGAAGCCGCT 5961 
IIII 1 11 11111111 1111 1111 111111111 111 1111 1111 11 111 
Sal TGGCTGGGGTGAGCTGGGCTGGGCTGCGCTGAGCTGGGCTGGGCTGGGCTGGGCTGAGCTGGGCTGGGCT 1360 
Sg AGGCTGGGCTGGGCTGAGCTGGGCTGAACTGGGCTGAGCGGACGTGAGCTGAGCTGGGCTGGGTTGAGCA 6031 
IIII IIIIIIIIII IIIIIIII III 111 11 11 11111 111 Hill 1 11 
Sal GAGCTGAGCTGGGCTGACCTGGGCTGGGCTGACCTGGGCTGGGCTAAGCTGGACTGATCTGGGCTAGGCT 1430 
Sýt GAGCTGGGGGCTGAGCTGGGCTGGGCTGGGCTGAGTTAAGCTGGGCTGACCTGGGCTGAGTTAAGCTGGG 6101 
1 111111 1111 11 1111 11 1 111 11 1111111 11 11 11 11 1111 
Sal (iGGCTGGG--CTGACCTAAGCTGAGCCAGACTGGGCTGAGCTGGGTGAGCTTAGGTGGATTGAGCCTGGA 1498 
Sg CTGACCTGGGCTGAGCTAAGCTGGGTTGAGCCGATCCGGGCTGGGCTGGGCTGGGCTGAGCCAGGCTAGG 6171 
III 111 11111111 1111 1 11 111 11111 1111 111 11 11 1 11 11 
Sal LTGGGCTGAGCTGAGCTGGGCTGAGCTGGACTGGGCTAGGCTGAGCTGAGCT-TGGTTGGGTTGACCTGGG 1568 
137 
Sýj TTGAGCTGGGCTGGGCTGGGCTCTGCTGTGCTGTGCTGAACAGGGCTGAGCTGAACTGAGCTGAGCTGGG 6241 
Sal 
1111111 1111 lill I III lill 1111 Hill III lill III IIIIII 
CTGAGCTGAGCTGAATTGGGTTGACCTGGGCTGAGCTGGGTTCGGCTGGGCTAGGCTGACCTGGGCTGGG 1638 
Sý CTGAGCTG-GCTCTGCTGTGCTGTGCTGAGCTAGGGCTGAGCTGAAGCGTGCTGAGCTGGGTTCAGCTAA 6310 
sa I 
11111111 111 111 1 11 11111111 111111 1 11 11 1111 111111111 11 
CTGAGCTGAGCTAGGCTTGGATGAGCTGAGCT-GGGCTGGGTTGGACTGCGCTGGGCTGGGTTGGACTGG 1707 
Sýt GCTAGGCTGGGCTGGGCTGAGCTGGGATGAGCTGGGCTGGGCTGGGCTGGGCTCTGCTGTGCTGTGCTGA 
11 Hill 111 1111 111 1 11 111 
6380 
Sal 
111 1111 11111111 111 1111 1111 
TCTGGGCTGACCTGAGCTGTACTGAGCTGGTCTGACCTGTGCTGAGCTGGGCTGGGCTAGGCTGAGCTGG 1777 
Sg ACAGGGCTGAGCTGAACTGAGCTGAGCTGGGCTGAGCTGAGCTCTGCTGTGCTGTGCT W CAGGGCTGA 6450 
11 111 1 11 111 lill III lill III 111 1111 1111 1 1111 1 111 
Sal GCTGACCTGTGTTGGGCTGGGCTGGGCTAAGCTGGGCTAGGCTGGGCTGAGCTGGACGGAGCTGACCTGG 1847 
Sýt GCTGAACTGGGCTGAGCTGGGCTGAGCCGGGCTGAGTTGAGCAGAGCTGGGTTGAGCAGAGCTGGGCTGG 6520 
1 111 11 11 111 1111111 11 1111 11 11 1111 1 11 11 11 111 11111 
Sal G-TGAGCTTAAGTGGACTGAGCTGAGCTGGACTGACCTGGGCTAAGCTAAGCTGGGCTGACCTGTGCTGG 1916 
Sg GCTGGGCTGAGTTGAGCCAGGCTGACCTGGGCTGAGCCAAGCTGGGTTGAGCC W CTGGGCTGGGCTGG 6590 
IIIIIIIII 1 11 111111 1111 111111 1111 1 11111 1 Hill 11 1111 
Sal GCTGGGCTGGACTAGGCTGGGCTGAGCTGGACTGAGCTGAGCTAGACTGAGCTGAGCTGGG-TGAGCTGA 1985 
Sg GCTGAGCCAGGCTGGATTGAGCTGGGCTGGGCTGGGCTAAGCTGGGCTGTGCTGCACTGAGCTGGGCTGA 6660 
1 11 1 11111 11 1111 1111 11111 11 1111111 111 11 111111111 
Sal GGTGGACTGAGCTGGGCTGGGCTGAGCTGAGCTGGACTGGGCTGGGCGAA-CTGAGCTAGACTGGGCTGA 2054 
Sg GCTGGGTTGAACTGTGCTGAGCTGAGCTGGGCTGTGCTGAACTATGCTTAGCTGGGCTGGGCTATACTGG 
111111 1111 111 
6730 
Sal 
HIM III III 1 11 11111111 11111 1111 1 111 1111 
GCTGGGCTGAGCTGGGGTGGGCTGAGCTAGGCTGAGCTGGGGTGGGCTGAGCTGGGCTGAGCTAGGCTGA 2124 
Sg GCTTAGCTGGGCTGGGCTAAACTGGGCTTAGCTGGGCTGGGCTATACTGGGCTTAGCTGGGCTGGGCTAT 6800 
Sal GCTGAGCTGGGTTTGGTTGACATGGACTGAGCTGTGTTGAGCTGGGCTAGGCTAAGCTAGGCTGGGCGGG 2194 
SR ACTGGGCTTAGCTGGGCTGGGCTATACTGGGCTTAGCTGGGCTGGGCTGAGCTGAGATGGTCTTAGGTGG 6870 
11 111 1 1111111 111 11111111 111111111 111 1111 1 111 11 1 111 
Sal G-TGAGCTGGGTTGGGCTGAGCTGAACTGGGCTGGACTGGGCTGGACTGGGCTGGGCTGGGCTGGGCTGG 2263 
Sg TCTGAGCTCATCTGAGTTGGGCTGAGCTGAGCTTGGCTTTGCTGAGCTGGGGTGGGGTGC&GCTGGGCTGG 6940 
IIIIIII I Hill 11 11111111 11 111 11111111111 1111 11 lill 11 
Sal GCTGAGCTGAGCTGAGCTGTACTGAGCTGGCCTGGGCGA-GCTGAGCTGGGCTGGGCTGAGCTGTACTAA 2332 
Sg ATTGAGCTGGCCTGGGCTGGGATGAACTGGAGGACATGGCACTGGGCCAATCTTCATCATCTTGTTGGAC 7010 
Sal 
11 1111 1111 11111 111 11 1 111 11 1 11 
GCTGGCCTGGGCTGGCTGAGCTGTACTGAGCTGGCCTGGGCTGGGTTGACCTGGGCTGAGCTGGACTAAC 2402 
Appendix 3. Homology between the g and al switch regions. Sg and Sal sequences 
are aligned to show homologous pairing leading to the proposed Wed Switch 
recombination event. Sequence of the Sg and SO regions with identity to the U266 
switch recombination join is shown in red. 
138 
Sal GGCTTGGACGAGCTGGGCTGCCCTGGGTTGAGCTGAGCTGAGCTGAGCTGGGCTGGGTGAGCTGGGCTGG 1117 
11111 11 11 1 11 1 111 11 1111 1 
sp- AAACTGGACCGGGCTAAATTGATCTGGACTGACCATTCTCACCTGGCTAAGAGWCTGAGTCAGMGCA 2998 
11111111 1111 11 1111111 1 
Sýt GCTCAGCTG LIA%LTGAACTGGGCTGGGCTGAACTGGGCTGGGCTGAGCTGAGCTGAACibbbLIGG 5719 
Sal GCTGGGTTGGGCTGAGCTAGACTGGGCTGGGCTGGGCTGAGCTGGGCTAAGCTGGACTGGGCTGGGCTGG 
11111 lill I1 111 
1187 
S 
1 11 11 
AGCTGGTTGAGCTGGCTGGACTGAAATAAGAG M GCTGCCTGCAAGGGGAGGTCCTGGGUibALLibbu 
11 11111 11 11 
JU68 
Sýt 
1 lill 11 11 11 11 
GCTGAACTGGGCTGGGCTGAGCTGAGCTTGGATGAGCTGGGCTGAACTGGGCTGGGTTGAGL I GGGC I GG 5 789 
Sal GTTGGGCTGAACTGGGCTGGGCTGAGTTGGGCTGAGCTGGGCTGAGCTGAGTTGGGCTGAGCTGGGCTGA 
11 11 11 11 
1257 
S F, 





11111111 11 11 11 11 11 1 11 1111 
GCTGAGTTGAGCCAGACTGATCTGGGCTGAGCCGAGCTGGGTTAAGCCGAGCTGGGTTGGGCTGGGCTGG 5859 
Sal GCTGAGTTGGGCTGA. GCT , GGGCTAAGCTGGACCTGGCTGGGGTGAGCTGGGCTGGGCTGCGCTGAGCTGG 1237 
11 1 11 11111 111 11 111 
S F- ACTTGGCTGTCCCGGTGGGCAGAGCGGGGCTGGATACTGTU'ATTTTGGGGGTACCTAGAGCAGACTTCAA 3208 
I IIIII IIIIIII III II III I 
Sg GTTGGGCTGGGCTGAGCCGGACTGGGTTGGGCTGAGCTGAGCTGGACTGGGCTGAGCTGAGCTGGTCTGG 5929 
Sal GCTGGGCTGGGCTGGGCTGAGCTGGGCTGGGCTGAGCTGAGCTGGGCTGACCTGGGCTGGGCTGACCTGG 1397 
1 11 1111 11 11111 111 11 11 
SE GACUPAULTAAACTGGGCTCCAGGGGC-AGGATGGGCTGGGGACTTGGGACTCCAGGCCAGGGGCGAAGGU 3218 
111111 1111111 11 111111 
Sý' bU I bbL I GAGC I GAGC I'GTAGTTGAAGCCGCTAGGCTGGGCTGGGCTGAGCTGGGCTGAACTGGGCTGA( 5999 
Sal GCTGGGCTAAGCTGGACTGATCTGGGCTAGGCTGGGCTGGGCTGACCTAAGCTCAGCCAGACTGGGCTGA 1467 
1111111 111 1 11 1111 11 11 
S F- CCACGC'FGTACAGACCGCAC-TATCTGGGCCAGGG1'TCTGTGGTGGGAGGGACTGACTGCCTGGGGCATCA 3348 
1 11 1 11 1111 11 111111 
Sg CGGACGTGAGCTGAGCTGGGCTGGGTTGAGCAGAGCTGGGGGCTGAGCTGGGCTGGGCTGGGCTGAGTTA 6069 
Sal GCTGGGTGAGCTTAGGTGGATTGAGCCTGGACTGGGCTGAGCTGAGCTGGGCT&AGCTGGACTGGGCTAG 1537 
SE 
111 111 11111 11 11 
GGGCAAGTC II CCULiCUCTCCCCTAGAGGTCAGGGGTGGGCAGAGCACCATGGGGGTCTGGCAGGTCAGG J418 
S[t 











1 11 11 111 11 11 
GGCTGGGCTGGGCTGGGCTGAGCCAGGCTAGGTTGAGCTGGGCTGGGCTGGGCTCTGCTGTGCTGTGCTG 6209 
Appendix 4. Homology between Sr- and the Sal and Sg regions. The epsilon switch 
region (SF-) is compared to the alpha 1 (Sal) and mu (Sg) switch regions. Identity with the 






















1401 CATGAGAAAAGGATTGTTTATCTTAGGAGGCATGCTTACTGTTAAAAGACAGGATATG M GAAGTGGCT 
1471 TCTGAGAAAAATGGTTAAGAAAATTATGACTTAAAAATGTGAGAGATTTTCAAGTATATTAATTTTTTTA 





1891 TGAAAGTGCTCTACTGAGCAAAACAACACCTGGACAA M GCGTTTCTAAAATAAGGCGAGGCTGACCGA 











2731 CTGCATTTGCTTCTCTTAAAACTTTGTATTTGACGTCTTA M CCACTAGAAGGGGAACTGGTCTTAATT 
2801 GCTTGATGAAGAGCAGGAGACTCATTTATGTGAGTCTTTTGAGTGACCATTGTCTGGGTCACTCCCATTT 
2871 AACTTTCCCTAAAGCCCA M GAAGGAGAGGTCGCACGAGCTGCTCCACAACCTCTGAATGGGGATGGCA 
2941 TGGGTAATGATGCTTGAGAACATACCAAGCCCCACTGGCATCGCCCTTGTCTAAGTCATTGACTGTAGGT 
















3641 TGAGCTGAGCTGAACTGGGCTGAGTTGAACTGGGTTGAGCTGAUC IGAGCTGAGCTGGGCTAAGTTGCAC 
SKS281/A5-2(Sg/SE) 
11 
3711 CAGGTGAGCTGAGCTGAGCTGGGCTTGGCTGCACTAAGCTGGGCTGAGCTGGGCAbbbL I U66L I UAK I 
HJS7-1(SýUSE) 2ClO(Sg/Sy4/Se) pSC1.7-56(S4/S-y4/SE) 
II.. 1 


























































































































































Appendix 5. Location of switch recombination events in the mu locus. The position 
Of JH5, JH6, the immunoglobulin enhancer (Eg), and the mu constant region exons (Cg 1 -4) 
are shaded in grey. The positions of switch recombination events are marked vi/ith the 























pSC1.5 - l(Se/Sy4) /pSCl. 1- 7(SýUSE) 
1191 CCTGAGCCAGGGCGATCGGGGCTGGCCCGGGCCAGGCGGGTTTAGCTGAGTTGAGTGAGTGGýTGGýTA 


















pSC1.7-6/pSC1.8-23(Sg/Se) pSC1.7-56(SR/Sy4/SE) pSC1.7-2(Sg/SE) 



























A5 -1 (sýI ISF-) A5-2(Sg/Se) 
11 
2731 ATTCAGCTGGGCTGGCCTGGCCTCGGCTGGGCTGGGTTCAGCTGGGCTGGGL 1 LiAbL%GCCTGAGCAGG 
2801 ATTAGTTGAGCTGGTCGTAACTGGATTTAACTAGCTAGGCTAGGCTTAACTGACTAAGCTGATCTGGACT 


















































Appendix 6. Location of switch recombination events in the epsilon locus. The 
position of the germline--c exon (GL-f, ), and the epsilon constant region exons (Cel-4) are 
shaded in grey. The positions of switch recombination events are marked with the 
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Our work provides strong evidence that local regulation of 
IgE synthesis by IL-4 may occur in nasal B cells. Further 
studies are needed to strengthen this conclusion, but there 
are several implications: local regulation of IgE synthesis 
could account for the efficacy of topical steroid treatment 
in hayfever patients, and could be the basis for the devel- 
opment of new therapeutic strategies. It may also explain 
why only a proportion of "atopic" individuals (with a ge- 
netic predisposition to exhibit exaggerated IgE responses) 
develop hayfever, while others have either no clinical 
manifestations or develop atopic disease (such as asthma 
or eczema) in other anatomical locations. 
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Figure 6. Results of immunohistoIogy to detect IgE in nasal 
biopsy specimens. An anti-IgE Ab was used to detect IgE in nasal 
biopsy samples obtained outside the pollen season from grass 
pollen-sensitive hayfever patients (0) and non-atopic normal con- 
trol subjects (0). Solid bars represent median values. 
Our failure to detect IgE protein within nasal B cells by 
immunohistochernical methods may be a consequence of 
low levels of IgE expression and/or of secretion rather than 
intracellular accumulation of a major portion of the prod- 
uct. It may be that relatively few committed B cells go on 
to secrete IgE in large amounts. This would be consistent 
with our failure to detect CF, -positive CD38' plasma cells in the nasal biopsy sections. It is possible, on the other 
hand, that there are too few plasma cells secreting large 
amounts of IgE to have been detected in our assay sam- 
ples. Very few plasma cells may, however, secrete large 
amounts of IgE. Bonnefoy and co-workers [38] were 
unable to detect IgE in sections from lung-associated 
lymphoid tissue, but found that IgE was produced by the 
isolated tissue in culture. The synthesis of mRNA by nasal 
B cells is prima facie evidence of protein synthesis. 
The present study is only the second in which germ-line 
gene transcripts have been observed in vivo. Ia transcripts 
were previously observed by Cebra and co-workers [39] in 
Peyer's patches isolated from mouse gut. However, Peyer's 
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Figure 7. Colocalization of IgE with mast cell and B cell markers. 
Biopsies from the nasal mucosa of hayfever patients were probed 
by double immunohistochcmistry, using anti-IgE and phenotypic 
markers for mast cells (anti-tryptase) B cells (anti-CD20) and 
plasma cells (anti-CD38). 
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patches are recognized as gut-associated lymphoid tissue, 
whereas the nasal mucosa is not a previously recognized 
locus for heavy chain switching. The expression of Ie tran- 
scripts by nasal B cells is consistent with the view that 
switching occurs in this tissue, but further proof is 
required. 
Our results (Figs. 3-5) substantially reinforce the hitherto 
fragmentary evidence for local regulation of IgE synthesis. 
Since IL-4 is required for targeting class switching to IgE, 
it may be conjectured that the allergen-induced elevation 
of IL-4 gene expression in nasal T cells and/or mast cells is 
responsible for the IE transcripts observed at the same time 
in neighboring B cells. The inhibition of IL-4 gene tran- 
scription by FP eliminates both the increase in IL-4' and 
IE' cells in response to allergen, in accord with the conclu- 
sion that IL-4 induces IE transcription. FP has been shown 
to have no systemic bioavailability [40], and must there- 
fore exert its effects locally. FP therapy did not cause any 
obvious reduction in the background of Cc' cells 
(Fig. 5A), and may therefore be ineffective towards cells 
already committed to IgE synthesis. However, it could also 
alter the ratio of E chain mRNA for the membrane-bound 
and secreted forms of IgE, by analogy with other known 
perturbations of B cells [3-5,41]. Further work is required 
to investigate this possibility. Until this is done, we cannot 
speculate on the relationship between local IgE and the 
improvement in patients' symptoms. 
The second signaling agent required for heavy chain 
switching to IgE in B cells is CD40L. Transient activation 
of CD40L expression is induced by antigen presentation to 
T cells. Allergen challenge may therefore have another 
critical consequence for local switching to IgE in uncom- 
mitted B cells if there is also a local source of IgE. Aller- 
gen can bind to IgE antibodies via IgE receptors on APC, 
leading to antigen presentation to T cells [42]. Our results 
(Figs. 4 and 7) demonstrate that IgE may be found at 
higher levels in the nasal mucosa of hayfever patients 
between seasons than in normal individuals. On allergen 
challenge or on arrival of the pollen season, this IgE may 
act to prime APC for presentation of allergen to Th2 cells, 
and so enable them to express IL-4 and CD40L simultane- 
ously and form the necessary contact with local B cells to 
induce switching to IgE. Local IgE may influence the 
allergic status of an individual by its effects on APC as well 
as mast cells. 
Local switching would not exclude the possibilities that 
some of the CE' B cells are generated elsewhere and mi- 
grate to the tissue, or that mast cells and basophils trans- 
port IgE to the tissue. In a study of IgE trafficking in the 
rat, Bell and co-workers [43] observed that IL-4 induced 
the specific transport of circulating IgE to the gut. The rel- 
ative contributions of the different mechanisms by which 
mast cells and APC in the nasal mucosa accumulate IgE 
cannot be resolved by the present methods: neither traf- 
ficking studies to detect cell populations homing to the 
nasal mucosa, nor kinetic studies, using serial biopsy sam- 
ples from a single patient to obtain stronger circumstantial 
eidence for local switching, would gain ethical approval 
because they are too invasive. Future experiments are 
planned with nasal biopsy samples cultured ex vivo. 
2904 S. R. Durham et al. 
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Figure 4. Comparison of e gene transcripts in hayfever patients 
and non-atopic normal control subjects. Results of in situ hybrid- 
ization using antisense probes for RNA for Ce (A) and Ie (B) of 
nasal biopsy samples outside the pollen season in hayfever pati- 
ents and non-atopic normal control subjects are shown. 
(tryptase positive), and there was no detectable localiza- 
tion to either CD20' B cells or CD38' plasma cells 
(Fig. 7). 
4 Discussion 
Following the recognition of IgE as the "reaginic anti- 
body" [30], IgE was detected in nasal secretions [31-34]; 
this raised the possibility that there might be local IgE syn- 
thesis. Ohashi et al. further detected IgE in nasal tissue 
homogenates [35]. Platts Mills [34] demonstrated grass 
ollen-specific IgE in nasal but not salivary secretions of PfvrpS. 
C, 
yI 
IgE syn ss 
ha ee atient Huggins and Brostoff [31] suspected 
ca the I on clinical grounds in some patients 
With clear-cut seasonal hayfever symptoms but no positive 
Eur. J. Immunol. 1997.2Z 2899-2906 
skin prick test or detectable grass pollen-specific IgE in the 
serum. Grass pollen sensitivity was confirmed by nasal 
provocation with a grass pollen extract, and specific IgE 
was detectable in nasal fluid in amounts comparable to 
those in hayfever sufferers, who also showed positive skin 
tests and elevated allergen-specific serum IgE. However, 
these observations, while demonstrating the presence of 
IgE, did not establish whether the IgE resulted from 
plasma exudation of IgE, from the recruitment of cells 
carrying IgE on surface receptors, from migratory IgE- 
producing plasma cells, or from in situ production of IgE 
by B cells in the nasal mucosa. The last of these possibil- 
ities was examined by Ganzer and Bachert [36] who, by 
use of immunohistology, were able to detect small num- 
bers of IgE' B cells in cervical glands and tonsillar tissue, 
but not the nasal mucosa of hayfever patients. 
Here we have shown that the E gene is expressed in nasal 
B cells. In hayfever patients between seasons we found 
only transcripts of the rearranged e gene (e chain mRNA), 
but after local allergen provocation we observed germ-line 
gene transcripts in additional cells. The proportion of 
B cells that express c chain mRNA appears to be 
extremely high (assuming that CD20' cell counts in Ta- 
ble 1 represent a large proportion of the total B cell 
population), certainly greater than the 1 in 10000 cells 
reported to be IgE' in the circulation [37]. The distorted 
isotype ratio is confirmed by our observation that compa- 
rable numbers of cells express Cc RNA and Cy RNA 
(Fig. 4A, D). Interestingly, the population of mRNA' 
cells within the nasal mucosa in hayfever patients appears 
to be several times greater than that found in normal indi- 
viduals: this may be diagnostic of their condition. 
A Placebo Fluticasone B Placebo Fluticasone 
25- P. 0.006j P. 1.0 .4 
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20 IL-4 aC Figure 5. In situ hybridization using antisense probes for RNA in nasal biopsy samples 
15 a obtained before and after nasal allergen pro- 
vocation. (A, B) Cc and le in placebo- and 
10 4 W; ý_14 topical corticosteroid-treated patients. Cy and 
- : q- IL-4 mRNA' cells were also examined in the 
52 same samples (C, D). Solid horizontal bars 
represent median values. Within-group compa- 
00 risons (before/after allergen) were made using 
P-0.01 P-0.03 the Wilcoxon test. Between-group compari- 
sons (FP vs. placebo) were made using the Before After Before ter Before A er 6fore ifter Mann-Whitney U Test. Levels of statistical sig- Ag Ag Ag Ag Ag Ag Ag Ag 
nificance are shown. 
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--- INC [igmt, 3. Immunohistology and in sau liýhridization of nasal hiopsy specimens. (A) CD20' B cells, (B) IL-4 mRNA' cells, (C) IgE 
CE' cells after allergen challenge which are colocalized to CD20' cells, (D) by use of double immunohistochemistry/in situ hybridiza- 
tion. IE expression after allergen is compared in placebo and topical corticosteroid-treated patients in panels (E) and (F). 
Increases in the number of cells expressing IE and Ce RNA 
were accompanied by a rise in the number expressing IL-4 
RNA (Fig. 5C). However, the magnitudes of these effects 
were not correlated, reflecting the fact that IL-4 expres- 
sion occurs in different cell types, whereas the parallel 
increases in numbers of Ce' and Ic' cells are likely to refer 
not only to the same cell type but to identical cells. 
A Cy probe was used to compare the effect of allergen 
challenge on expression of E and y chain genes in the hay- 
fever patients. In contrast to the ratio of the immunoglo- 
bulins in serum (IgG: IgE = 10 000: 1), the populations of Cy' and CE' cells in the nasal mucosa before allergen chal- 
lenge were about equal. Furthermore, allergen challenge 
resulted in a significant decrease in the Cy' population, 
contrasting to an increase in CF' cells (Fig. 5A, D). 
3.5 Effects of topical corticosteroid therapy in hayfever 
patients 
Topical corticosteroid therapy resulted in inhibition of 
these allergen-induced changes within the nasal mucosa 
(Fig. 5A-D). Thus, in FP-treated patients there were no 
significant changes in either CE, IE, IL-4 or Cy RNA' cells. 
The differences between them and placebo-treated pa- 
tients were all highly significant (Fig. 5). 
3.6 Immunolocalization of IgE 
IgE protein-POsitive cells were more numerous in biopsy 
samples from atopic, grass pollen-scrisitive patients out- 
side the pollen season when compared with non-atopic 
normal subjects (Fig. 6). Double immunihistochemistry 
revealed that the majority of these cells were mast cells 
2902 S. R. Durham et al. 
rank method. Statistics were performed using a statistical 
package (Minitab Statistical Software, Minitab, In. PA 
16801-2756, USA). p values less than 0.05 were taken as 
significant. 
3 Results 
3.1 Clinical data 
The clinical features of the 21 patients with summer hayfe- 
ver examined in this study are shown in Table 1. Patients 
treated with placebo or topical corticosteroid (FP) were 
well matched for age, gender and circulating grass pollen- 
specific IgE concentration. Clinical results of nasal aller- 
gen provocation are summarized in Fig. 2. Allergen pro- 
vocation resulted in early and late increases in sneezing, 
nasal blockage and secretions (all p<0.01) in the 
placebo-treated group. These effects were all markedly 
, reduced in the topical steroid-treated group. 
Colocalization of F, gene transcripts to B cells 
CD20' B cells were present in the nasal epithelium and 
submucosa in about the same numbers in atopic and nor- 
rnal subjects and did not change after allergen challenge 
(Table 1, Fig. 3A). Each Cs' cell was identified by a dis- 
crete cluster of silver grains (Fig. 3C). In three individuals, 
double immunostaining/in situ hybridization showed that 
rnore than 95 % of Cc' cells were identified as CD20' 
13 cells (Fig. 3D). From typical sections such as this it was 
apparent that a high proportion of the B cells in this tissue 
express the F, chain gene. 
3.3 Expression of Ce and IE RNA in hayfever patients 
and normal controls 
The numbers of Cs' and Ie' cells in the nasal mucosa were 
examined in hayfever patients out of season and compared 
with corresponding cell counts in normal healthy control 
subjects. No cells positive for Iz were detected in either 
group. Interestingly, however, the mean value for the num- 
ber of Cc+ (mRNA+) cells was several times higher in hay- 
fever patients than in normal controls (Fig. 4). 
Table 1. Clinical features of 21 patients with summer hayfever 
Eur. J. Immunol. 1997.27. - 2899-2906 
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(e . &. - Figure 2. Nasal allergen provocation tests. Data are presented as 
individual values after FP (0) or placebo (0) nasal spray. All 
symptoms (early and late) were inhibited by topical corticosteroid 
(all p<0.01, except late blockage p<0.03; Mann-Whitney 
U Test). 
3.4 Effect of local allergen challenge on expression of le, 
Cc, Cy and 11,4 RNA in hayfever patients 
Patients with hayfever showed a marked increase in the 
number of Cc' cells 24 h after allergen challenge (Fig. 5A) 
and le' cells became clearly detectable (Fig. 513). There 
was a significant positive correlation between the number 
of Ic' cells and the increase in Cc' cells (r = 0.76, 
p<0.01); i. e. the number of IE' cells was similar to the 
increase in the number of Cc' cells in individual patients. 
Simultaneous in situ hybridization of allergen-challenged 
biopsy samples from four patients with Cc and Ie probes 
revealed that all Ic' cells were also Cc'. However, only 
65 % (60-70 %) of Cc' cells were Cc' and IF', i. e. a mean 
of 35 % of Cc' cells were Cc' and 1C. These findings dem- 
onstrate that the two probes are equally sensitive and that 
Ie- Cc' RNA is F, chain mRNA (Sect. 1.2). 
Placebo FP 
Number 11 10 
Age (years) 31.3(2.7) 30.0(2.4) 
Gender 6M, 5F 4M, 6F 
serum total IgE (KUA) 50.9(17) 92(23) 
Serum grass pollen-specific 2.7(0.4) 3.0(0.3) 
JjjE (Phadebas scale 0-5) 
ij cells (CD20") in nasal Before allergen 7(3-17) 7(1-21) 
N4ucosa (cellslhpf)') After allergen 2(1-30) 2(1-12) 
a) B cell counts are expressed as medians 
(interquartile ranges) per high power field (hpf). 
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with antisense riboprobes, following pretreatment of sec- 
tions with RNase as described [19]. Controls were per- formed with sense probes (having an identical sequence to 
messenger RNA) (Fig. 313, C, E, F). 
Immunohistochemical staining for IgE was performed on biopsy specimens from 9 grass pollen-sensitive patients and 12 non-atopic normal subjects outside the pollen season. 
Double immunohistochemistry was performed on biopsy 
specimens from 7 pollen-sensitive patients using anti-IgE (immunoperoxidase method, in which positive cells stain brown), followed by the phenotypic Ab markers (APAAP 
method, in which positive cells stain red), resulting in 
double-positive cells, which stain red-brown [25,26]. 
Tissue sections were assessed using an Olympus BH2 
microscope with an eyepiece graticule at 200 X magnifica- 
tion. Counts were made along the whole length of nasal biopsy samples to a depth of 0.45 mm (including the whole 
samples lamina propria, where the majority of inflamma- 
tory cells were located). Counts were expressed per high- 
power field (hpf, 0.202 MM2) . The coefficient of variation between observers was <5 % for in situ hybridization and 
8% for immunohistology counts. 
2.3 Genetic probes 
Our Is probe (Fig. 1) corresponded to the sequence from 
the start site of E germ-line gene transcription, referenced 
as nucleotide 1, to the end of the Is exon at position 650. 
This was generated by cloning the indicated Barn HI frag- 
ment (top line; accession no. X56797) into Bluescript Ksp. 
The plasmid, linearized with Xba I or Hind 111, was tran- 
scribed in the presence of [32 P]UTP with T7 polymerase for 
the antisense probe and with T2 polymerase for the sense 
probe used as a negative control [27]. 
The CE probe was generated from an E chain cDNA clone 
[28]. The sequence corresponded to a 1150-base Hind III 
fragment from pSC213, encompassing 24 bases of Ccl and 
the rest of the Cc sequence. This fragment was cloned into 
pGEM [231, cut at a Sma I site and transcribed with SP6 
polymerase for the antisense probe (526 nucleotides), and 
cut at the Barn HI site and transcribed with 77 polymerase 
for the sense probe, used as a negative control. 
For the consensus y chain constant region probe (Cy), a 5' 
end-labeled 30-base oligonucleotide was used, corre- 
sponding to the Cy2 region (IgG1, nucleotide 1206-1235 of 
accession no. J00228; IgG2, nucleotide 1204-1233 of 
J00230; IgG3, nucleotide 1785-1814 of X03604; IgG4, 
nucleotide 1205-1234 of K01316). The consensus Cy probe 
had complete homology to all four IgG subclasses. 
The IL-4 probe was prepared by inserting a human IL-4 
cDNA of 500 bp (generously provided by Dr. J. -Y. Bonne- foy, Glaxo Institute for Molecular Biology, Geneva, Swit- 
zerland) into pGEM as described above. 
2.4 In situ hybridization 
Double immunostaining and in situ hybridization [20] (see Fig. 3D) were performed with anti-CD20 Ab, visualized 
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Figure 1. Identity of the Is and CF and probes. Top line: the C 
germ-line locus (DNA), showing sites of digestion with BamHl, 
the start site of transcription (P), the switch region (SE) and the Is 
exon and the exons encoding the four e chain constant regions 
(CEl-4). Middle line: the unprocessed F, germ-line gene tran- 
script. Bottom line: the mature RNA c germ-line gene transcript 
after RNA splicing, and the sequences corresponding to the Is 
and CF probes. Exposure to IL-4 induces transcription of the V; 
germ-line gene from the promoter site (P). Transcription proceeds 
through the e chain constant region-coding exons CF-1-Cr; 4, but 
RNA splicing joins the Is and Cel exons. When genetic recombi- 
nation occurs, the DNA between the recombined sequences in the 
homologous switch regions (Se), including the Is exon, are 
deleted and replaced by a transcription unit containing the s chain 
variable region coding exons. The Is probe thus detects the tran- 
sient appearance of E germ-line gene transcripts, which precedes 
rearrangement of the gene and the synthesis of mRNA. The CE 
probe detects both the E germ-line transcript and c chain mRNA- 
by diaminobenzidine (DAB) brown staining. In situ 
hybridization was then performed using a "S-labeled com- 
plementary RNA probe, followed by autoradiography. 
Individual double-positive cells were evident as brown 
cells within a clump of black silver grains at 400 x magni- 
fication. 
Simultaneous in situ hybridization with probes coding for 
CE and IE was performed as described [29]. In brief, the CE 
probe was labeled with digoxigenin and the IE probe with 
"S-labeled UTP. The probes were applied simultaneously 
to 10-ttm cryostat sections of nasal biopsy samples from 
four patients who had received placebo nasal treatment at 
24 h after allergen provocation with grass pollen extract. 
Hybridization was performed at 42'C for 12 h. The Cc 
probe was visualized with antibody to digoxigenin labeled 
with chromogen. Slides were then exposed for 10 days and 
Ic RNA was visualized by autoradiography. 
2.5 Statistical analysis 
Patients were stratified according to their level of skin 
prick test sensitivity to grass and hayfever severity before 
random selection to receive either FP or matched placebo 
nasal spray. This resulted in closely matched groups for 
comparison (Table 1). All biopsy samples were coded in 
random order and sections counted blind, independently 
of the clinical protocol. Within-group comparisons (base- 
line/allergen) were based on the Wilcoxon matched-pairs 
signed-ranks test. Between-group comparisons (magni- 
tude of changes between baseline and allergen for subjects 
on FP compared with those on placebo nasal spray) were 
performed using an unpaired analysis (Mann-Whitney 
U test). Correlations were performed using Spearman's 
2900 S. R. Durham et al. 
at 24 h. We and others [22] have also found that nasal tis- 
sue harbors a population of B cells, the extent of which is 
unaffected by allergen challenge. In a double-blind trial 
vve further showed that pretreatment with the topical corti- 
costeroid, fluticasone propionate (FP), inhibits allergen- 
induced early and late nasal responses, as well as the 
associated recruitment of Th2 cells and expression of IL-4 
[23]. This suggested that the release of IL-4 by mast cells 
and/or T cells on activation by allergens may induce heavy 
chain switching to IgE in situ and that some of the commit- 
ted cells may go on to secrete IgE. 
To resolve this question in respect of nasal tissue, we have 
re-examined the number of B cells and IL-4-expressing 
cells in the nasal mucosa of hayfever patients exposed to 
allergen, including those pretreated with FP, using previ- 
ously described methods of immunohistology and in situ 
hybridization on nasal biopsy sections [19,20,24]. In addi- 
tion we have used new RNA probes to detect whether resi- 
dent B cells have the capacity to express IgE or undergo 
allergen-induced local switch recombination to IgE. 
1.2 Experimental approach 
IL-4 and IL, 13 direct heavy chain switching to IgE by stim- 
ulating the transcription of the E germ-line gene [8]. Germ- 
line gene transcripts contain a specific sequence, the le 
sequence, which is spliced to the sequence that codes for 
the constant region of the e chain (CF1-CF4) (Fig. 1). 
14owever, the le exon contains a number of stop codons 
and hence the germ-line gene transcript is not translated 
into protein. Tle IE exon is deleted in the switch, so that 
the le sequence is absent from F chain mRNA transcribed 
frorn the rearranged gene. Thus it provides a specific probe 
fcýr the detection of the F_ germ-line gene transcripts. We 
bave been able to determine in this way whether the 
increase in IL-4 mRNA (and presumably protein), induced 
L, y allergen challenge in the nasal mucosa of hayfever pati- 
ents, indeed leads to the appearance of F_ germ-line gene 
transcripts in neighboring B cells, as we predicted. 
probing for transcripts of the rearranged gene presents 
greater difficulty. 
We have used an F_ chain constant region 
probe, the CE probe, complementary to the sequence 
in 
chain mRNA that codes for the CE2-Cc4 region of the 
chain. However, this sequence also occurs in germ-line 
gene transcripts. 
These contain a single copy of 16 and 
. 2-Cc4 sequences 
(Fig. 1), and the two probes which we CE 
have prepared are of similar lengths (650 and 526 nucleo- 
tides, respectively; Sect. 2.3). When 
labeled under the 
same conditions they should therefore afford comparable 
sensitivity. 
Sensitivity may not be an issue anyway, since we 
, leasured the number of positive cells, not 
the amounts of 
, NA per cell. 
All cells that contained RNA in excess of p 
the lower limit of detection were counted. The difference 
between the numbers of cells detected with the CF_ and IE 
probes was then the number 
that express F_ chain mRNA. 
Several experimental observations justified the subtraction 
procedure. 
Thus, double in situ hybridization of nasal 
biopsy sections with the le and CF probes revealed that 
, ssentially 
all Is' cells are also CE', but not vice versa 
(Sect. 3.4). Moreover, we found that nasal biopsy samples 
from hayfever patients between seasons and normal indivi- 
duals contained only CF' cells, but after allergen challenge 
Eur. J. Immunol. 1997.27., 2899-2906 
there was an increase in the number of CF-' cells above this 
background, equal to the total number of IF-' cells (Sect. 
3.4 below). 
We have used the combination of IE, Ce and IL-4 probes to 
determine the concentrations of B cells expressing F, germ- 
line gene transcripts, E chain mRNA and ILA mRNA in 
the nasal mucosa of hayfever patients before and 24 h 
after allergen challenge, and after 6 weeks treatment with 
FR Parallel experiments were carried out with a probe for 
y chains (the Cy probe) to compare the effects of allergen 
challenge and steroid treatment on expression of E and 
y chain genes. We have also used double immunohisto- 
chemical staining with differentially labeled antibodies 
against IgE plus either CD20 (for B cells), CD38 (for 
plasma cells) or tryptase (for mast cells) in an attempt to 
distinguish IgE associated with these cell types in the nasal 
biopsy sections. 
2 Materials and methods 
2.1 Patients 
The study was performed with the approval of the Royal 
Brompton Hospital Ethics Committee and the patients' 
written informed consent. Twenty-one patients with sum- 
mer hayfever were studied. Inclusion criteria for the pa- 
tients included a history of at least 2 years of summer hay- 
fever and a positive skin prick test (greater than 5 mm) to 
Timothy grass pollen extract (Phleum pratense, Soluprick, 
ALK, Denmark). Patients were all non-smokers. None 
had received topical or oral medication in the previous 6 
months, or immunotherapy in the previous 5 years. Nor- 
mal subjects were non-atopic (negative skin test) non- 
smokers with no nasal symptoms. Baseline blood samples 
and nasal biopsies were performed out of season at a time 
when the patients were asymptomatic. Patients were ran- 
domized to receive 6-week pretreatment with topical nasal 
corticosteroid (200 mg FP, two sprays per day) or a 
matched placebo nasal spray containing the aqueous dilu- 
ent. After treatment all patients underwent local nasal 
provocation with grass pollen extract, followed by a second 
nasal biopsy after 24 h. Nasal provocation was performed 
with 1000 biological U of grass pollen extract (P pratense, 
ALK, Denmark) applied on a 4-mm filter paper disc to the 
under-surface of the inferior nasal turbinate. Nasal biop- 
sies were taken from the site of allergen challenge using 
2.5-mm diameter cup-and-ring forceps (Gerritsma for- 
ceps) as described [191. 
2.2 Immunohistology 
The mAb used were anti-CD20 for B cells (Dako Ltd., 
High Wycombe, GB), anti-IgE (Vectra Ltd., GB), anti- 
tryptase antibody G3 for mast cells (kindly provided by Dr. 
L. Schwartz, Richmond, VA), and anti-CD38 antibody for 
plasma cells (Dako). 
Immunohistology of nasal biopsies was performed on 6- 
[trn cryostat sections using-a modified alkaline phosphatase 
anti-alkaline phosphatase (APAAP) method (241 (Fig. 3A). 
In situ hybridization was performed on 10-[tm cryostat sec- 
tions, pre-fixed in 4% paraformaldehyde and hybridized 
Eur. J. Immunol. 1997.27: 2899-2906 Local IgE in nasal allergy 2899 
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provide a local source of IgE in the nasal mucosa, then 
there are two further possibilities. B cells may switch to 
IgE before or after they migrate to the tissue. 
Immunoglobulin E (IgE) mediates allergic reactions by 
binding to its high-affinity receptor, RERI, on mast cells 
and basophils. Cross-linking of the attached IgE by multi- 
valent antigen then triggers the allergic response. IgE anti- bodies on the mast cells of the nasal mucosa are cross- 
linked by airborne allergens, leading to the symptoms of 
hayfever. The provenance of the IgE on nasal mast cells (and indeed on mast cells at other mucosal surfaces, such 
as the lung, gut and skin) is unknown [1]. IgE may be se- 
creted by B cells and bound to receptors on mast cell pre- 
cursors and basophils elsewhere and transported to the 
nasal mucosa, or it may be produced by B cells within the 
nasal mucosa itself. IgE is the least abundant class of Ab 
(- 100 ng/ml in normal serum, compared to 10 mg/ml for 
IgG). The critical step in the commitment of B cells to the 
synthesis of IgE is referred to as heavy chain switching, 
and comprises somatic recombination within the immu- 
noglobulin heavy chain gene cluster to transform the E 
germ-line gene into the rearranged gene. This then gives 
rise to mRNA for the 6 heavy chain of IgE [2]. If B cells do 
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Evidence in favor of local IgE synthesis has recently come 
from studies of cultured B cells derived from human nasal 
secretions, which express IgE at both the mRNA and the 
protein level [3-5]. It is not clear, however, that these cells 
ever resided in the nasal mucosa. Heavy chain switching 
occurs in B cells within lymphoid tissue in vivo [6,71 and 
in isolated B cells in vitro. It is not known whether B cells 
within non-lymphoid tissues ever undergo switching. 
Two signals are required for heavy chain switching to IgE 
both in vitro and in vivo. IL-4 and the recently described 
IL-13 are agents that target the c gene for recombination; 
cross-linking of CD40 on the B cell membrane then ini- 
tiates recombination to proceed in a proportion of the cells 
[8]. IL-4 is released from cytoplasmic stores on activation 
of mast cells [91 and, like IL-13 [101, is secreted by a subset 
of T helper cells (Th2 cells) [11]. CD40 ligand (CD40L) is 
constitutively expressed by tissue mast cells and induced 
on T cells, following activation by antigen [12,131. IL-4 is 
required for the differentiation of T cells into theM2 phe- 
notype, which secrete their own IL-4, and thereafter auto- 
crine production of IL-4 supports cell proliferation [14]. 
Thus it has been inferred that activation of mast cells by 
allergen may promote the differentiation of T cells into 
Th2 cells and initiate switching to IgE in local B cells [12, 
15-18]. The resulting Th2 cells, upon activation by anti- 
gen, could then continue the process. 
We observed earlier that allergen provocation in the nasal 
mucosa of hayfever patients resulted in early (0-60 min) 
and late (1-24 h) nasal symptoms, accompanied by the 
recruitment of Th2 cells (predominantly CD4' Th2 lym- 
phocytes) expressing IL-4 [19,20] and IL-13 [21], assessed 
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The Transcription Factor B Cell-Specific Activator Protein 
(BSAP) Enhances Both IL-4- and CD40-Mediated Activation of 
the Human E Germline Promoter' 
Cortlandt P. Thienes, *" Lucia De Monte, * Silvia Monticelli, * Meinrad Busslinger, t 
Hannah J. Gould, " and Donata Vercelli'* 
induction of isotype switching to a particular C, gene correlates with the transcriptional activation of the same gene in germline 
configuration. Induction of correctly spliced germline transcripts is necessary to target a switch region for recombination and 
switching. Different cytokines activate transcription at different germline promoters. Because binding sites 
for the B cell-specific 
transcription factor BSAP are located upstream of several switch regions in the Ig locus, BSAP might play a role in isotype 
switching by regulating germline transcription. We investigated whether BSAP plays a role in the transcriptional regulation of 
the e germline promoter in human B cells. We identified human EBV-negative B cell lines that express e germline transcripts 
upon stimulation with IL-4. Electrophoretic mobility shift assay analysis showed that the human e germline promoter binds 
BSAP. BSAP activity was expressed constitutively and was not affected by stimulation with IL-4 and/or anti-CD40 mAb. Reporter 
assays with constructs containing a luciferase gene driven by the E germline promoter, with or without mutations 
in the BSAP 
binding site, showed that BSAP plays a role in both IL-4-dependent induction and CD40-mediated up-regulation of human e 
germline transcription. Furthermore, e germline promoter activity was abrogated in REH cells that express a BSAP polypeptide 
truncated in the trans-activation domain. Among the transcription factors that regulate E germline expression, BSAP is unique, 
in that it is B cell-specific and is at the merging point of two signaling pathways that are distinct but both critical for the 
induction of IgE switching. The Journal of Immunology, 1997,158: 5874-5882. 
sotype switching results from a DNA recombination event 
that juxtaposes different downstream CH genes to the ex- 
pressed VDJ gene, thus changing the effector function, but 
not the specificity, of the Ab molecule. Isotype switching is not a 
random event, but is directed by cytokines in conjunction with the 
regulation of B cell proliferation and differentiation (reviewed in 
Refs. I and 2). Molecular analysis has shown that cytokine-depen- 
dent induction of isotype switching to a particular CH gene almost 
invariably correlates with the transcriptional activation of the same 
gene in germline configuration. Several murine and human germ- 
line transcripts have been cloned and share structural similarities. 
The germline transcripts initiate from TATAA-less promoters a 
few kilobases upstream of the switch region and proceed through 
short exons (lj exons), the switch regions, and CH exons. The 1, 
exon is then spliced to the first exon of the C1. gene. During re- 
combination, the region containing the germline promoter and the 
1, exon is deleted as part of a switch circle (3,4). 
induction of correctly spliced transcripts is thought to be nec- 
essary to target the appropriate switch region for recombination 
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and switching (5-7). Therefore, it is important to understand how 
the induction of germline transcripts is regulated. Different cyto- 
kines specifically activate transcription at the appropriate germline 
promoter. In particular, IL4 has been shown to induce e germline 
transcripts in murine (8 -10) and human (11,12) B cells. 11,4- 
dependent E gem-dine transcription in B cells is strongly up-regu- 
lated upon CD40 engagement (13). This transcriptional effect of 
CD40 may be critical for switching (14), because optimal levels of 
transcription through the switch region may be required to target 
recombination. 
Several cis-acting elements have been characterized that regu- 
late IL, 4-induced transcription. A highly conserved DNA se- 
quence 5' to the major initiation sites for murine germline e RNA 
has been shown to contain an IL4-responsive region that binds 
three transcription factors: a member of the STAT family, STAT6, 
one or more members of the C/EBP3 family, and NF-KB/p50 (15). 
Mutation of any of the binding sites for these factors abolished or 
reduced the IL4 inducibility of the e promoter (15). A binding site 
for STAT6 has been identified in the human e germline promoter 
as well (16-18). 
A region in the murine e germline promoter 3' to the STAT6 
binding site has been shown to bind a constitutively expresý'ed 
transcription factor, B cell lineage-specific activator protein 
(BSAP) (19). BSAP is encoded by Pax5, a member of the Pax 
gene family of homeodomain transcription factors, and is the 
mammalian homologue of the sea urchin tissue-specific transcrip- 
tion activator protein, a regulator of late histone genes. BSAP is C, 
3 Abbreviations used in this paper: NF-icB, nuclear factor-ICB; BSAP, B cell lin- 
eage-specific activator protein; C/EBP, C/enhancer-binding protein; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; EMSA, electrophoretic mobility 
shift assay; COUP, chicken ovalbumin upstream promoter; luc, luciferase; RSV, 
Rous sarcoma virus; A-gal, A-galactosidase; RT-PCR, reverse transcription-poly- 
merase chain reaction. 
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expressed in pro-B, pre-B, and mature B lymphocytes, but not in 
terminally differentiated plasma cells (20). BSAP knockout mice 
show a complete block of early B cell differentiation at the pro- 
pre-BI stage (21). Binding sites for BSAP have been identified in 
the promoter of several B cell-related genes such as CD 19 (22), the 
surrogate light chains k5 and VpreB 1 (23), X box binding protein 
1 (24), the tyrosine kinase blk (25), as well as upstream of several 
lg switch regions (A, yl, y2, e, and a) and in the control region 
located 3' of Cot (26,27). Interestingly, BSAP contributes to the 
activity of the CD 19 promoter (22), but has a negative ekýct on the 
Ig 3' a enhancer (26,27) and on the promoters of the X box 
binding protein 1 (24) and J chain (28) genes. A deregulation of 
Pax5 transcription due to translocation of the Ejk enhancer of the 
fgH locus next to the Pax5 promoter has been recently proposed to 
contribute to the pathogenesis of small lymphocytic lymphomas 
ývith plasmacytoid differentiation (29). 
Conflicting reports exist about the role of BSAP in the regula- 
aon of e germline transcription in murine B cells. Mutation (10) or 
deletion (19) of the BSAP binding site abrogated induction of E 
germline promoter activity in B cells stimulated with IL-4 and 
LPS. Activity was restored by the introduction of a BSAP binding 
site from the sea urchin histone gene H2A-2.2 (19). In contrast, 
deletions in the BSAP binding region were unable to affect the 
inducibility of the promoter in cells stimulated with IL-4 but not 
LPS (15). We investigated whether BSAP plays a role in the tran- 
,, criptional regulation of the e germline promoter in human B cells. 
Our data show that BSAP binds to the human e germline promoter 
4ýd is essential for both IL-4-dependent induction and CD40-me- 
diated up-regulation of human e germline transcription. 
Materials and Methods 
Cell lines and cultures 
The EBV-negative, sIgM' B cell lines BL-2 and BJAB were provided by Dý G. Aversa (DNAX Research Institute, Palo Alto. CA) and Dr. E. Kieff (Harvard Medical School, Boston, MA). respectively. The cell line REH 
we$ originally established from a patient with acute lymphoblastic leuke- 
taia (30). The T cell line Jurkat was obtained from American Type Culture Oollection (Rockville, MD). All cell lines were maintained in RPMI 1640 
f We Technologies, Gaithersburg, MD) supplemented with 10% FCS (Bi- Oogical Indusuies, Kibbutz Beit Haemek, Israel). For stimulation, B cells Were incubated for 48 h with rIL-4 (provided by Dr. J. E. de Vries, DNAX Research Institute) at 100 U/ml and/or with anti-CD40 mAb 626.1 (a gift ftom Dr. S. M. Fu, University of Virginia, Charlottesville, VA) at 5 Ag/ml. IýWiminary experiments had shown that these concentrations resulted in (9timal induction of e germline transcripts. 
INA isolation and semiquantitative reverse transcription 
iR7)-PCR 
RNA was isolated from B cells as described by Chomczynski and Sacchi U. and cDNA was synthesized and subjected to serniquantitative PCR as Previously described (32). For each PCR reaction, one primer was 5' la- beled and added in a 1: 10 molar ratio with cold primer. e germline tran- ICTipts were detected as a 409-bp band amplified by primers corresponding tu the 3' end of human Ie (5'-GACGGGCCACACCATCCACAGGCAC CAAATGGACGAC, 
nucleotide +93/+129 in Fig. IB) and the 5' end of C*2 (5'-CAGGACGACTGTAAGATCTTCACG, 
nucleotide 1754-1777, GeRBank 
accession No. J00222). As a control, a 438-bp band correspond- 9't'O GAPDH transcripts was amplified using appropriate primers (5'- AAGGTGAAGGTCGGAGTC 
and 5'-CTGATGATMGAGGCTO 'To. 
nucleotides 1456-1476 and 3818-3848, GenBank accession no. 3' PCR was performed on a thermocycler (Hybaid, Teddington, 
t 
f'-. r 25 cycles (I min each at 94,65, and 74*C) for E germline tran- 'OiP(s and for 15 cycles (I min each at 94,60, and 74*C) for the GAPDH cýtml- The number of amplification cycles was such that the maximum '911al intensity for a set of samples was within the linear portion of a Noduct 
vs the template amplification curve. 
5875 
Oligonucleotides and probes for electrophoretic mobility 
shift assays (EMSA) 
The -24/+12 probe was generated by isolating a single-stranded template 
by asymmetric PCR with the upper strand (5'-TTAGCTGAAAGCACTG 
AGGCAGAG, nucleotide -24/-1 in Fig. IB) at I AM and the lower 
strand (5'-GGGTAGGGGGAGCTCT, nucleotide -4/+5) at 0.05 PLM. 
The -24/+64 probe was generated by producing a single-stranded tem- 
plate by asymmetric PCR with the upper strand (nucleotide -24/-1, as 
above) at I jiM and the lower strand (5'-CCCAGATGATCAGTAACCG 
TG, nucleotide +44/+64) at 0.05 jkM. Ile second strand was synthesized 
with Taq polymerase in the presence of [a_32P]dATP and the lower strand 
oligonucleotide (I tLM). 
For competition, oligonucleotides were synthesized that correspond to 
known BSAP binding sites in the murine 5' Sy2a region (NF-HB, 5'- 
GATCAGAATTGTGAAGCGTGACCA) and in the histone H2A-2.2 pro- 
moter (5'-TGTGACGCAGCGGTGGGTGACGACT) (19,26). Mutant 
BSAP competition oligonucleotides were generated by PCR by using as 
forward primers DSAPIXMUT (5'-TTAGCTOAAAGCACTGAGGAAG 
AG) and BSAP`2XMUT (5'-TTAGCTGAAAGCACTGAGTAAGAG*, nu- 
cleotide -24/+12 in Fig. IB) and as reverse primer 5'-CCCAGATGAT 
CAGTAACCGTG (nucleotide +44/+64 in Fig. IB) for both mutants. An 
unrelated oligonucleotide (chicken OVA upstream promoter (COUP); 5'- 
TCGACTCTATGGTGTCAAAGGTCAAACT-rCTOAC) was used as a 
control. All oligonucleotides were obtained from PRINIM (Milan, Italy). 
Competition oligOnucleotides were annealed in 100 mM NaCl, 10 mM Tris 
(pH 8), and 0.1 mM EDTA by heating to 95*C for 10 min and cooling 
slowly to the annealing temperature. All probes and competitors were pu- 
rified on polyacrylamide gels. 
Preparation of nuclear extracts 
Cells (2-3 X 106) were washed in PBS and resuspended in 400 tLI of buffer 
A (10 mM HEPES, 1.5 MM MgC'2,10 mM KCI, and 0.5 mM DT"r) with 
protease inhibitors (PMSF (0.2 mM), aprotinin (I gglml), and antipain, 
pepstatin, and leupeptin (all at 3 1kgIml)) and phosphatase inhibitors (I MM 
benzamidine, I mM orthosodium vanadate, I mM sodium fluoride, and 5 
mM P-glycerol phosphate). After aI 0-min incubation on ice, the release of 
nuclei was judged by trypan blue staining. The nuclei were sedimented in 
a microcentrifuge for 12 s at 4'C and then resuspended in 2 pellet volumes 
of buffer C (20 mM HEPES, 25% glycerol, 1.5 MM MgCl2,0.2 mM 
EDTA, and 0.5 mM DTT, with protease and phosphatase inhibitors). The 
total volume of the nuclei was measured, and the nuclei were transferred to 
a new tube. One volume of buffer C containing 840 mM NaCI was then 
added, and the nuclei were extracted for 20 min on ice, with occasional 
mixing. The preparation was sedimented in a microcentrifuge for 5 min at 
4'C, and the extracts were frozen on dry ice and stored at -70'C. Protein 
concentrations were determined by the BCA protein assay (Pierce Chem- 
ical Co., Rockford. IL). 
EMSA 
Nuclear extracts (5 ILg) were added to binding buffer (10 mM Tris (PH 8). 
0.5 MM MgC'2, I mM[ EDTA, and I mM DTT; 20 1LI), with poly (dl-dC) 
(Pharmacia, Uppsala, Sweden; 5 jug) and 
32 P-labeled probe (5 fmol) in the 
presence or the absence of competitors. NaCl and glycerol were adjusted to 
0.1 M and 10%. respectively. After a 30-min incubation on ice, the binding 
reactions were run on a 4% polyacrylamide gel in 50 mM Tris, 50 mM 
boric acid, I mM EDTA (PH 8), and 4% glycerol at 30 mA for 2 to 5h at 
4*C. Supershifts were performed by preincubating the nuclear extracts with 
the appropriate antisera (0.25 td/reaction) for 30 min on ice before adding 
the probe and competitors. Polyclonal rabbit antisera against human BSAP 
were previously described (20). One antiserum is directed against the 
paired domain of BSAP (amino acids 17-145) and blocks DNA binding; 
the other is directed against C-ternlinal sequences (amino acids 189-391) 
and causes supershifting in EMSA. A polyclonal antiserum against the 
human transcription factor HOXB3 was a gift from Dr. G. Viale (San 
Raffaele Scientific Institute, Milan, Italy). 
e germline promoter reporter constructs 
Figure IA shows the map of the human le exon and Cc locus. Figure IB 
shows part of the genomic sequence contained in the e germline promoter 
construct. Position -291 (not shown) corresponds to the A in the Rsal site 
(nucleotide 241, GenBank accession No. X56797) used to clone the region 
in the reporter vector. To obtain the human e germlinc promoter construcL 
a 422-bp fragment (-291/+131) that encompasses the promoter (17) and 
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FIGURE 1. Map of the human germline c gene and e transcripts. A, Restriction map of the unrearranged Cc gene, with the le exon and the Se 
region. The region contained in the GL-luc reporter construct is indicated 
by arrows. B, Part of the genomic sequence contained in the germline 
e promoter construct. Position -291 (not shown) corresponds to the A in the Rsal site (nucleotide 241, 
GenBank accession No. X56797) used to 
clone the region in the pGL3 reporter vector. The major transcription start sites in BL-2 and BJAB cells were 
determined by primer extension and 
are indicated by arrows. Position +11 corresponds to the major e RNA start site in 
BL-2 cells. The 3' end of the construct is marked by a dashed 
vertical line. The splice site for Cel is indicated by an arrowhead. The binding sites 
for transcription factors identified in the murine (10,15,19, 
42,55) and human (16,17,18,46,58) c germline promoter are boxed. The asterisks mark the evolutionarily conserved sequence, a segment highly 
(>80%) homologous between human and murine sequences. Stop codons are underlined. 
ends 9 bp upstream of the splice site for Cc, was inserted into the 
promoterless pGL3 basic vector (Promega, Madison, 
WI), that contains 
a luciferase (luc) reporter gene. Because of the discrepancies between 
the sequences published for the region containing the human c germline 
promoter 0 1,33), we used PCR with Pfu DNA polymerase (Stratagene, 
La Jolla, CA) to amplify this region from genomic DNA of three nona- 
topic donors. The forward primer was 5'-CCTGGGAGTGAGTACAA 
GGTGAG, and the reverse primer was 5'-GGTGGGCTGGOATACCT 
GAAG (nucleotides 25-47 and 661-681 of GenBank accession No. 
X56797). The PCR product was digested with Rsal and Haell. The 3' 
end was made blunt and ligated into the Smal site of pGL3, thus ob- 
taining the e GL-luc construct. The insert and the junctions were se- 
quenced by the dideoxynucleotide chain termination/extension method 
(34) using the Sequenase version 2.0 kit (U. S. Biochemical Corp., 
Cleveland, OH). Two clones from each of the three donors were fully 
sequenced. All six sequences were identical, except at position +97 
(Fig. IB), which was either aG or an A. This probably represents a 
polymorphism. The reporter activity of the luc constructs containing 
either the G or the A was identical (data not shown). 
The deletion mutant lacking the BSAP binding site (BSAP del-luc) 
was generated by PCR assembly of two fragments, using the e GL-Iuc 
construct as the template for amplification. A 274-bp PCR product ýAas 
obtained, using as forward primer 5'-CACCCCATTTTTAGCTCCCA 
GGCTCCACTGC, which corresponds to nucleotide -34/+24 in Fi. Oure 
IB and introduces a 27-bp deletion (nucleotide - 18/+9). The reverse 
primer was 5'-GCAGTTGCTCTCCAGCGGTTC (GL4 primer, Pro- 
mega), which maps to position 146-165 in pGL3. The other PCR prod- 
uct of 357 bp was generated using as forward primer 5'-CTAGCAAA 
ATAGGCTGTCCC (RVp3 primer, Promega), which maps to position 
4761-4780 in PGL3, and as reverse primer 5'-AGCTAAAA 
ATGGGGTG, which maps to position -34/-19 in the insert. The two 
PCR products were assembled by a second round of amplification using 
primers RVp3 and GL4, then digested with Kpnl and Hindlll and di- 
rectionally cloned into pGL3. 
The BSAP mutl-luc construct was generated using as forward primer 
RVp3 and as reverse primer 5'-GGGAGCTCTTCCTCAG (nucleotide 
- 111+5 in Fig. IB), where aG is replaced by a T. The BSAP mut2-luc 
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FIGURE 2. ILA induces E germline transcripts in human lympho- 
blastoid B cells. BL-2 and BJAB cells were treated with IL-4 (100 U/ml) 
and/or anti-CD40 mAb (5 Ag/ml) for 48 h, and then assessed for levels 
of E germline transcripts by semiquantitative RT-PCR. PCR was per- 
formed for 25 cycles for E germline transcripts and for 15 cycles for the 
GAPDH control. 
construct was obtained using as reverse primer 5'-GGGAGCTCTTACT 
CAG, where GC is replaced by TA. The PCR products were digested with 
Sacl and inserted in the Sacl sites of E GL-luc. The deletion and the mu- 
tations were confirmed by sequence analysis. All plasmids were prepared 
for transfection by two rounds of purification on CsCl density gradients. 
Transfections and reporter assays 
Lymphoblastoid B cells (10 X 1()6) were transiently cotransfected with hic 
constructs ( 10 ýLgý and a control plasinid (Rous sarcoma virus (RSV) /ý- 
galactosidase (0-gal); 6 Ag) by treatment with DEAE-dextran (PharnlaClii, 
0.5 mg/ml) for 30 min at 37'C. A luc plasmid (4 jig) driven by the RS\ 
promoter and enhancer was used as a positive control in each set of wm, 
fections. After transfection, the cells were split into aliquots and cultuted iiL 
the presence or the absence of IL-4 (100 U/ml) and anti-CD40 mAb 626.1 
(5 jigghnl). Each transfection was performed in duplicate. After 48 h, cell 
extracts were prepared, and luciferase activity was determined according to 
the Luciferase Assay System (Promega) protocol. The same cell extracts 
were used to determine P-gal activity using the chemiluminescent Galacto- 
Light kit (Tropix, Bedford, MA) according to the manufacturer's instruc- 
tions. All readings were taken using a Lumat 9501 luminometer (Berthold, 
Wildbach, Germany). The results obtained for each transfection were nor- 
malized to O-gal activity and expressed as relative luciferase activity. The 
values obtained for mock-transfected cells (< 100 light units for luciferase 
and <2(X) light units for P-gal) were subtracted as background. 
Results 
IL-4 induces E germline transcripts in human B cell lines 
A number of human B cell lines were initially screened by semi- 
quantitative RT-PCR for the expression of e germline transcripts 
upon IL-4 stimulation (data not shown). Among those that ex- 
pressed E germline transcripts, two EBNA-negative lines, BL-2 
and BJAB, were chosen for subsequent studies. Indeed, EBV-encoded 
protein(s) provides B cells with a signal(s) that triggers IgE switching 
( 12,35), possibly by interfering with the CD40 signaling pathway (36, 
37). Fioure 2 shows that E germline Lý transcripts were undetectable in 
unstimulated BL-2 and BJAB cells, but were readily induced follow- 
ing a 48-h incubation with IL-4 (100 u/ml), As expected ( 13), E germ- 
line transcription was not induced by anti-CD40 mAb alone (5 [Lg/ 
mI), but was strongly up-regulated when CD40 was engaged in the 
presence of 
IL-4 (Fig. 2, right panel). 
-Mom- 
40 
FIGURE 3. BSAP binds to the hurnan E gerniline promoter. EMs. \ 
were performed using nuclear extracts from unstimulated BJAB cells 
and a probe (-24/+12) that spans the BSAP binding site in theEgerm- 
line promoter. Nuclear extracts were preincubated with rabbit Abs 
(0.25 jil/reaction) specific for the paired (DNA binding) domain of 
BSAP (amino acids 17-145), the C-terminal region of the protein (ami- 
no acids 189-391), or human HOXE13 for 30 min on ice before adding 
the probe and the competitors. Competitors (NF-HB and COUP) were 
added at aI 00-fold molar excess. The arrow indicates the band cor- 
responding to the BSAP complex. 
BSAP binds to the human E gernifine promoter 
To assess whether BSAP binds to the human E germline promoter, 
EMSA analysis was performed using a probe (nucleotide -24/ C, 
+ 12 in Fig. I B) that spans the region homologous to the 13SAP 
binding site identified in the murine E promoter (19). Figure 3 
shows that nuclear extracts from unstimulated BJAB cells contain 
a constitutively expressed protein that retards the migration of the 
BSAP probe. The formation of the DNA-protein complex was spe- 
cifically competed by a BSAP site located upstream of the murine 
5878 
S, y2a region (NF-HB) and by the BSAP site in the sea urchin 
histone H2A-2.2 promoter (data not shown), but not by an unre- 
lated oligonucleotide (COUP). An identical EMSA pattern was 
observed using nuclear extracts from unstimulated BL-2 cells (data 
not shown). Consistent with the B cell specificity of BSAP ex- 
pression (20), the BSAP complex was undetectable in nuclear ex- 
tracts from Jurkat T cells (data not shown). 
To unambiguously identify the protein that binds the BSAP 
probe, we tested the effect of anti-BSAP antisera in EMSA. Figure 
3 shows that an antiserum against the C-terminal region of BSAP 
(amino acids 189-391) supershifted the BSAP complex, whereas 
an antiserurn against the DNA binding domain of BSAP (amino 
acids 17-145) blocked the formation of the complex. In contrast, 
an antiserurn against an unrelated transcription factor (HOX133) 
had no effect on the binding of BSAP. These results conclusively 
demonstrate that BSAP binds to the human E germline promoter. 
BSAP binding activity in human B cells is not regulated by 
IL-4 andlor CD40 engagement 
BSAP binding activity in splenic murine B cells has been shown to 
be up-regulated by proliferative stimuli (mitogens, cross-linking of 
s1gr), or CD40) (38) and down-regulated by OX40 ligand cross- 
linking (39). We therefore investigated by EMSA whether a 48-h 
stirriulation with IL-4 and/or anti-CD40 mAb could modulate 
BSAP activity in the human lymphoblastoid cells under study. 
Figure 4 shows that BSAP binding activity, as defined by use of 
the BSAP-specific competitor NF-HB, was comparable in nuclear 
extracts from unstimulated and stimulated BL-2 cells. In contrast, 
vigorous induction of E germline transcripts was observed in the 
-same experiments (data not shown). These results indicate that 
BSAP binding activity is not regulated by IL-4 and/or CD40 
engagement. 
The highly conserved C in the BSAP site is essential for 
ONAlprotein interactions 
A cytosine residue (nucleotide -5 in Fig. IB) in the BSAP con- 
sensus sequence recently 
identified is highly conserved in the 
known BSAP binding sites (40,41). A point mutation (C-A) at 
tt, is site has been shown to be sufficient to strongly impair the 
bin(jing of BSAP to the sea urchin tissue-specific transcription ac- 
tivator protein site (20). In preparation for subsequent functional 
stLjdies, EMSA were performed to assess whether a 
DNA fragment 
containing the 
C-A mutation could efficiently compete binding 
of hurnan 
BSAP to a probe (nucleotide -24/+64) containing the 
wilcl-type sequence. 
Figure 5 (left panel) shows that the wild-type 
sequence competed 
BSAP binding partially when used at a 10-fold 
molar excess and almost completely when used at a 
30-fold molar 
excess- Introduction of the 
C-A mutation (mut 1) strongly re- 
duced competition over the whole molar excess range. AG residue 
I base 5' to the mutated C is also contained in the BSAP consensus 
sequence 
(40). When the conserved G residue was mutated to aT 
jr, addition to the C-A mutation (mut 2), no further reduction in 
c, rlipetition was observed. 
Thus, the conserved C in the BSAP site 
is essential for in vitro DNA/protein interactions. This conclusion 
was further supported 
by the finding that a -24/+ 12 BSAP probe 
containing the 
C--ý-A mutation (mut 1) was unable to bind BSAP 
in F_MSA (Fig. 5, right peinel). 
j3.5Ap regulates both the IL-4-dependent induction and the 
CC)40-rnediated up-regulation Of E germline transcription 
To functionally characterize the role of BSAP in the regulation of 
holinan e germline transcription, reporter assays were performed 
using constructs that contain a region encompassing the 
human E 
gerrnline promoter 
(17), with or without mutations in the BSAP 






FIGURE 4. BSAP binding activity is not regulated by IL-4 and/or 
CD40 engagement. FMSA were performed using a probe (- 24/+ 12) 
that spans the BSAP binding site in the 4E germline promoter, and nu- 
clear extracts from BL-2 cells incubated for 48 h in the presence of 
medium, IL-4 (100 U/ml), and anti-CD40 mAb (5 Ag/ml), alone or in 
combination. Competitors (NF-HB and COUP) were added at a 100- 
fold molar excess. The arrow indicates the band corresponding to the 
BSAP complex. 
binding site. The human GL-luc construct was obtained by insert- 
ing a 422-bp fragment of the promoter into the promoterless pGL3 
luc vector. The BSAP mut I -luc and BSAP del-luc constructs con- 
tained the C- A mutation at nucleotide -5 (Fig. I B) and a 27-bp 
deletion encompassing the BSAP binding site (nucleotide - 18/ 
+9), respectively. The reporter constructs were transiently trans- 
fected into the lymphoblastoid B cell lines, after transfection, the 
cells were divided into aliquots and incubated in the presence or 
the absence of IL-4 and anti-CD40 mAb. Luciferase activity was 
assessed 48 h later. An RSV-13-gal plasmid was always cotrans- 
fected with the reporter constructs as an internal control for vari- 
ations in transfection efficiency. 
Preliminary experiments indicated that expression of the luc 
constructs was inducible at higher and more consistent levels in 
BL-2 than in BJAB cells (data not shown). BL-2 cells were there- 
fore used for this set of studies. Figure 6 (right panel) shows that 
IL-4 stimulation of' BL-2 cells transfected with the construct con- 
taining the intact promoter (GL-luc) resulted in a 4.9-fold induc- 
tion of luciferase activity. Transcription driven by the e germline 
promoter was enhanced modestly by anti-CD40 mAb, but was 
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FIGURE S. The conserved C in the BSAP binding site is essential for DNA/protein interactions. Left panel, Nuclear extracts from unstimulated 
BJAB cells were incubated with a probe (-24/+64 in Fig. 16) containing the wild-type (VVT) BSAP binding site. The wild-type competitor is 
identical with the probe. Mut I competitor contains a C-A mutation at the highly conserved C at position -5 in the BSAP binding site. Mut 2 
contains both a C-A and a G-T mutation. Wild-type and mut competitors were added at 10-, 30-, and 100-fold molar excesses. NF-HB and 
COUP were added at aI 00-fold molar excess. The arrow indicates the band corresponding to the BSAP complex. Right panel, Nuclear extracts 
from unstimulated BJAB cells were incubated with a probe (-24/+ 12) corresponding to the wild-type BSAP binding site or with the mut I probe, 
in which the C at position -5 had been replaced with an A. The two oligonucleoticles were also used as competitors and added at 25- and I 00-fold 
molar excesses. 
up-regulated 14.9-fold when IL-4 and anti-CD40 mAb were added 
in combination. The introduction of the C-A mutation at position 
-5 in the BSAP binding site (BSAP mut I -luc) reduced the IL-4 inducibility of the promoter by >50% and the response to the 
combination of IL-4 and anti-CD40 mAb by 65% even though the 
synergism between the two signals was preserved. Deletion of the 
entire BSAP binding site (BSAP del-luc) had comparable effects. 
These results indicate that BSAP regulates both the IL-4-depen- 
dent induction and the CD40-mediated up-regulation of E germline 
transcription in human B cells. Notably, the deletion and the mu- 
tation introduced in the BSAP site did not affect the basal expres- 
sion of the reporter constructs in BL-2 cells (Fig. 6, left panel). Thus, unlike the elements that bind STAT6 and HMG-I(Y), which 
are involved in both activation and repression of the E promoter 
(17,42), the region that binds BSAP seems to be involved only in 
activation. 
e germline PrOMOter activity is abrogated in REH cells that 
express a BSAP protein truncated in the trans-activation 
domain 
It has been recently shown that the human acute lymphoblastic 
leukemia cell line REH carries a frameshift mutation in one Pax5 
allele that results in premature termination of translation and trun- 
cation of the trans-activating 
domain of BSAP. Thus, REH cells 
synthesize both full-length BSAP and a truncated polypeptide that 
lacks the trans-activating function (43). Interestingly, transcripts 
for CD 19, a BSAP target gene, are strongly reduced in REH cells 
compared with most other human 
B cell lines (22). The lower 
levels of CD 19 mRNA are thought to reflect either the lower level 
of trans-activation-competent BSAP and/or negative interference 
by the mutated protein. Because of these peculiar properties, we 
used the REH cell line as an additional model to characterize the 
role of BSAP in the activation of the E germline promoter. To this 
purpose, REH cells (and BL-2 cells, as a control) were transiently 
transfected with the GL-luc reporter construct and subsequently 
stimulated with IL-4 in the presence or the absence of anti-CD40 
mAb. No iE promoter activity was detected in REH cells, whereas, 
as expected (see Fig. 6), a vigorous response was elicited in BL-2 
cells (data not shown). Furthermore, RT-PCR analysis failed to 
reveal expression of endogenous E germline transcripts in REH 
cells treated with IL-4 and anti-CD40 mAb (data not shown). 
While the full extent of the functional defect in REH cells re- 
mains to be established, our results suggest that a functional BSAP 
protein is essential for activation of the E germline promoter not 
only within an artificial reporter construct, but also in its natural 
chromatin context. We are currently testing the effects of BSAP 
overexpression on the phenotype and function of REH cells. 
Discussion 
Binding sites for BSAP are located upstream of several switch 
regions in the Ig heavy chain gene cluster(19,44,45). This finding 
led to the hypothesis that BSAP might play a role in isotype 
switching by regulating germline transcription, a process known to 
be a prerequisite for switch recombination. However, the evidence 
























FIGURE 6. Results of reporter assays with E germline promoter luc constructs. BL-2 cells were transiently transfected with the luc 
constructs using DEAE-dextran and split into aliquots that were incubated in the presence or the absence of ILA (100 U/ml) and anti-CD40 111, \h 
(5 ýLg/ml). Luc activity was assessed 48 h later. A P-gal control plasmid was cotransfected with the reporter construct to normalize for transfe(tion 
efficiency. Values obtained in mock-transfected cells were subtracted as background. Left, Basal expression of luc reporter construct in BL-2 colls. 
Results are reported as relative luciferase activity after subtraction of background (mock transfection). Right, Expression of the reporter construr tý 
in BL-2 cells stimulated with IL-4 (100 U/ml) and/or anti-CD40 mAb (5 ptg/ml) for 48 h. Fold induction represents the ratio of luc actl,. ity 
(normalized for )3-gal activity) between treated and untreated cells. The results show the mean t SE of three independent experiments, e, i( 11 
performed in duplicate. 
for activation of the E germline promoter in murine B cells stim- 
ulated with LPS and IL-4 (10,19). In contrast, in two subsequent 
studies, one in murine (15) and the other in human (46) B cells, 
several mutations in the BSAP binding site had no impact on the 
IL-4 inducibility of the E germline promoter. However, the highly 
conserved C at position -5 in the BSAP binding region was 
spared by those mutational analyses. Notably, the activity of the 
BSAP-regulated promoters that contain the conserved C was con- 
sistently abolished or drastically reduced whenever that residue 
was mutated ( 19,28,47,48). Indeed, the C at the border of the 3' 
half-site of BSAP contributes critically to an optimal interaction 
with the N-terminal portion of the paired domain and thus to the 
overall affinity of the BSAP recognition sequence (40). Over and 
above other technical differences (e. g., boundaries of the reporter 
constructs, cell lines, or stimulation protocols), we believe that in 
the absence of the mutation at position -5, the ability of BSAP to 
interact with the germline promoter may not be significantly 
impaired. 
Our present results strongly support a major role for BSAP in 
regulating the activity of the human E germline promoter. Inter- 
estingly, the regulatory elements identified to date in this promoter 
are involved in either IL-4 (17) or CD40 (49) responsiveness. The 
BSAP site seems to be unique in that it contributes to both IL-4- 
dependent induction of L- germline transcription and CD40-medi- 
ated up-regulation of the promoter. This complexity of effect may 
reflect the ability of BSAP to act in concert with other nuclear 
factors to activate or repress target genes. Repression of the Ya 
enhancer (hsl. 2) or activation of the Ya enhancer-hs4 by BSAP 
involves the combined efforts of a common set of factors, such as 
octamer binding proteins, NF-KB-like complexes, and, in the case 
of the Yu enhancer (hsl, 2), a novel G-rich DNA binding protein 
(47,48). The choice between activation or repression seems to be 
strictly dependent on the topology of the binding sites for these 
factors and may result from direct occlusion of their activation 
domains or from the recruitment of another factor(s) that mediate,; 
repression or activation (50). This model is predicated on direý: ý 
protein-protein interactions among multiple transcription factors. 
Indeed, BSAP was shown to directly interact with the POU domain 
of octamer binding proteins (47) and may well interact with other 
factors that bind the E gennfine promoter. 
All efforts to date to demonstrate signal-dependent post-trans- 
lational modifications of BSAP, such as phosphorylation, have 
failed (43). This supports the possibility that BSAP, a constitu- 
tively expressed protein, controls activation of the e germline pro- 
moter by interacting with other factors that are regulated by spe- 
cific signals. In particular, an interaction between BSAP and 
NF-KB may be involved in the CD40-dependent up-regulation of 
,F germline promoter activity observed in our experiments. CD40 
pGL3 GL-luc mutl-luc BSAPdel-luc pGL3 GL-luc mut I-luc BSAPdel-luc 
The Journal of Immunology 
engagement has been shown to rapidly activate NF-KB and to sup- 
port NF-KB-dependent gene expression in human B cells (51). 
Furthermore, e germline transcripts were undetectable in B cells 
from p50/NF-KB -/- mice stimulated with IL-4, IL-5, and CD40 
liaand (52), suggesting that NF-KB is essential for activation of 
transcription through the oE switch region. The human e germline 
promoter contains two putative KB binding sites, one correspond- 
ing to the site identified in the IL-4-responsive element of the 
murine e promoter (15), and the other located at position -43/ 
-34, a few bases upstream of the BSAP binding site (L. De 
Monte, S. Monticelli, and D. Vercelli, manuscript in preparation). 
Reporter assays recently performed in our laboratory have shown 
that mutation of the NF-KB binding site at -43/-34 in the e GL- 
luc construct resulted in a marked (>60%) inhibition of the CD40- 
dependent up-regulation of E germline promoter activity. In con- 
trast, IL-4 inducibility was unaffected (data non shown). It will be 
of interest to assess whether BSAP acts in concert with NF-KB and 
possibly with another factor(s) capable of binding the promoter. 
A region that spans the 3' portion of the BSAP binding site has 
been recently reported to contain a CD40-responsive element (49) 
distinct from the one that mediates IL-4 responsiveness of the e 
germline promoter (17). By contrast, in our studies BSAP was 
shown to be essential for the response of the promoter to both IL-4 
and CD40 engagement. Differences in a number of critical param- 
eters may underlie this discrepancy, such as the sequence compo- 
sition of the reporter vectors, the transfection approach, and, most 
importantly, the B cell lines used for reporter assays. Indeed, the 
vectors used in our study did not include the splice site for Cel and 
were transfected transiently, rather than stably, into EBV-negative 
13 cell lines. The expression of EBV-encoded genes known to be 
functionally linked to the CD40 signaling pathway (36,37,53) 
may critically influence the outcome of reporter assays, possibly 
by inducing and/or up-regulating transcription factors that contrib- 
ute to e promoter regulation. 
Although binding sites for BSAP have been identified in the 
vicinity of several germline promoters, such as murine -yl, 'y2a, 
and a (45,54), E is the only promoter shown to be regulated by 
BSAP to date. If regulation of the e germline promoter by BSAP 
really requires interaction(s) with other transcription factors, it is 
possible that binding sites for the appropriate BSAP partners are 
absent in promoters other than E and/or are not accessible because 
of topologic constraints. 
Except for BSAP, none of the nuclear factors reported to date to 
be critical for e germline transcription (e. g., STAT6, C/EBP, NF- 
KB, or HMG-I(Y)) (15,17,42,55) is expressed exclusively in B 
cells, yet gerinline transcription is exquisitely B cell-specific. We 
are currently investigating whether the B cell specificity of germ- 
line transcription is functionally linked to BSAP expression. An 
additional possibility is that BSAP contributes to coupling germ- 
line transcription and switching to cell proliferation. Indeed, 
switch recombination to -/I and expression of yl and e germline 
transcripts were severely reduced after incubation of activated mu- 
rine B cells with DNA synthesis inhibitors (56). BSAP activity is 
known to be up-regulated by stimulation of murine B cells with 
mitogens or CD40 ligand, and down-regUlated by cross-linking of 
OX40 ligand (39). Antisense-mediated down-regulation of BSAP 
resulted in a dramatic decrease in cell proliferation and in the in- 
hibition of class switching to IgG I induced by IL-4 and LPS (38). 
A clue to the mechanisms underlying the link between BSAP and 
B cell proliferation has been offered by recent results demonstrat- 
ing that BSAP represses transcription of the tumor suppressor gene 
p53 (57). p53 appears to control the cell cycle by activating down- 
stream target genes that arrest cells in late GI phase and, further- 
more, mediates apoptosis in a variety of cell types. BSAP expres- 
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sion in the early stages of B cell differentiation would inhibit p53 
expression, leading to rapid growth and partial differentiation, 
while preventing cellular decisions concerning apoptosis. 
In conclusion, among the several transcription factors that reg- 
ulate 4E germline expression identified to date, BSAP seems to be 
unique in that it is B cell-specific, is constitutively expressed rather 
than inducible, is involved in activation but not in repression of the 
promoter, and, most importantly, is at the intersection of two si 0 
naling pathways that are distinct but both critical for the induction 
of switching to IgE. 
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IL-13 Down-Regulates CD14 Expression and TNF-a 
Secretion in Normal Human Monocytes' 
Giovanna Cosentino, * Elisa Soprana, * Cortlandt P. Thienes,, *t Antonio G. Siccardi, * 
Giovanna Viale, ** and Donata Vercelli'" 
*Molecular Immunoregulation Unit, DIBIT/San Raffaele Scientific Institute, Milan, Italy; 'The Randall Institute, King's 
College London, London, United Kingdom; *Department of Biology and Genetics, University of Milan, Italy; and SDivision 
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CD14, a glycosylphosphatidylinositol (GPI)-linked protein expressed on monocytes and neutrophils, regulates 
monocyte-lymphocyte interactions and serves as the LPS receptor. We showed previously that I L-4 down-regulates 
the expression of human CD14 by acting at the transcriptional level. We now investigate whetherCD14 expres- 
sion could also be regulated by IL-1 3, another member of the chromosome 5 cytokine gene family. IL-1 3 dose- 
dependently inhibited CD1 4 expression on human monocytes. By contrast, expression of CD23 and CD1 Ib was 
enhanced strongly. Down-regulation of CD14 involved neither shedding nor activation of endogenous GPI an- 
cýor-cleaving enzymes. Indeed, soluble CD1 4 was not increased in the supernatants of IL-1 3-stimulated mono- 
cytes, and expression of CD55/DAF, another GPI-linked protein, was unaffected by IL-1 3. CD1 4 transcript levels 
were reduced sixfold in IL-1 3-treated monocytes. These results suggest that IL-1 3 down-regulates membrane CD1 4 
by suppressing CD14 RNA expression. IL-13-dependent down-regulation of CD14 resulted in the inhibition of 
CD14-mediated events. Indeed, CD14-mediated release of TNF-a was inhibited markedly (-75%) in monocytes 
stimulated with LPS (100 ng/ml) after a 72-h preincubation with IL-13. However, IL-13 also directly inhibited 
monokine secretion, because it blocked PMA-induced, CD14-independent TNF-a release. Down-regulation of 
CD14 and TNF-a secretion may play a major role in the anti-inflammatory effects of IL-13 on LPS-stimulated 
monocytes. The Joumal of Immunology, 1995,155: 3145-3151. 
C D14 is a glycosylphosphatidylinositol (GPI)3_ 
linked glycoprotein expressed on monocytes, 
macrophages, and neutrophils (1,2). CD14 has 
been shown to trigger monocyte activation (3) and to serve 
as the receptor for LPS (4). A soluble form of CD14, 
present in the serum at high concentrations (5), enables 
responses to LPS by CD14 cells, possibly by forming a 
complex with LPS and then binding additional membrane 
Received for publication August 17,1994. Accepted for publication June 30, 
1995. 
The costs of publication of this article were defrayed in part by the payment of 
page charges. This article must therefore be hereby marked advertisement in 
accordance with 18 U. S. C. Section 1734 solely to indicate this fact. 
' This work was supported by Grant R29-CA56277 from the National Cancer 
Institute (to D. V. ), by a Burroughs Wellcome Fund Developing Investigator 
Award in Immunopharmacology of Allergic Disease (to D. V. ), by Grant 
9306-39 from Istituto Superiore di Saniti (to D. V. ), and by Grant CNR-ACRO 
94.01227. PF39.115.14430 (to G. V. ). 
L 
2 Address correspondence and reprint requests to Dr. Donata Vercelli, Molec- 
ular -mmunoregulation Unit, DIBIT/San Raffaele Scientific Institute, Via Olget- 
tinz, 38,20132 Milano, Italy. 
3 Abbreviations used in this paper: GPI, glycosylphosphatidylinositol; DAF, 
decay accelerating factor; MR, mean fluorescence intensity; RT-PCR, reverse 
transcriptase-mediated PCR. 
Copyright 0 1995 by The American Association of Immunologists 
proteins (6,7). In this capacity, CD14 plays a pivotal role 
in endotoxin-induced monokine release during Gram-neg- 
ative infections (4,8), as confirmed by in vivo studies with 
transgenic mice (9). Furthermore, CD14 plays an impor- 
tant role in the regulation of human T and B cell functions. 
Engagement of selected CD14 epitopes by specific mAbs 
terminates T cell proliferation by delivering a negative sig- 
nal to T cells (10) and inhibits the synthesis of all Ig iso- 
types by acting at the B cell level (11). 
CD14 expression is regulated by cytokines (reviewed in 
Ref. 12). We have shown that IL-4 down-regulates CD14 
by acting at the transcriptional level (13). Recently, it has 
become clear that a number of functional properties of 
IL-4 are shared by IL-13 (14-16), a cytokine produced by 
T cells and mast cells that is also encoded in the cytokine 
family on chromosome 5 (14,17-19). In particular, IL-13 
has been shown to affect the morphology, phenotype, 
function, and cytokine production of human monocytes 
(14,20-22). We investigated whether rIL-13 is able to 
regulate the expression of CD14 and CD14-depcndent 
events in monocytes. We show herein that, similar to IL-4, 
0022-1767/95/$02.00 
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Table 1. RT-PCR for monocytes genes: primers, product sizes, and annealing temperatures 
cDNA Primer Pair (upper strand; lower strand) Size (bp) T (*Q 
CD14 TAAAGGACTGCCAGCCAAGC 280 60 
AGCCAAGGCAGTTTGAGTCC 
CD23 CGAAGTTCCTCCAGTTCCTGTGAAATCTGCGTGGACTG 402 65 
GAGGACAGACACAGGCTCCAAACTCCACTAACCAGAG 
CD55 GCTGCTGCTGGTGCTGTTGTG 475 65 
GCCACCTGGTACATCAATCTGAC 
fl-actin GGATCTTCATGAGGTAGTCAGTCAGG 632 65 
GAGCACAGAGCCTCGCCTTTGC 
IL-13 down-regulates CD14 expression. CD14 down-reg- 
ulation resulted neither from increased shedding of soluble 
CD14 nor from triggering of endogenous GPI anchor- 
cleaving enzymes but, rather, was due to inhibition of 
CD14 RNA expression. 
Materials and Methods 
Reagents 
Purified and phycoerythrin-conjugated Leu-M3 mAb (anti-CD14, clone P9, IgG2b), isotype control mAbs, and FITC-conjugated goat anti-mouse 19 (GAMIG) were purchased from Becton Dickinson (Mountain View, 
CA). IOM2 mAb (anti-CD14, IgG2a) and IOB8 mAb (anti-CD23, IgGI) 
were purchased from AMAC (Westbrook, ME). OKM1 mAb (anti- C1311b, IgG2b) was obtained from Ortho Diagnostics (Raritan, NJ). 
MEM-18 mAb (anti-CD14, IgGI) (5) and IA10 mAb (anti-CD55/decay 
accelerating factor, DAF: IgG2a) (23) were a kind gift of Dr. V. Bazil Systemix, Palo Alto, CA, and Dr. E. Medof (Case Western Reserve Uni- 
versity, Cleveland, OH), respectively. An Ig62b isotype control was pur- 
chased from Zymed (South San Francisco, CA). Eschetichia coli-de- 
rived, purified human IL-13 (specific activity 1.6 x 106 U/mg) was 
obtained as described previously (14) and was kindly provided by Dr. R. de Waal Malefyt (DNAX Research Institute of Cellular and Molecular Biology, Palo Alto, CA), whereas purified human rIL, 12 (specific activ- ity 1.7 X 10' U/mg) was a kind gift of Dr. M. Gately (Hoffmann-La Roche, Nutley, NJ). Purified human rIL, 4 (specific activity 2X 106 U/mg) was purchased from R&D Systems (Minneapolis, MN). LPS from 
Saccharomyces minnesota was obtained from Sigma Chemical Co. (St. 
Louis, MO). TNF-ci concentrations in culture supernatants were deter- 
mined by ELISA (Endogen, Boston, MA. - lower limit of sensitivity 10 
pg/ml). The human neuroblastoma cell line IMR-32 was obtained from American Type Culture Collection (Rockville, MD). 
Isolation and culture of PBM 
Monocytes were prepared as described previously (24). In brief, PBMC 
were isolated from heparinized venous blood of healthy human donors by 
Ficoll-Hypaque density gradient centrifugation. The cells were then re- 
suspended in RPMI 1640 (Life Technologies, Gaithersburg, MD) sup- 
plemented with 10% AB' serum (Sigma), 2 mM glutarnine, 50 Ag/mI 
streptomycin, and 100 U/mi penicillin (complete medium), and adhered 
for I to 4h at 37*C in a 5% C02 atmosphere in plastic Petri dishes, each 
containing 10 to 15 X 107 mononuclear cells. After removing the non- 
adherent cells, the dishes were washed extensively with warm medium 
and then incubated with cold PBS on ice for 15 min. Adherent monocytes 
were recovered subsequently by vigorous pipetting, washed, and resus- 
pcnded in complete medium at 2X 106 cells/ml. Cell viability, as de- 
termined by trypan blue exclusion, was always >959o. Purified mono- 
cytes (2 )< 106 cells/ml) were cultured in the presence or absence of 
cytokines. Preliminary experiments established that optimal down-regu- 
lation of CD14 was observed using IL-13 at 100 U/ml. This concentra- 
tion, therefore, was used in all subsequent experiments. Supernatants for 
TNF-a assessment were collected after 20 h and stored at -20*C. 
Immunofluorescence staining 
For direct immunofluorescence, purified monocytes (2 X 10' cells/n-A) in 
staining buffer (RPMI 1640-10% AB+ serum, containing 0.01% sodium 
azide) were incubated with fluorochrome-conjugated mAbs or isotype 
controls for 40 min at VC The cells were then washed extensively and 
fixed in 2% p-formaldehyde. For indirect immunofluorescence, niono- 
cytes were incubated with purified Abs followed by FITC-conjugated 
GAMIG. Percentages of positive cells and mean fluorescence intensity 
(MFI) were analyzed by a FACScan (Becton Dickinson) gating on the 
monocyte population, as defined by forward and side light scatter. 
Biosynthetic labeling 
Purified monocytes (2 X IG' cells/ml) were incubated in the presence of 
medium or rIL-13 (100 U/ml) for 42 h. Cells were then washed and 
incubated for 6h in methionine- and cysteine-free RPMI 1640, supple- 
mented with 10% dialyzed AB' serum and containing [2"S]methionine 
and [35S]cysteine (Pro-mix, Amersham, Arlington Heights, IL4 10 mCi/ 
ml) in the presence or absence of rIL-13. The monocyte supernatants 
(i. e., the labeling medium) were then collected and centrifuged for Ih at 
100,000 X g. For immunoprccipitation, supernatants were precleared by 
overnight incubation with normal mouse serum (2 ; kl) and 20 Al of 
packed protein G-agarose beads (Boehringer Mannheim, Indianapolis, 
IN). The following day, supernatants were recovered and incubated for 
4h with anti-CD14 mAb P9 or isotype control (10 ; Lg) and protein 
G-agarose beads (20 ul). lle beads were then washed extenso ely in 
lysis buffer, resuspended in loading buffer, and boiled. Samples contain- 
Ing equal amounts of protein were analyzed by 12% SDS-PAGE under 
reducing conditions followed by autoradiography. 
Semiquantitative reverse transcriptase-mediated PCR 
Levels of mRNA for CD14 and other monocyte surface molecules were 
assessed by a serniquantitative reverse transcriptase-mediated PCR 
(RT- 
PCR) assay. Total cellular RNA was extracted by the method of Choin- 
czynski (Z5). cDNA was synthesized using Moloney leukemia virus re- 
verse transcriptase (Life Technologies) and random primers. 
PCR 
primers were 5'-Iabeled using T4 polynucleotide kinase (Life Technol- 
ogies; 5 U/10 pmol of primer) and 30 IkCi [-t- 32p]AIT (3000 
Ci/MMOI, 
Amersham). For each reaction, one primer was labeled and added 
in 2 
1: 10 molar ratio with cold primer. The number of amplification cycles 
chosen for each primer pair was such that the maximum signal intensity 
for a set of samples was within the linear portion of a product vs template 
amplification curve. Each sample was assayed initially 
for ampi; etable 
cDNA using primers specific for 13-actin, which is known to bc anaf- 
fected by our experimental conditions. Based on the amount of 
p-actin 
PCR product in this assay, aliquots of RT product representing equivalent 
amounts of 13-actin were amplified using primers for CD14, CD23, and 
CD55 (Table 1). Each reaction was performed in a final volume of 
20, u], 
containing 20 pmol of each primer, cDNA (2 pl), PCR reaction 
buffer 
(Promega, Madison, WI), 1.5 MM MgC'2,200 AM dNTPs, 0.1 ýJ Of 
Tween 20, and 0.25 U of Taq polymerase (Promega). Amplifications 
were performed in a thermocycler (Omnigene, Hybaid, Teddington, 
UK) 
as follows: I min at 94*Cý followed by 20 to 35 amplification cycics 
(primer annealing temperature as specified in Table 1,1 min), 
I min at 
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rIGURE 1. Kinetics of IL-1 3-dependent inhibition of CD14 
expression. Human monocytes (2 X 10' cells/ml) were cul- 
tured for 24,48, and 72 h in the presence or absence of IL-1 3 
(100 Ulml). CD14 expression was assessed by indirect im- 
munofluorescence, using mAb Leu-M3 (open profile) or an 
isotype-matched control (solid profile). The data are repre- 
sentative of five separate experiments. 
74*C, and maintenance at 4*C until analysis. Aliquots (10 Al) of each 
amplification were analyzed by electrophoresis on 4% acrylamide gels 
followed by autoradiograpby using Kodak diagnostic film X-OMAT AR. 
Scanning densitometry analysis was performed on a 300E Computer 
Densitometer (Molecular Dynamics, Sunnyvale, CA). DNA sizes were 
compared against DNA m. w. standards derived from an HpaIl digest of 
pi3iuescript II SK and KS (Stratagene, La Jolla, CA), labeled with 
fa_3'P]dCTP (Amersham) using Klenow DNA polymerase I (Promega). 
Results 
rIL-13 down-regulates CD14 expression on normal 
human monocytes 
To assess whether the cytokine IL-13 plays a role in the 
regulation of CD14 expression, normal human monocytes 
were incubated with rIL-13 (100 U/ml) and CD14 expres- 
sion was assessed by flow cytometry at various time 
points. Figure 1 shows that CD14 expression remained 
virtually stable in unstimulated monocytes. By contrast, 
the percentage of CD14+ cells progressively decreased in 
the ; -. resence of IL, 13 and was reduced by >50% at day 3. 
Figure 2 shows that, as expected (3), CD14 down-regula- 
tion was also observed in monocytes stimulated with IL-4, 
3147 
FIGURE 2. Cytokine-dependent modulation of CD14 ex- 
pression. Human monocytes (2 X 106 cells/ml) were cultured 
for 48 h in the presence of medium, IL-4 (5 ng/ml), IL-1 3 (100 
U/ml), and IL-12 (I ng/ml). CD14 expression was then as- 
sessed by indirect immunofluorescence, using mAb Leu-M3 
(solid profile) or an isotype control (open profile). The data 
are representative of four separate experiments. 
whereas an unrelated cytokine, rIL-12, only modestly de- 
creased CD14 MFI and had no effect on the percentage of 
CD14+ cells (data not shown). Finally, the down-regulat- 
ing effect of IL-13 was CD14-specific, because incubation 
with IL-13 substantially enhanced the expression of 
CD11b (Fig. 3, top) and CD23 (Fig. 3, bottom). Tbus, 
IL-13 can exert specific and opposite effects on the ex- 
pression of different monocytic Ags. 
IL-13-induced down-regulation of CD14 involves 
neither shedding nor GPI-anchor cleavage 
CD14 is anchored to the cell membrane by a GPI linkage 
(1) and is shed upon activation of monocytes (26). Indeed, 
shedding was shown to be responsible for down-regulation 
of CD14 by phorbol esters and IFN--y (26). We investi- 
gated, therefore, whether the IL-13-induced decrease in 
membrane CD14 resulted from shedding. To this purpose, 
monocytes were cultured for 42 h in the presence or ab- 
sence of rIL-13 (100 U/ml) and then labeled for 6h with 
[35S]methionine/cysteine. Supernatants were then col- 
lected, and immunoPrecipitation was performed with anti- 
CD14 mAb P9. Figure 4 shows that a band corresponding 
to soluble CD14 was precipitated from supernatants of un- 
stimulated monocytes by m. Ab P9 (lane 1), but not by an 
IgG2b isotype control (lane 3). Soluble CD14 did not in- 
crease after incubation with rIL-13 (lane 2). These results 
ruled out protein shedding as the mechanism responsible 
for IL-13-induced down-regulation of membrane CDA. 
To test whether triggering of endogenous GPI anchor- 




MF 1: 136 
IL-1*3 DOWN-REGULATES CD14 IN HUMAN MONOCYTES 
CD23 
30 
FIGURE 3. IL-11 3 up-regulates CD1 Ib and induces CD23 
on human monocytes. Human monocytes (2 X 10' cells/ml) 
were cultured for 48 h in the presence or absence of IL-1 3 
(1100 U/ml). Expression of CD1 Ib and CD23 was assessed by 
indirect immunofluorescence, using mAb OKM1 or 10138 
(solid profile) or isotype controls (open profile). The data are 
representative of three separate experiments. 
down-modulation of C1314, monocytes incubated with 
IL-13 for 24 and 48 h were assessed by immunofluores- 
cence for the expression of CD55 (DAF), a GPI-linked 
protein (27,28) expressed at high levels on unstimulated 
monocytes (23). Figure 5 shows that IL-13 had a modest 
effect on CD55/DAF expression, indeed not comparable 
with the one observed on CD14. Thus, IL-13-induced 
down-regulation of CD14 seems to involve neither cleav- 
age of GPI anchors nor shedding. 
IL- 13 down-regulates CD 14 transcript levels 
To elucidate further the mechanism(s) of CD14 down- 
modulation by IL-13, we then investigated the effect of 
IL-13 on CD14 transcript levels using a serniquantitative 
RT-PCR assay. Human monocytes were cultured for 36 h 
in the absence or presence of rIL-13 (100 U/ml), total 
RNA was extracted, and cDNA was synthesized and am- 
plified with radioactive primers after normalizing for am- 
plifiable cDNA levels. Figure 6 shows that CD14 RNA 
was well expressed in monocytes cultured in medium but 
was down-regulated markedly (sixfold) after incubation 
with rIL-13. Consistent with the Ag expression patterns 
observed by immunofluorescence, IL-13 induced a modest 
(1.8-fold) decrease in CD55 RNA and a marked (three- 
fold) up-regulation of CD23. The RT-PCR was specific, 
because no band corresponding to CD14, CD23, or CD55 
RNA was ýjmplified from cDNA of the neuroblastoma cell 
FIGURE 4. CD1 4 shedding is not affected by IL-1 3. hluw, in 
monocytes (2 X 106 cells/ml) were cultured for 42 h in the 
absence or presence of HL-13 (100 U/ml) and labeled with 
["Sjmethionine/cysteine during the last 6h of culture. Cell su- 
pernatants were then collected and immunoprecipitated with 
anti-CD 14 mAb P9 or isotype control (10 tkg) and analyzed by 
12% SDS-PAGE under reducing conditions, followed by auto- 
radiography. Lane 1, supernatants from unstimulated mono- 
cytes, immunoprecipitated with mAb N; lane 2, supernatants 
from IL-13-stimulated monocytes, immunoprecipitated with 
mAb P9; lane 3, supernatants from unstimulated monocytes, 
immunoprecipitated with lgG2b isotype control. The data are 
representative of two separate experiments. 
line IMR-32. These results suggest that 11,43-induccd 
down-regulation of membrane CD14 results from a reý! ýic- 
tion in transcript levels. 
IL-13 inhibits both ( /)/-I nw(lww(l mid it0c, f)t vl- 
secretion of TNF-a 
CD14 has been shown to act as thc I-I'S icccptoi (4), thu" 
mediating LPS-induced monokine release (8). We invc,, - 
tigated, therefore, whether IL-13-dependent down-regula- 
tion of CD14 could affect LPS-induced release of TNF- 
Table 11 shows that purified monocytes secreted lar, -, c 
amounts of TNF-a in response to a 20-h stimulation Will, 
LPS (100 ng/ml). TNF-a release was CD14-dependcifl, 
because it was virtually abolished by mAb MEM I ý,, 
which recognizes a CD14 epitope in the LPS-bindini! -ilc 
(8,29). A 72-h preincubation with IL-13 strongly (--I ,) 
inhibited LPS-induced TNF-ot release. MEM-18 n: \il 
completely abrogated the residual response to LPS of 
H-- 
13-stimulated monocytes, suggesting that the latter was 
mediated by residual CD14 expression. Notably, Table 
It 
also shows that preincubation with IL-13 markedlý 
(-76%) inhibited the CD14-independent secretion ot 
TNF-a induced by PMA (8). Thus, IL-13 inhibits bott, 
CD14-mediated and -indcpendent TNF-a release. 
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FIGURE . 5. 
Efect of IL-13 on CD55 expression. Human 
mc)nocytes (2 X 
106 cells/ml) were cultured for 24 and 48 h in 
the presence or absence of IL-I 30 00 U/ml). CD55 expression 
was assessed 
by indirect immunofluorescence, using mAb 
k IAI 
0 (solid profile) or an isotype control (open profile). The 
data are representative of three separate experiments. 
, DiscLjssion 
I he cytokine IL-13 has been shown to exert pleiotropic 
effects on monocytes 
in both mice (30) and humans (20). 
IL- 13 -dependent 
down-modulation of human CD14 had 
be n observed previously 
(20); however, the mechanisms 
undeflying 
this effect of IL-13 were not investigated. 
, 
CD14 expression can be regulated through different path- 
, ways. 
IFN--y, phorbol esters, and calcium ionophore 
dow][1-rilodulate 
CD14 by inducing activation of mem- 
, 
brane-bound protease(s) with rapid shedding (26). IL-4, on 
: the other hand, reduces 
CD14 by inhibiting the expression 
-13 3f Cr)14 
RNA (13). Our present data show that IL 
Irese 
Mbles IL-4 in its ability to 
interfere with CD14 RNA 
ion. Although the sequence homology between 
, Xpress 
, 
IL-13 and IL-4 is only -30%, all residues that contribute 
the hydrophobic core of 
IL-4 are conserved or have 
-13 (31). Fur- 
,, )nservative 
hydrophobic replacements in IL 
More, receptors 
for IL-4 and IL-13 may share a subunit 
, he Indeed, an IL-4 mutant protein that binds IL-411 with (31). 
high affinity competitively 
inhibits receptor binding of 
both IL-4 and IL-13 and blocks 
induction of IgG4 and IgE 
ýyrithesis 
by b. oth cytokines (32). However, IL-4 and IL-13 
as Xell as their receptors are 
by no means identical. IL-13 
dc, es riot 
bind to COS-3 cells transfected either with 
for the 130-kDa IL-4R and/or the y-chain (33). 
, DNAS 
Purtb, frnore, unlike IL-4, IL-13 has no effects on human T 
QC11S (31) and 
does not seem to activate directly human 
Pre-13 cells 
(16). The elucidation of the respective roles of 
II, _4 and 
IL-13 in physiologic conditions will require in- 
f, -rvation 
about the structure and distribution of IL-13 re- 
L ptors, as 
well as a detailed analysis of the mechanisms 










FIGURE 6. IL-13 down-regulates CD14 transcript levels. 
Total RNA was isolated from peripheral blood monocytes 
cultured for 36 h in the absence or presence of rIL-1 3 (100 
U/ml), clDNA was synthesized, and analyzed by semiquan- 
titative RT-PCR. Amplification cycles used were as follows: 
35 for CD55 and CD23,20 for CD14, and 24 for )3-actin. 
Table 11. Preincubation with IL-13 inhibits both CD14-mediated 
and V-independent release of TNF-a from human monocytes, 
Stimulant IL-1 3 Anti-CD14 mAb TNF-a (pg/ml) 
Nil 47 -t 7 + 15 t4 
LIDS 25,225 ± 5,782 
+ 154 ± 15 
+ 7,575 ± 2,832 
++ 61 - 10 
PMA - 
+ 
2,775 ± 1,062 
675 ± 170 
' Human monocytes (2 X 106 cells/ml) were cultured for 72 h in the pres- 
ence or absence of IL-1 3 (100 U/ml), washed, resuspended in complete me- 
dium, and stimulated with LPS (100 ng/ml) or PMA (50 ng/ml) in the presence 
or absence of anti-CD14 mAb MEW 8 (1: 200). After 20 h, supernatants were 
harvested and TNF-a concentrations were determined by ELISA. The table 
shows the mean ± SE of results obtained in four experiments. 
The ability of IL-13 to down-regulate the expression of 
CD14 has important functional implications. We and oth- 
ers have shown that the LPS-dependent release of proin- 
flammatory monokines is decreased strikingly in IL-13- 
treated monocytes, whereas IL-Ira secretion is enhanced 
(20). Although these results pointed to a major anti-in- 
flammatory effect of IL-13, the mechanisms underlying 
such an effect remained to be determined. Because LPS is 
the stimulus commonly used to elicit the release of proin- 
flammatory monokines and CD14 is the major LPS recep- 
tor (reviewed in Ref. 34), the anti-inflammatory effect of 
IL-13 in LPS-driven systems may depend entirely on 
CD14 down-modulation. Indeed, we (Table II) and others 
(8) have shown that addition of Abs specific for the LPS- 
binding site on CD14 is sufficient to block LPS-in- 
duced monokine release by untreated (i. e., CD I 4-bearing) 
3150 
monocytes. The results presented here now demonstrate 
that, in addition to the effect on CD14, IL, 13 directly 
inhibits the release of proinflammatory cytokines, because 
it suppresses PMA-induced secretion of TNF-ci. Thus, 
IL-13-dependent inhibition of monokine release results 
from complex mechanisms, both CD14-mediated and 
-independent. 
Finally, IL-13 has been shown to suppress HIV-1 rep- 
lication in monocytes (35), cells that serve as a reservoir 
for the persistence of the virus in the host (36). This effect 
of IL-13 on HIV-1 may synergize with its ability to down- 
regulate CD14. LPS is a potent stimulator of HIV-1 ex- 
pression in monocytes (37), and CD14 is required for 
LPS-dependent induction of HIV-1 expression both in 
chronically and latently infected monocytes (38). Thus, an 
IL-13-induced decrease of CD14 expression in monocytes 
from HIV patients infected with Gram-negative bacteria 
would raise the threshold for LPS-dependent activation of 
HIV-1 expression, thus contributing to maintaining provi- 
ral latency. 
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ABSTRACT There is controversy as to whether deletional 
rearrangement occurs between the IgM and IgE switch regions 
(S,, and S,, respectively) during switching to the IgE isotype. 
We have addressed the issue by stimulating normal human B 
cells, sorted for lack of expression of surface IgE, to produce 
IgE by infection with Epstein-Barr virus (EBV) in the presence 
of interleukin 4 (HA). Genomic DNA was amplified for S,, /S. 
switch junction fragments by utilizing the nested-primer poly- 
Inerase chain reaction. Switch junction fragments were ampli- 
red from B cells infected with EBV in the presence of IL4 but 
not from B cells infected with EBV alone. The DNA sequence 
of these I 'switch fragments" revealed direct joining of S. to S, 
in each case. The recombination sites within S, were clustered 
within 900 base pairs at the S' end of the switch region, 
suggesting that there are "hot spots" for recombination within 
S.. The S, recombination sites were scattered throughout the 
S, region. These findings indicate that IL4-induced isotype 
switching to IgE production in human B cells is accompanied 
by DNA rearrangements with joining of S, to S,. 
piversification of antibody biological function is achieved by 
the process of heavy chain class switching. Isotype switching 
occurs by molecular recombination between switch (S) re- 
gions (1-3) located upstream of each heavy chain constant 
(CH) region gene with intramolecular deletion of the DNA 
segment between the recombined S regions (4-6). Mitogens 
and T-cell-derived lymphokines regulate isotype switching. 
These agents presumably modulate the accessibility of spe- 
cific S regions to a putative switch recombinase (7-9). 
Switching to IgE requires interleukin 4 (IL-4) and a B-cell 
activation signal provided by T cells (10,11) or by infection 
with Epstein-Barr virus (EBV) (12,13). Recent studies have 
suggested that, unlike switching to other 
isotypes, switching 
to IgE expression may not involve DNA rearrangement 
(14-16) but would instead occur by alternative splicing of a 
long mRNA transcript or transsplicing of a productive vari- 
able-diversity-joining 
(VDJ),, transcript to a downstream 
germ-line transcript. 
On the other hand, Thyphronitis et al. 
(17) have recently demonstrated by Southern blot analysis 
the rearrangement of one CHe gene and deletion of both CH. 
genes in two EBV-transformed 
IgE-secreting B-cell clones, 
suggesting that 
deletional. mechanisms could underlie isotype 
switching to 
IgE. However, because these two clones were 
derived from an unfractionated population of B cells, it was 
not clear -whether they represented cells that were actually 
induced by ILA to undergo isotype switching. More impor- 
tantlY, because of its limited sensitivity, Southern blot anal- 
ysis may not 
be useful for the study of populations of B cells 
in which only a small percentage have undergone switching. 
The publication costs of this article were defrayed in part by page charge 
payment. 
This article must therefore be hereby marked "advertisement" 
ill accordance with 18 U. S. C. §1734 solely to indicate this fact. 
Here we utilized the nested-primer polymerase chain re- 
action (PCR) to demonstrate that deletional recombination 
occurs in human B cells, sorted for lack of expression of 
surface IgE (sIgE-) and stimulated to switch to IgE synthesis 
by EBV infection in the presence of recombinant IL4 
(rIL4). Sequence analysis of amplified S, /S, "switch frag- 
ments" revealed direct joining of S. to S, with a clustering of 
S, recombination sites within the 5' end of the S region, 
suggesting possible "hot'Spots" for recombination within SA. 
Thus, nested-primer PCR provided the sensitivity to analyze 
switching in polyclonal populations of cells that was not 
available with Southern blotting techniques. 
MATERIALS AND METHODS 
B-Cell Preparation/EBV Transformation. B-cell-enriched 
populations were prepared from peripheral blood mononu- 
clear cells of nonatopic subjects (serum IgE < 70 interna- 
tional units/ml) as previously described (10). slgE- B cells 
were sorted as previously described (13). EBV B-cell trans- 
formation in the presence or absence of rIL-4 has been 
described (18). Growth and passaging of the cells has been 
previously described (13). 
IgE Assay. Cell lines were cultured at 0.5 X 10' cells per ml 
and supernatants were collected for assay after 3-4 days of 
growth. IgE was measured by a radioimmunoassay (19) with 
a limit of sensitivity of 150 pg/ml. 
Preparation of Cellular DNA and Southern Blotting. High 
molecular weight DNA was prepared from 50 X 106 cultured 
cells by utilizing the A. S. A. P. genomic DNA isolation kit 
(Boehringer Mannheim). After cleavage with restriction en- 
donucleases, the DNA was fractionated in 0.7% agarose gels 
and transferred to nylon membranes (Schleicher and 
Schuell). The CH. probe was prepared by nick-translation 
(ref. 20, pp. 10.6-10.10) of the gel-purified 0.88-kilobase (kb) 
Hinfl fragment encompassing the first two exons of the CH* 
gene and the introns bordering CHe2 (described in ref. 13). 
Blots were hybridized and washed as described in the pro- 
tocol for Nytran membranes (Schleicher and Schuell). 
PCR Primers, Amplification of S, 1S, Switch Fragments. 
Thirty-base-pair (bp) single-stranded DNA oligonucleotide 
primers for PCR were prepared by utilizing the PCR-Mate 
DNA synthesizer (Applied Biosystems). PCR amplification 
of the S, 1S, fragment from the IgE-secreting plasmacytoma 
U266 (21) was performed with primers S6/S4 (see Fig. 2) in 
a reaction mixture containing each dNTP at 200 AM, 5 mM 
KCI, 1.0 MM MgC12,10 mM Tris-HCI (pH 8.3), 0.01% gelatin, 
1 mM dithiothreitol, 150 ng of each PCR primer, 1 /. tg of 
genomic template DNA, 2.5 units of AmpliTaq DNA poly- 
Abbreviations: S, switch; CH, heavy chain constant; VDJ, variable- 
diversity-joining; EBV, Epstein-Barr virus; IL-4, interleukin 4; 
rIL, 4, recombinant IL-4; sIgE-, surface IgE-negative. ýTo whom reprint requests should be addressed. 
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merase (Perkin-Elmer), and 0.5 unit of Perfect Match poly- 
merase enhancer (Stratagene) in a 50-kLl volume under a 50-Al 
layer of mineral oil. The reaction mixture was cycled in a 
Perkin-Elmer/Cetus DNA thermal cycler for 35 cycles with 
I min at 94*C, 1 min at 65*C, and 4.5 min at 72'C. PCR 
amplification of S, /S, fragments from the EBV-transformed 
B cell DNA was similarly performed with primers S6/S4 
followed by a second round of PCR utilizing the nested 
primers S8/S3 (Fig. 2) in a reaction mixture containing the 
same concentrations of all of the above constituents, except 
for 1.5 MM M902 and a 5-jLl aliquot of the previous PCR 
reaction mixture that served as DNA template. The reaction 
mixture was cycled in the thermal cycler under the same 
conditions as described above. 
Purification, Cloning, and Sequencing of PCR-Amplified 
DNA Fragments. PCR-amplified fragments were fractionated 
on 5% polyacrylamide gels, electroeluted from cut sections of 
the gel, and isolated by precipitation with ethanol (ref. 20, pp. 6.28-6.29,6.39-6-44). Purified fragments were ligated into 
the Sma I site of pUC19 (22). Regions of the cloned fragment 
were subcloned in the replicative form I DNA for M13mp18 
and M13mp19 (Pharmacia LKB), and single-stranded tem- 
plate DNA was isolated according to the protocols of New 
England BioLabs. All cloning steps utilized the Escherichia 
coli strain JM109 (23), a recombination-deficient strain that 
protects against bacteria] -directed mutation or recombina- tion within cloned fragments. Constructs were sequenced by 
the dideoxy chain-termination method (24) using Sequenase Version 2.0 (United States Biochemical). Additional 17-bp 
sequencing primers were prepared with the PCR-Mate DNA 
synthesizer. 
RESULTS 
Analysis of Cell Lines. Table 1 lists the cell lines studied. IgE was detected only in culture supernatants of B cells infected with EBV and cultured in the presence of IL-4. The 
percentage of cells in each cell line with intracytoplasmic IgE 
never exceeded 5% (13), even in the A5 cell line, which 
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Table 1. Cell lines 






U266 NA NA NA 74,909 
A5 + > 180 59,797 
Sernie >180 <150 
HJS6 + + 43 2,199 
HJS7 + + 44 5,687 
HJS02 + 57 <150 
NA. not applicable. 
*A + denotes that B cells were sorted for lack of expression of 
surface IgE prior to initiation of culture. 
tCell lines were incubated with (+) or without (-) rIL-4 at the time of 
EBV infection. rIL-4 was maintained in the media of the + cell lines. 
secreted IgE in levels comparable to those secreted by the 
U266 plasmacytoma line. 
Southern Blot Analysis of IgE-Secreting B-Cefl Lines. We 
performed Southern blot analysis (Fig. 1A) on the high-IgE- 
producing line A5 and on the non-IgE-producing line Semie, 
which were derived from unsorted B cells from two different 
donors. A5 had been cultured with rIL-4, while Semie had 
been grown in the absence of rIL-4. U266 and ak library 
clone derived from human placenta that contains the S, and 
CH, region in the unrearranged configuration (25) were used 
as controls. The EA clone shows no rearrangement involving 
S, (5.5-kb Pst I fragment). U266 DNA had a single rearrange- 
ment (3.3-kb Pst I fragment) corresponding to the S, /S, 
recombination event depicted in Fig. IB. The single rear- 
rangement in U266 indicates either that both chromosomes 
are identically rearranged or that only one copy of this region 
is present in the cell line. The second explanation is more 
likely, since karyotype analysis revealed that U266 is not 
diploid for chromosome 14 (data not shown). The Southern 
blot pattern for both the IgE-secreting and non-IgE-secreting 
cell lines was that of an unrearranged chromosome (5.5-kb 
Pst I fragment). These results indicated that Southern blot 
analysis for the detection of S,, /S, recombination events in 
polyclonal populations of B cells is not informative. 
A Hf Hf B 6001ý 24678 SIL SE 
CH, B/P P RIP P R/P P B/P P 
VnDnJm Jn 
p- s S- p- 
CH)t pHSK 8--- 
5.5 kb 













pK8 CH, pB 
if i --p ri r-i r-i Ly to 
i -- 3.3 kh 
-I-Bkb --4 2.6 kb 
1.8 kb 
FIG. I. Arrangement of the S. region in U266, IgE-secreting (A5), and non-IgE-secreting (Semie) lymphoblastoid lines. (A) Southern blot analysis of cell lines Compared with the k clone 38A (25), isolated from a human placenta genomic library. High molecular weight DNA samples isolated from the FA clone (lanes 1 and 2), U266 (lanes 3 and 4), and lymphoblastoid cell lines (A5 in lanes 5 and 6 and Semie in lanes 7 and 8) were digested with Bamffl/Psi I (B/P) or with Psi I (P) alone. Samples on this Southern blot were hybridized with the 0.88-kb Hinfl 
fragment 
encompassing CH, j and CH. 2 (shown above CH. in B). All four DNA samples show the 1.8-kb BamHI-Pst I fragment encompassing CHE that 
does not undergo rearrangement (lanes 1,3,5, and 7). The A clone has an unrearranged S, region represented by a 5.5-kb Psi I fragment (lane 
2). The additional bands in lanes I and 2 are the result of incomplete digestion with Psi 1. U266 DNA has only a 3.3-kb Psi I fragment, consistent 
with rearrangement involving the S, region (lane 4). Both A5 and Semie cellular DNA have a 5.5-kb Psi I fragment, denoting an unrearranged 
S, region (lanes 6 and 8). No other bands were detected in the lymphoblastoid cell lines, even with overexposure of the autoradiogram. (B) 
Diagrammatic summary of the rearrangement event that occurred in U266. Brackets represent the probable extent of the switch regions. B, 
BamHl; H, Hindill; Hf, Hinfl; K, Kpn L, P, Psi 1, S, Sac I. 
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PCR Amplification and Sequencing of the Switch Fragment 
from U266. Genomic DNA from the U266 cell line was 
subjected to one round of PCR amplification utilizing the 
primers S6/S4 or S8/S3 (Fig. 2). Amplified fragments were 
subcloned and DNA sequencing showed that a complex 
rearrangement had occurred between S,, and S, regions. A 
243-bp internal deletion occurred within S, _ 
followed by an 
additional 186 bp of S,, sequence (Fig. 3B). At the termination 
of the S, sequence, there was a 34-bp 
insertion segment, not 
hornologous to either S, or S, (Fig. 4). Part of this insertion 
segment contained pentameric repeats typical of S region 
sequences (26,27). However, comparison of this insertion 
segrnent with S,, S, and S. 4 sequences (28) 
failed to reveal 
arl unambiguous origin for this insert. The 34-bp insertion 
segment was ligated to an S, sequence that continued down- 
stream without interruption into the IgE heavy chain gene 
coding region, CH. (Fig. 3B). 
FIG. 2. PCR amplification of S, /S, junc- 
tion fragments. A representative fragment 
containing an S,, /S, junction is shown. The 
PCR primers used for amplification of the 
region are pictured below the map. For 
nested primer PCR, the first round uses 
primers S6/S4 while the second (nested) 
round of PCR uses primers S8/S3. B, 
BamHl; K, Kpn 1; P, Pst 1. 
The sequence of the fragment amplified by PCR from U266 
DNA was identical to the sequence of a fragment isolated 
from a U266 genomic library that encompassed the S,, /S, 
junction (unpublished data). Thus, PCR-amplified switch 
fragments accurately reflect the switch rearrangement in 
genomic DNA. 
Nested-Primer PCR Amplification of Switch Fragments 
from IgE-Secreting B-Cell Lines. Because <5% of B cells in 
our cell lines contained cytoplasmic IgE, we tested the 
sensitivity of the PCR amplification method used above. 
Various dilutions of U266 DNA were mixed with fibroblast 
genomic DNA such that the final concentrations of U266 
DNA in the mixtures were 20%, 2%, 0.2%, 0.02%, and 
0.002%. The final dilution represented the DNA equivalent of 
two to three U266 cells in a 1-gg sample of fibroblast DNA. 
When PCR was performed utilizing the primers S6/S4 (Fig. 
2), no PCR-amplified fragments were identified by gel elec- 
U266 A5 HJS6 "JS7 14JS02 
A1234 56789 10 MW 
qM FiG. 3. Nested primer PCR 
products of U266, IgE-secreting 
(A5, HJS6, and HJS7), and non- 
IgE-secreting (HJS02) lympho- 
blastoid lines. (A) Agarose gel 




Each pair of samples represents 
SKS271- -I ý35 kb two 
independently run nested- 
SKS251 SKS2 115- 1 ý08 kb primer PCR products from the 5KS252--' 
SKS2 14- 
0 - . 07 kb same genomic DNA preparation. 
-0ý60 kb The indicated fragments were iso- 
lated, cloned in plasmid vectors, 
-0.31 kb and sequenced. (B) Diagrammatic 
summary of the sequenced DNA 




S, junction. The genomic map of 
e CHII ,sKB Hs S 
the unrearranged SA and S, re- 
sP PPs 
f 
t SmS HS m 
F-I r-16j6 , gions 
is compared with the switch o fragments isolated from U266 and 
the EBV B-cell lines. Three frag- 
KB SKS214 
ments (SKS214, SKS251, and 
PP (U266) 
SKS274) have internal deletions of 
S,. One fragment (SKS214) has an 
P 
K 
SKS251 insertion segment of unclear origin 
(A5) joining S, to S, (represented as 
W). One fragment (SKS251) has a 
P SKS252 26-bp duplication of a portion of (A5) 
S. at the 3' end of the S. se- 
P sK SKS271 quence. 
One example ofan unre- 
(HJSG) producibly amplified fragment z 
from the non-IgE-secreting cell 
P SH s SKS274 ; line (14JS02) is shown in lane 9; (HJS7) == 
this fragment is not present in the 
H SH sK SKS275 replicate sample shown in lane 10. P 
(HJS7) Brackets represent the probable 
extent of the switch regions. B, 
P sK SKS278 BamHl; H, Hindill; K, Kpn 1; P, 
(HJS02) Pst 1; S, Sac 1; Sm, Sma 1. 
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CTGAGCTGGGCTGGGCTGAGCTGr. GCTrýr. GCrGrrj CRSCTGRGCGGSGTT 
FIG. 4. Sequence of the S, /S, switch junction in the cloned 
fragments. The DNA sequence data encompassing the S, /S, switch 
junction of the fragments in Fig. 3B are shown. The key at the top 
indicates origins of the nucleotides. Nucleotides that could originate 
from either S, or S. generally encompass pentameric repeat se- 
quences that are common to both switch regions. The presence of 
sequences common to both S. and S, as in fragments SKS277 and 
SKS278 is indicative of in vitro artifactual switching. The common 
sequence in the SKS252 fragment is interrupted by a nucleotide not 
present in either switch region, thus suggesting that this fragment is 
not artifactual. The origin of the insertion segment in SKS214 is not 
known. The 26-bp duplicated segment in SKS251 is identical to bp 
888-914 and is shown between brackets within the sequence. The 
hyphen in the SKS274 sequence represents a I-bp deletion. The 
sequence of unknown origin in SKS275 within the S, region may not 
be a true insertion/deletion but may represent a polymorphism. 
trophoresis, even when 20% of the template DNA was from 
U266. We hypothesized that this failure resulted from com- 
petition for the primers by unrearranged DNA. To dilute out 
this competition, we performed a second round of nested- 
primer PCR amplification utilizing primers S8/S3 (Fig. 2) on 
an aliquot from each first round of PCR. The expected 618-bp 
U266 switch fragment was amplified from all the samples 
(data not shown). These results demonstrated that nested 
primer PCR could amplify an S, /S, switch fragment when it 
was present at only two or three copies in a sample of 
unrearranged DNA. 
Genomic DNA samples from three IgE-secreting cell lines 
(A5, HJS6, HJS7) and one cell line that did not produce IgE 
(HJS02) were amplified by the nested-primer PCR technique. 
As expected, no amplified fragments were detected in the 
DNA from the cell lines after the first round of PCR (data not 
shown). However, after the nested-primer round of PCR, 
multiple fragments were reproducibly detected in replicate 
samples from all three IgE-sccrcting cell lines (Fig. 3A). In 
contrast, PCR amplification of DNA from non-IgE-secreting 
cell lines revealed either no PCR fragments or, only occa- 
sionally (<30% of all PCR runs), gave rise to PCR fragments 
that were never reproducibly observed in duplicate runs. An 
example of one such fragment is seen in lane 9 of Fig. 3A; this fragment was not seen in the duplicate PCR run shown in lane 
10. Similarly, PCR fragments were occasionally amplified 
from fibroblast DNA (data not shown). Sequence data re- 
vealed that these fragments represented artifactual PCR- 
generated "in vitro switching" (see below). 
Sequence Analysis of Switch Fragments from IgE-Secreting 
B-Cell Lines. Five switch fragments (SKS251, SKS252, 
SKS271, SKS274, and SKS275) reproducibly amplified from 
DNA of the IgE-secreting cell lines were purified, cloned, 
and sequenced. Fig. 3B compares these cloned fragments to 
the genomic S, and S. maps. The sequences of these frag- 
ments around the S, /S, junction are shown in Fig. 4. In each 
case there was direct joining of S, to S.. Two of the five 
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fragments (SKS251 and SKS274) had internal deletions 
within S, of 551 bp and 10 bp, respectively (Fig. 3B). 
However, these deletions had different 5' and 3' ends than the 
deletion seen in U266. 
Analysis of the sites of switch recombination and internal 
deletion within S, demonstrated a clustering of these sites 
within 900 bp at the 5' end of the S region. In contrast, the S. 
recombination sites were scattered throughout the S, region. 
These data suggest that there may be hot spots for recom- 
bination within the S, region. 
The S, /S. sequence of the PCR fragment amplified from 
the DNA of the non-IgE-secreting cell line HJS02 (lane 9, Fig. 
3A) is shown as SKS278 in Fig. 4. Unlike switch fragments 
amplified from the IgE-secreting cell lines, SKS278 contained 
at the junction between S, and S, a 9-bp sequence that is 
common to S,, and S, regions and, therefore, could have 
derived from either S region. Allowing for two mismatches, 
the sequence in SKS278 common to both S regions would be 
26 bp. Switch fragment SKS278 likely represents an in vitro 
artifact that arose because single-stranded PCR products 
bound to each other due to complementarity at their 3' ends. 
Elongation of the annealed product resulted in amplification 
of the fragment leading to artifactual in vitro switching. The 
sequence of the switch junction of an artifactual. PCR frag- 
ment amplified from fibroblast genomic DNA (SKS277) 
similarly contains a segment at the S,, /S, junction (16 bp) that 
is common to the two S regions. We have confirmed the 
presence of the switch fragments in the IgE-secreting cell 
lines and the artifactuality of fragments amplified from HJS02 
and fibroblast DNA by using another pair of primers (S7 and 
S9) for the nested-primer round of PCR. Switch fragments of 
the expected sizes were amplified with these primers from 
DNA of the IgE-secreting cell lines. In contrast, none of the 
artifactual switch fragments were amplified from either 
HJS02 or fibroblast DNA (data not shown). 
One of the amplified fragments (SKS252) from the IgE- 
secreting cell lines had a segment at the S,, /S, junction that 
could have derived from either S, or S,. However, this 
fragment could not have arisen by in vitro switching because 
within the 12-bp sequence common to S,, and S, is a nucIe- 
otide insertion (adenine) not present in either S, or S.. 
Moreover, this fragment was reproducibly amplified from A5 
genomic DNA, and this PCR product from two different 
isolates of A5 DNA had identical sequences. These data 
indicate that this fragment represents a true switch recom- 
bination event. 
DISCUSSION 
To date, direct analysis of switch recombination has been 
restricted to clonal populations of cells because Southern blot 
analysis, as illustrated in our study, is not applicable to the 
study of B-cell populations in which only a small percentage 
of cells have undergone isotype switching. In the present 
study, we have used the nested-primer PCR technique to 
demonstrate deletional S, to S, switch recombination in 
polyclonal normal human B cetls induced to switch in culture 
to IgE isotype expression by stimulation with EBV and IL-4. 
Deletional switch recombination must have occurred de 
novo, because B cells were sorted for lack of expression of 
surface IgE prior to culture. 
Nested-primer PCR can amplify a switch fragment even 
when it is present as only a single copy among more than 
250,000 unrearranged DNA segments. Though this procedure 
occasionally amplifies PCR fragments from DNA of non-IgF__ 
secreting cell line controls and from fibroblast DNA, this 
amplification is not reproducible and the overlapping se- 
quence at the switch junction indicates that these fragmerlts 
are generated via an artifactual in vitro switching event. 
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Three of the switch fragments (SKS214, SKS251, and 
SKS274) had internal deletions within S,. One switch frag- 
ment had a 26-bp duplication of a portion of S,, sequence 
juxtaposed to thejunction with S,. Several point mutations or 
1-bp insertions or deletions were also observed in the vicinity 
of switch junctions. These findings are consistent with the 
lnodels in which error-prone DNA synthesis occurs during 
switch recombination (29-31). 
The data presented here do not exclude the possibUity that 
S, JS, recombination occurred on chromosomes that have 
not undergone productive VDJ rearrangement. Nonproduc- 
tive chromosomal rearrangements have been described in 
hybridomas and normal murine B cells (32-34). The fact that 
we observed S, /S, rearrangements only in IgE-secreting 
Jymphoblastoid cells, and not in the non-IgE-secreting con- 
trols, strongly suggests that S, /S, switch fragments have the 
necessary upstream VDJ regions for productive IgE expres- 
sion. The recent observation that an EBV-transformed B-cefl 
clone has deleted CH. on both chromosomes indicates that 
S 'L 
IS. switching occurs on chromosomes that have produc- 
tiVely rearranged their VDJ regions (17). 
our observations of S, /S, deletional switch recombination 
are in contrast to the results of MacKenzie and Dosch (15), 
who failed to detect S, /S, recombination by Southern blot 
analysis of IgE-secreting human B-cell clones. The discrep- 
ancy may be due to different modalities used to induce IgE 
synthesis. MacKenzie and Dosch cultured unsorted B cells in 
the presence of EBV and irradiated T-T hybridoma filler cells 
in the absence of exogenous IL-4. Nonetheless, our results 
cannot exclude nondeletional mechanisms of IgE isotype 
switching. 
The approach we have used to study the mechanism of 
isotype switching to IgE by nested-primer PCR amplification 
of SJS, junctions is applicable to the study of switch 
recombination to other isotypes and could prove useful in the 
study of potential isotype switch defects in patients with 
antibody deficiency syndromes. 
We thank the Clinical Genetics Laboratory at Children's Hospital 
for providing primary fibroblast cell lines. We thank L. Scaduto, for 
karyotype analysis of the U266 cell line. This work was supported by 
National Institutes of Health Grants 5ROlAI22058 and 
5P50CA39542. S. K. S. is supported by National Institutes of Health 
Training Grant GM07748-10. D. V. was supported by the Charles H. 
Ijood Foundation. 
1. Davis, M. M., Calame, K., Early, P. W., Livant, D. L., Joho, 
R., Weissman, I. L. & Hood, L. (1980) Nature (London) 293, 
733-739. 
2. Sakano, H., Maki, R., Kurosawa, Y., Roeder, W. &Tonegawa, 
S. (1980) Nature (London) 286,676-683. 
3. Kataoka, T., Kawakami, T., Takahashi, N. & Honjo, T. (1980) 
proc. Nad. Acad. Sci. USA 77,919-923. 
4. Matsuoka, M., Yoshida, K., Maeda, T., Usuda, S. & Sakano, 
H. (1990) Cell 62,135-142. 
5. Schwedler, U., Jdck, H. -M. & Wabl, M. (1990) Nature (Lon- 
don) 3459 452-456. 
Proc. NatL Acad. ScL USA 88 (1991) 
6. Iwamoto, T., Shimuzu, A., Hohjo, T. & Yamagishi, H. (1990) 
Cell 62,143-149. 
7. Yancopoulos, G. D., DePinho, R. A., Zimmerman, K. A., 
Lutzker, S. G., Rosenberg, N. & Alt, F. W. (1986) EMBO J. 5, 
3259-3266. 
8. Stavnezer-Nordgren, J. & Sirlin, S. (1986) EMBO J. 5,95-102. 
9. Lutzker, S., Rothman, P., Pollock, R., Coffman, R. & Alt, 
F. W. (1988) Cell 53,177-184. 
10. Vercelli, D., Jabara, H. H., Arai, K. & Geha, R. S. (1989) J. 
Exp. Med. 169,1295-1307. 
11. Vercelli, D., Jabara, H. H., Lauener, R. P. & Geha, R. S. 
(1990) J. Immunol. 144,570-573. 
12. Thyphronitis, G., Tsokos, G. C., June, C. H., Levine, A. D. & 
Finkelman. F. D. (1989) Proc. Nail. Acad. Sci. USA 86, 
5580-5584. 
13. Jabara, H. H., Schneider, L. C., Shapira, S. K., Alfieri, C., 
Moody, C. T., Kieff, E., Geha, R. S. & Vercelli, D. (1990) J. 
Immunol. 145,3468-3473. 
14. Snapper, C. M., Finkelman, F. D., Stefany, D., Conrad, D. H. 
& Paul, W. E. (1988) J. Immunol. 141,489-498. 
15. MacKenzie, T. & Dosch, H. -M. (1989) J. Erp. Med. 169, 
407-430. 
16. Chan, M. A., Benedict, S. H., Dosch, H. -H., Huy, M. F. & 
Stein, L. D. (1990) J. Immunol. 144,3563-3568. 
17. Thyphronitis, G., Max, E. E. & Finkelman, F. D. (1991) J. 
Immunol. 146,14%-1502. 
18. Umetsu, D. T., Yunis, E. J., Matsui, Y., Jabara, H. H. & 
Geha, R. S. (1985) J. Immunol. 15,356-361. 
19. Umetsu, D. T., Leung, D. Y. M., Siraganian, R., Jabara, 
H. H. & Geha, R. S. (1985) J. Exp. Med. 162,202-214. 
20. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) Molecular 
Cloning: A Laboratory Manual (Cold Spring Harbor Lab. 
Press, Cold Spring Harbor, NY) 2nd Ed. 
21. Seno, M., Kurokawa, Y., Ono, H., Onda, H., Sasada, R., 
Igarashi, K., Kikuchi, M., Sugino, Y.. Nishida, Y. & Honjo, T. 
(1983) Nucleic Acids Res. 11,719-726. 
22. Messing, J. (1983) Methods Enzymol. 101,20-78. 
23. Yanisch-Perron, C., Vieira, J. & Messing, J. (1985) Gene 33, 
103-119. 
24. Sanger, F., Nicklen, S. & Coulson, A. R. (1977) Proc. Nail. 
Acad. Scl. USA 74,5463-5467. 
25. Max, E. E., Battey, J., Ney, R., Kirsch, 1. R. & Leder, P. 
(1982) Cell 29,691-699. 
26. Nikaido, T., Nakai, S. & Honjo, T. (1981) Nature (London) 
292,845-848. 
27. Kataoka, T., Miyata, T. & Honjo, T. (1981) Cell 23,357-368. 
28. Mills, F. C., Brooker, J. S. & Camerini-Otero, R. D. (1990) 
Nucleic Acids Res. 18,7305-7316. 
29. Kenter, A. L. & Watson, J. V. (1987) J. Immunol. Methods 
97,111-117. 
30. Dunnick, W., Wilson, M. & Stavnezer, J. (1989) Mol. Cell. 
Biol. 9,1850-1856. 
31. Dunnick, W. & Stavnezer, J. (1990) Mol. Cell. Biol. 10, 
397-400. 
32. Radbruch, A., MUller, W. & Rajewsky, K. (1986) Proc. Nail. 
Acad. Sci. USA 83,3954-3957. 
33. Hummel, M., Berry, J. K. & Dunnick, W. (1987) J. Immunol. 
138,3539-3548. 
34. Kepron, M. R., Chen, Y. -W., Uhr, J. W. & Vitetta, E. S. 
(1989) J. Immunol. 143,334-339. 
(ot) 
